CN102190643B - Antitumoral compounds - Google Patents
Antitumoral compounds Download PDFInfo
- Publication number
- CN102190643B CN102190643B CN201110073931.0A CN201110073931A CN102190643B CN 102190643 B CN102190643 B CN 102190643B CN 201110073931 A CN201110073931 A CN 201110073931A CN 102190643 B CN102190643 B CN 102190643B
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- alkynyl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 143
- 230000000259 anti-tumor effect Effects 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- -1 methoxyl group Chemical group 0.000 claims description 279
- 229910052739 hydrogen Inorganic materials 0.000 claims description 147
- 239000001257 hydrogen Substances 0.000 claims description 146
- 125000000304 alkynyl group Chemical group 0.000 claims description 100
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- 150000002431 hydrogen Chemical class 0.000 claims description 69
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 66
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 48
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 abstract description 2
- 229910052727 yttrium Inorganic materials 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 318
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 286
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 202
- 239000000243 solution Substances 0.000 description 193
- 238000003786 synthesis reaction Methods 0.000 description 149
- 230000015572 biosynthetic process Effects 0.000 description 145
- 239000002585 base Substances 0.000 description 140
- 235000019439 ethyl acetate Nutrition 0.000 description 137
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 135
- 238000003756 stirring Methods 0.000 description 112
- 238000005160 1H NMR spectroscopy Methods 0.000 description 111
- 238000000034 method Methods 0.000 description 92
- 239000000203 mixture Substances 0.000 description 87
- 239000011734 sodium Substances 0.000 description 82
- 239000012071 phase Substances 0.000 description 77
- 239000003921 oil Substances 0.000 description 76
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 238000004440 column chromatography Methods 0.000 description 56
- JESXATFQYMPTNL-UHFFFAOYSA-N 2-ethenylphenol Chemical compound OC1=CC=CC=C1C=C JESXATFQYMPTNL-UHFFFAOYSA-N 0.000 description 52
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000011541 reaction mixture Substances 0.000 description 51
- 239000012074 organic phase Substances 0.000 description 50
- 230000008569 process Effects 0.000 description 50
- 238000003818 flash chromatography Methods 0.000 description 47
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 46
- 125000003118 aryl group Chemical group 0.000 description 45
- 238000001035 drying Methods 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 43
- 239000012043 crude product Substances 0.000 description 43
- 125000000623 heterocyclic group Chemical group 0.000 description 43
- 239000000284 extract Substances 0.000 description 41
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 38
- 229910052736 halogen Inorganic materials 0.000 description 38
- 150000002367 halogens Chemical class 0.000 description 38
- 229920006395 saturated elastomer Polymers 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 35
- 125000000217 alkyl group Chemical group 0.000 description 34
- 239000007864 aqueous solution Substances 0.000 description 34
- 230000009467 reduction Effects 0.000 description 33
- 238000009834 vaporization Methods 0.000 description 33
- 230000008016 vaporization Effects 0.000 description 33
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 229910052760 oxygen Inorganic materials 0.000 description 30
- 0 C*C(C(*)[C@]1C2C(*)C1C*)OC2=O Chemical compound C*C(C(*)[C@]1C2C(*)C1C*)OC2=O 0.000 description 28
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 28
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 25
- 150000002148 esters Chemical class 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- 125000002769 thiazolinyl group Chemical group 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 229910052786 argon Inorganic materials 0.000 description 19
- 230000000903 blocking effect Effects 0.000 description 19
- 238000004140 cleaning Methods 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 19
- 239000007789 gas Substances 0.000 description 19
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 18
- 125000004429 atom Chemical group 0.000 description 18
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 17
- 150000001299 aldehydes Chemical class 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 16
- 239000000376 reactant Substances 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 229910052731 fluorine Inorganic materials 0.000 description 14
- 230000007935 neutral effect Effects 0.000 description 14
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
- 235000019270 ammonium chloride Nutrition 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 239000011737 fluorine Substances 0.000 description 13
- 239000012266 salt solution Substances 0.000 description 13
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 13
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 12
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 12
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 12
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 12
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 6
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 5
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 5
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 150000003014 phosphoric acid esters Chemical class 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 230000002633 protecting effect Effects 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 4
- 150000003333 secondary alcohols Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 3
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- BLEYHULIDORYOY-UHFFFAOYSA-N CC(C(I)=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I Chemical compound CC(C(I)=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I BLEYHULIDORYOY-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 150000003448 sulfenic acid esters Chemical class 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LURSSRBNTGOWFV-UHFFFAOYSA-N C=C.[I] Chemical compound C=C.[I] LURSSRBNTGOWFV-UHFFFAOYSA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- PYXIDNGUMUYAQO-UHFFFAOYSA-N Cl.C1(C=CC=C1)[Zr+3] Chemical compound Cl.C1(C=CC=C1)[Zr+3] PYXIDNGUMUYAQO-UHFFFAOYSA-N 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- 241001092040 Crataegus Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010012944 Tetragastrin Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- QKNDAUTYSODFJV-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;sodium Chemical compound [Na].C[Si](C)(C)N[Si](C)(C)C QKNDAUTYSODFJV-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 235000019628 coolness Nutrition 0.000 description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- TZMFJUDUGYTVRY-UHFFFAOYSA-N ethyl methyl diketone Natural products CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- 229960005499 (+)-discodermolide Drugs 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- NHOWDZOIZKMVAI-UHFFFAOYSA-N (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol Chemical compound C=1N=CN=CC=1C(C=1C(=CC=CC=1)Cl)(O)C1=CC=C(Cl)C=C1 NHOWDZOIZKMVAI-UHFFFAOYSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- IBFDLVHJHUMSAC-UPHRSURJSA-N (z)-3-iodoprop-2-enoic acid Chemical compound OC(=O)\C=C/I IBFDLVHJHUMSAC-UPHRSURJSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XJKSTNDFUHDPQJ-UHFFFAOYSA-N 1,4-diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 XJKSTNDFUHDPQJ-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- MFVOUINLZVZHIP-UHFFFAOYSA-N 1-[hydroxysulfanyl(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(SO)(C=1C=CC=CC=1)C1=CC=CC=C1 MFVOUINLZVZHIP-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 1
- FSDCOFYXQALRJL-UHFFFAOYSA-N 1-chloroaziridine-2,3-dione Chemical class ClN1C(=O)C1=O FSDCOFYXQALRJL-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- BGUAPYRHJPWVEM-UHFFFAOYSA-N 2,2-dimethyl-4-pentenoic acid Chemical compound OC(=O)C(C)(C)CC=C BGUAPYRHJPWVEM-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- DBRDEBUVFZJFQV-UHFFFAOYSA-N 2-chloro-2-(4-methylphenoxy)acetic acid Chemical compound CC1=CC=C(OC(Cl)C(O)=O)C=C1 DBRDEBUVFZJFQV-UHFFFAOYSA-N 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 1
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LDZNCSVWVMBVST-UHFFFAOYSA-N 2-trimethylsilylethyl hydrogen carbonate Chemical compound C[Si](C)(C)CCOC(O)=O LDZNCSVWVMBVST-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HIWIIHPKFGJZSX-UHFFFAOYSA-N 9-phenyl-9h-thioxanthene Chemical compound C12=CC=CC=C2SC2=CC=CC=C2C1C1=CC=CC=C1 HIWIIHPKFGJZSX-UHFFFAOYSA-N 0.000 description 1
- BDOPDUBMAGITMI-UHFFFAOYSA-N 9h-fluoren-9-yl methyl carbonate Chemical compound C1=CC=C2C(OC(=O)OC)C3=CC=CC=C3C2=C1 BDOPDUBMAGITMI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- RTWUFWJHIKJKJD-UHFFFAOYSA-N CC(C)(C)C(C(OCCC=C)=O)NC Chemical compound CC(C)(C)C(C(OCCC=C)=O)NC RTWUFWJHIKJKJD-UHFFFAOYSA-N 0.000 description 1
- YEBMYTUSVVFYHN-JHJMLUEUSA-N CC(C)(C)[C@@H](C(O)OCCC=C)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(O)OCCC=C)NC(OC(C)(C)C)=O YEBMYTUSVVFYHN-JHJMLUEUSA-N 0.000 description 1
- PBGDRNXXVIESHZ-NONLVXQPSA-N C[C@H](C(CC=C1OC)OC1O)/C=C/I Chemical compound C[C@H](C(CC=C1OC)OC1O)/C=C/I PBGDRNXXVIESHZ-NONLVXQPSA-N 0.000 description 1
- XUAPIOBVRVIRJR-WRSFFWLLSA-N C[C@H]([C@H](CC=C1OC)OC1=O)/C=C(\C)/C#C Chemical compound C[C@H]([C@H](CC=C1OC)OC1=O)/C=C(\C)/C#C XUAPIOBVRVIRJR-WRSFFWLLSA-N 0.000 description 1
- MLLLPJUWXUDVCQ-BDOJOPHNSA-N C[C@H]([C@H](CC=C1OC)OC1=O)/C=C(\C)/C=C\C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C\C)O)=O)=O Chemical compound C[C@H]([C@H](CC=C1OC)OC1=O)/C=C(\C)/C=C\C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C\C)O)=O)=O MLLLPJUWXUDVCQ-BDOJOPHNSA-N 0.000 description 1
- GIYYEWGVENMUSX-BZOHSWPFSA-N C[C@H]([C@H](CC=C1OC)OC1=O)/C=C\C#C/C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C\C)O)=O)=O Chemical compound C[C@H]([C@H](CC=C1OC)OC1=O)/C=C\C#C/C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C\C)O)=O)=O GIYYEWGVENMUSX-BZOHSWPFSA-N 0.000 description 1
- RJZGSOUHMILRMA-OMZXRMGVSA-N C[C@H]([C@H](CC=C1OC)OC1=O)/C=C\C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C(\C)/Cl)O)=O)=O Chemical compound C[C@H]([C@H](CC=C1OC)OC1=O)/C=C\C=C/C(N[C@@H](C(C)(C)C)C(N/C=C\C[C@H](C/C=C(\C)/Cl)O)=O)=O RJZGSOUHMILRMA-OMZXRMGVSA-N 0.000 description 1
- 241000862992 Chondromyces Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical class C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 241001290275 Discodermia dissoluta Species 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DPSPDGWFQCKLBQ-UHFFFAOYSA-N ICC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I Chemical compound ICC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I DPSPDGWFQCKLBQ-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- ULWYIVYFPIPRRK-UHFFFAOYSA-N N1C=CC=CC=C1.[S] Chemical compound N1C=CC=CC=C1.[S] ULWYIVYFPIPRRK-UHFFFAOYSA-N 0.000 description 1
- DOTUPSMWKZFYEY-UHFFFAOYSA-N NC(C(Cc1c[nH]c2ccccc12)NC(C(CCC1)N1C(CCCCCc1ccccc1)=O)=O)=O Chemical compound NC(C(Cc1c[nH]c2ccccc12)NC(C(CCC1)N1C(CCCCCc1ccccc1)=O)=O)=O DOTUPSMWKZFYEY-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical group OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Natural products OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LGASALULTQVJOF-UHFFFAOYSA-N [O]C(=O)CCl Chemical compound [O]C(=O)CCl LGASALULTQVJOF-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N alpha-naphthoic acid Natural products C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- POVMLHUBPOZMEP-UHFFFAOYSA-N azanide;cobalt(2+) Chemical compound [NH2-].[NH2-].[Co+2] POVMLHUBPOZMEP-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- USKRHFHDJIMKIB-UHFFFAOYSA-N butyl 2-methylpropyl carbonate Chemical compound CCCCOC(=O)OCC(C)C USKRHFHDJIMKIB-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940126082 compound 92a Drugs 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229930186592 crocacin Natural products 0.000 description 1
- YIOSSWUAQNGRSJ-UHFFFAOYSA-N crocacin D Natural products COC(=O)CNC(=O)CCCC=CNC(=O)C=C(C)C=CC(C)C(OC)C(C)C(OC)C=CC1=CC=CC=C1 YIOSSWUAQNGRSJ-UHFFFAOYSA-N 0.000 description 1
- XHTUDGVBJDVOEZ-PSXYSELWSA-N crocacin-a Chemical compound COC(=O)CNC(=O)\C=C/C\C=C/NC(=O)/C=C(\C)/C=C/[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC)\C=C\C1=CC=CC=C1 XHTUDGVBJDVOEZ-PSXYSELWSA-N 0.000 description 1
- YIOSSWUAQNGRSJ-NRHCNNMKSA-N crocacin-d Chemical compound COC(=O)CNC(=O)CCC\C=C/NC(=O)/C=C(\C)/C=C/[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC)\C=C\C1=CC=CC=C1 YIOSSWUAQNGRSJ-NRHCNNMKSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZXSBDSGRQIWJPM-UHFFFAOYSA-N dimethylcarbamothioic s-acid Chemical compound CN(C)C(S)=O ZXSBDSGRQIWJPM-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- IFEOPCSQTDOBQW-UHFFFAOYSA-N ethyl 2-[ethylidene(diphenyl)-$l^{5}-phosphanyl]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1P(=CC)(C=1C=CC=CC=1)C1=CC=CC=C1 IFEOPCSQTDOBQW-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- IDNUEBSJWINEMI-UHFFFAOYSA-N ethyl nitrate Chemical compound CCO[N+]([O-])=O IDNUEBSJWINEMI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MEEWSBNOBXBASQ-UHFFFAOYSA-M fluoromethanesulfonate Chemical compound [O-]S(=O)(=O)[CH]F MEEWSBNOBXBASQ-UHFFFAOYSA-M 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- OGQVROWWFUXRST-UHFFFAOYSA-N hepta-1,3-diene Chemical compound CCCC=CC=C OGQVROWWFUXRST-UHFFFAOYSA-N 0.000 description 1
- ZGXMNEKDFYUNDQ-UHFFFAOYSA-N hepta-1,5-diene Chemical compound CC=CCCC=C ZGXMNEKDFYUNDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- XTBFPVLHGVYOQH-UHFFFAOYSA-N methyl phenyl carbonate Chemical compound COC(=O)OC1=CC=CC=C1 XTBFPVLHGVYOQH-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 1
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical compound OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZBOGUDPFEVIZIQ-UHFFFAOYSA-N toluene;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC=C1 ZBOGUDPFEVIZIQ-UHFFFAOYSA-N 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
Description
Invention field
The present invention relates to a kind of new antineoplastic compound, the pharmaceutical composition containing this antineoplastic compound and they are as the purposes of antineoplastic agent.
Background of invention
In nineteen ninety, Gunasekera SP etc. reports and isolate a kind of polyhydroxylated lactone newly from the Caribbean Sea sponge Discodermia dissoluta of deepwater field, (+) discodermolide (J.Org.Chem.1990 such as Gunasekera SP, 55,4912-4915 and J.Org.Chem.1991,56,1346).
Having disclosed this compound is a kind of potential antimitotic agent (Chem.Biol.1996 such as Hung DT, 3, the Biochemistry 1996 such as 287-293 and ter Haar E, 35,243-250), have and binding mode (Nature1979 such as Schiff PB, 277,665-667) like the taxanes proving carcinostatic agent clinically.Two kinds of natural products all by cell cycle arrest in the M phase, promote the formation of microtubule and to mammary cancer malignant tumour, there is similar inhibition (IC
50be respectively 2.4nM and 2.1nM).
On the other hand; some rare linear dipeptides containing N-acyl group alkene acid amides (N-acyl enamide) functional group have been subordinated in the slime bacteria of Chondromyces separates the (J.Antibiot.1994 such as Kunze B; 47; J.Org.Chem.1999, the 1085-1089 such as 881-886 and Jansen R).Specifically, these compounds are crocacin A, B, C and D, and are that an electron-like transmits inhibitor.
Crocacins A-D moderately inhibits the growth of some gram positive bacteriums, and is effective inhibitor of animal cell culture and some yeast and fungi.The most effectively crocacin D, the minimal inhibitory concentration (MIC) of its antimycotic yeast saccharomyces cerevisiae is 1.4ng/mL, and demonstrates strong toxicity (IC to L929 l cell culture
50for 0.06mg/L).
(the Russian Journal of Bioorganic Chemistry such as Gudasheva, 2007,44 (4), 413-420, with Pharmaceutical Chemistry Journal, 2006,40 (7), 367-372) design of the dipeptide compound based on interior raw tetrapeptide cholecystokinin-4 (CKK-4) structure is reported.In this respect, disclosed L-Trp derivative and had anxiety performance, D-trp derivative has growth-promoting anxiety performance.Disclosed two dipeptide compounds such as Gudasheva are as follows:
compound R
compound U
And the following compound disclosed as intermediate in the synthesis of compound R and U:
compound S
compound T
compound V
compound W
compound Y
compound Z
Cancer is animals and humans main causes of death.In order to obtain the antineoplastic agent that effectively and safely can be applied to the patient suffering from cancer, people have paid and have paid huge effort.The technical problem to be solved in the present invention is to provide the compound being used for the treatment of cancer.
Summary of the invention
On the one hand, the present invention relates to compound or its pharmacy acceptable salt, tautomer, prodrug or the steric isomer of general formula I,
Wherein, Y is selected from-CHR
ay-,-CHR
ay-CHR
by-,-CR
ay=CR
by-,-C ≡ C-,-CHR
ay-CHR
by-CHR
cy-,-CHR
ay-CR
by=CR
cy-and-CHR
ay-C ≡ C-;
R
ay, R
byand R
cyall independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl and substituted or unsubstituted C
2-C
12alkynyl;
R
1, R
2, R
3, R
4and R
5all independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl and substituted or unsubstituted C
2-C
12alkynyl;
R
6be selected from NR
8r
9and OR
10;
A is selected from
W is selected from O and NR
7:
R
7be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; Or, R
7and R
5and the corresponding atom N to be connected with them forms substituted or unsubstituted heterocyclic group together with C atom;
R
8be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base;
R
10be selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
The key that each represented by dotted arrows optionally adds, but work as and R
1and R
2when there is a triple bond between the carbon atom connected, R
1and R
2non-existent, when with R
3and R
4when there is a triple bond between the carbon atom connected, R
3and R
4non-existent;
And
When A is
time, so
R
9be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base, condition is, when Y is-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-and with R
3and R
4when there is singly-bound or double bond between the carbon atom connected, R
9substituted or unsubstituted C
4-C
12ene alkynyl base, and
When A is
time, so
R
9be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base;
R
16, R
17and R
18all independently selected from hydrogen, OR
a, OCOR
a, OCOOR
a, NR
ar
b, NR
acOR
band NR
ac (=NR
a) NR
ar
b, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl and substituted or unsubstituted C
2-C
12alkynyl;
R
19be selected from hydrogen, COR
a, COOR
a, CONR
ar
b, S (O) R
a, SO
2r
a, P (O) (R
a) OR
b, SiR
ar
br
c, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl and substituted or unsubstituted C
2-C
12alkynyl; And
R
a, R
band R
call independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group.
On the other hand, the present invention also relates to the compound of a kind of formula I as drug use, or its pharmacy acceptable salt, tautomer, prodrug or steric isomer.
On the other hand, the present invention also relates to a kind of compound being used as the general formula I of the medicine of Therapeutic cancer, or its pharmacy acceptable salt, tautomer, prodrug or steric isomer.
Another aspect, the present invention also relates to the compound of general formula I, its pharmacy acceptable salt, tautomer, prodrug or steric isomer at Therapeutic cancer or for the preparation of the application in the medicine of Therapeutic cancer.Other aspects of the present invention are methods for the treatment of and for the compound in these methods.Therefore, present invention provides a kind of method that treatment suffers from any Mammals, the particularly people of cancer, the method comprises the compound of the general formula I to this diseased individuals administering therapeutic significant quantity, or its pharmaceutically acceptable salt, tautomer, prodrug or steric isomer.
On the other hand, the present invention also relates to a kind of compound being used as the general formula I of carcinostatic agent, or its pharmacy acceptable salt, tautomer, prodrug or steric isomer.
On the other hand, the present invention relates to a kind of pharmaceutical composition, it includes compound or its pharmacy acceptable salt, tautomer, prodrug or the steric isomer of general formula I, and pharmaceutically acceptable carrier or thinner.
Preferred implementation describes in detail
The present invention relates to the compound of general formula I as defined above.
In these compounds, group can be selected according to following criterion:
Alkyl can be side chain or straight chain, and preferably has 1 to about 12 carbon atoms.The preferred alkyl group of one class has 1 to about 6 carbon atoms.It is even furthermore preferable that have the alkyl group of 1,2,3 or 4 carbon atom.Methyl, ethyl, propyl group, sec.-propyl and the butyl comprising the tertiary butyl, sec-butyl and isobutyl-are particularly preferred alkyl in compound of the present invention.Another kind of preferred alkyl group has 6 to about 10 carbon atoms, and more preferably has 7,8 or 9 carbon atoms.Heptyl, octyl group and nonyl be this kind of in preferred alkyl.
In compound of the present invention, preferred thiazolinyl and alkynyl can be side chain or straight chain, have one or more unsaturated link(age), and have 2 to about 12 carbon atoms.The preferred thiazolinyl of one class and alkynyl group have the carbon atom of 2 to about 6.More preferably there is thiazolinyl and the alkynyl group of 2,3 or 4 carbon atoms.Another kind of preferred thiazolinyl and alkynyl group have 4 to about 10 carbon atoms, are more preferably and have 6 to about 10 carbon atoms; And most preferably there are 7,8 or 9 carbon atoms.
Ene alkynyl base group definition is the alkyl group containing one or more double bond and one or more triple bond by we, and preferred Ene alkynyl base group is those groups with 4 to about 12 carbon atoms.The preferred Ene alkynyl base group of one class has 6 to about 10 carbon atoms.
The aromatic yl group be applicable in compound of the present invention comprises the compound of monocycle or many rings, comprises the polynuclear compound containing independence and/or fused-aryl group.Typical aromatic yl group comprises 1-3 independence or the ring that condenses and has 6 to about 18 carboatomic ring atoms.Preferred aromatic yl group comprises 6 to about 10 carboatomic ring atoms.Particularly preferred aromatic yl group comprises substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted xenyl, substituted or unsubstituted phenanthryl, substituted or unsubstituted anthryl.
The heterocyclic group be applicable to comprises containing 1-3 independent ring or fused rings and has heteroaryl and the heteroalicyclic group of 5-18 annular atoms.Preferred heteroaryl and heteroalicyclic group contain 5 to about 10 annular atomses, most preferably 5,6 or 7 annular atomses.The heteroaryl be applicable in compound of the present invention contains and is selected from N, one of O or S atom, two or three heteroatomss, and comprise such as: the tonka bean camphor base comprising 8-tonka bean camphor base, comprise the quinolyl of 8-quinolyl, isoquinolyl, pyridyl, pyrazinyl, pyrazolyl, pyrimidyl, furyl, pyrryl, thienyl, thiazolyl, isothiazolyl, triazolyl, tetrazyl, isoxazolyl, oxazolyl, imidazolyl, indyl, pseudoindoyl, indazolyl, indolizine base, phthalazinyl, pteridyl, purine radicals, oxadiazolyl, thiadiazolyl group, furan a word used for translation base, pyridazinyl, triazinyl, cinnolines base, benzimidazolyl-, benzofuryl, benzo furan a word used for translation base, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolyl, quinoxalinyl, naphthyridinyl, and furopyridyl.The heteroalicyclic group be applicable in compound of the present invention comprises one, two or three heteroatomss being selected from N, O or S atom, and comprises such as pyrrolidyl, tetrahydrofuran base, dihydrofuran base, tetrahydro-thienyl, tetrahydro thiapyran base, piperidyl, morpholinyl, thio-morpholinyl, thioxane base, piperazinyl, azetidinyl, oxetanyl, Thietane base, homopiperidinyl (homopiperidyl), amylene oxide base, thia cyclohexyl, oxaza heptane base, diaza
base, sulphur azepine
base, 1,2,3,6-tetrahydro pyridyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxane base, DOX base, pyrazolinyl, dithiane base, dithiolane base, dihydro pyranyl, dihydro-thiophene base, dihydrofuran base, pyrazolidyl, imidazolinyl, imidazolidyl, 3-azabicyclic [3.1.0] hexyl, 3-azabicyclic [4.1.0] heptyl, 3H-indyl and quinolizinyl.
Above-mentioned group can be replaced by one or more applicable group in one or more available position, described group such as OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R, shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclic group, wherein, each R ' group is independently selected from following groups: hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO alkyl, CO
2h, substituted or unsubstituted C
1-C
12thiazolinyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclic group.When these groups are substituted self, substituting group can be selected from above-mentioned list.
The halogenic substituent be applicable in compound of the present invention comprises F, Cl, Br and I.
The OH protecting group be applicable to is known to those skilled in the art.Wuts, PGM and Greene TW in " blocking group in organic synthesis " of the 4th edition Wiley-Interscience and Kocienski PJ all delivered in " blocking group " of the 3rd edition Georg Thieme Verlag in organic chemistry protecting group general introduction.These documents disclose the part about OH protecting group.The full content of all these documents is incorporated to herein in the mode quoted as proof.The example of this OH blocking group comprises ether, silyl ether, ester, sulphonate, sulfenic acid ester and-sulfinic acid ester, carbonic ether, carbamate.When ether, the blocking group of OH can be selected from methyl, methoxymethyl, methylthiomethyl, (xylylene silane) methoxymethyl, benzyloxymethyl, to Methoxybenzyloxymethyl, [(3,4-dimethoxy benezene) oxygen base] methyl, to nitro benzyloxymethyl, adjacent nitro benzyloxymethyl, [(R)-1-(2-nitrophenyl) oxyethyl group] methyl, (4-methoxyphenoxy) methyl, [(to phenyl) oxygen base] methyl, t-butoxymethyl, 4-amylene yloxymethyl, silica methyl, 2-methoxvethoxvmethvl, 2-cyanoethoxy methyl, two (2-Chloroethoxy) methyl, 2,2,2-tri-chloro ethoxyl methyl, 2-(trimethyl silyl) ethoxyl methyl, peppermint oxygen ylmethyl, o-two (2-acetoxyethoxy) methyl, THP trtrahydropyranyl, fluoridize THP trtrahydropyranyl, 3-bromo THP trtrahydropyranyl, tetrahydro thiapyran base, 1-methoxycyclohexyl, 4-methoxyl group THP trtrahydropyranyl, 4-methoxyl group tetrahydro thiapyran base, 4-methoxyl group tetrahydro thiapyran base, S, S-dioxide, 1-[(2-chloro-4-methyl) phenyl]-4-methoxy piperide-4-base, 1-(2-difluorophenyl)-4-methoxy piperide-4-base, 1-(4-chlorophenyl)-4-methoxy piperide-4-base, Isosorbide-5-Nitrae-diox-2-base, tetrahydrofuran base, tetrahydrochysene thio-furan base, 2,3,3 α, 4,5,6,7,7 α-octahydro-7,8,8-trimethylammonium-4,7-methylenebenzofuran-2-bases, 1-ethoxyethyl group, 1-(2-Chloroethoxy) ethyl, 2-hydroxyethyl, 2-bromoethyl, 1-[2-(trimethyl silyl) oxyethyl group] ethyl, 1-methyl isophthalic acid-methoxy ethyl, 1-methyl isophthalic acid-Benzyloxyethyl, 1-methyl isophthalic acid-benzyloxy-2-fluoroethyl groups, 1-methyl isophthalic acid-Phenoxyethyl, 2,2,2-tri-Chloroethyl, 1,1-veratryl-2,2,2-tri-Chloroethyl, 1,1,1,3,3,3-hexafluoro--2-propyloxy phenyl base, 1-(2-cyanoethoxy) ethyl, 2-trimethylsilyethyl, 2-(phenmethyl sulfo-) ethyl, 2-phenylselenyl ethyl, the tertiary butyl, cyclohexyl, 1-methyl isophthalic acid '-Cvclopropvlmethvl, allyl group, prenyl, cinnamyl, 2-cinnamyl, propargyl, p-chlorophenyl, p-p-methoxy-phenyl, p-nitrophenyl, 2,4-dinitrophenyl, 2,3,5,6-tetra-fluoro-4-(trifluoromethy) phenyl, phenmethyl, p-mehtoxybenzyl, 3,4-dimethoxy benezene, 2,6-dimethoxy benezene, o-oil of mirbane methyl, p-oil of mirbane methyl, pentadienyl oil of mirbane methyl, pentadienyl nitropiperonyl, halogeno-benzene methyl, 2,6-dichlorobenzene methyl, 2,4-dichlorobenzene methyl, 2,6-phenyl-difluoride methyl, p-cyanobenzyl, benzyl, 4-Fluoroalkyloxy phenmethyl, trimethyl silyl xylyl, to phenylphenylmethyl, 2-phenyl-2-propyl group, to amide group phenmethyl, to triazobenzene methyl, 4-azido--3-chlorphenylmethyl, 2-trifluoromethy phenmethyl, 4-trifluoromethy phenmethyl, p-(methyl sulfinyl) phenmethyl, p-silicon is for tetramethylene base phenmethyl, 4-acetoxyl group phenmethyl, 4-(2-trimethyl silyl) oxyethyl group mehtoxybenzyl, 2-naphthyl methyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, 2-quinolyl methyl, 6-methoxyl group-2-(4-aminomethyl phenyl-4-quinolylmethyl, 1-pyrenylmethy, diphenyl methyl, 4-methoxyl group diphenyl methyl, 4-phenyl diphenyl methyl, p, p '-dinitrobenzene diphenyl-methyl, 5-dibenzocycloheptyl, trityl group, three (4-tert-butyl-phenyl) methyl, Alpha-Naphthyl diphenyl methyl, p-p-methoxy-phenyl diphenyl-methyl, two (p-p-methoxy-phenyl) phenyl methyl, three (p-p-methoxy-phenyl) methyl, 4-(4 '-bromobenzene acyloxy) phenyl diphenyl methyl, 4,4 ', 4 "-three (4,5-dichloro-phthalimido phenyl) methyl, 4,4 ', 4 "-three (levulinic acyl-oxygen phenyl) methyl, 4,4 ', 4 "-three (benzoyloxy phenyl) methyl, 4,4 '-dimethoxy-3 "-[(TMSIM N imidazole ylmethyl)] trityl, 4,4 '-dimethoxy-3 "-[(TMSIM N imidazole base ethyl) carbamyl] trityl, two (4-p-methoxy-phenyls)-1 '-pyrenylmethy, 4-(17-tetra-benzo [a, c, g, i] fluorenyl methyl)-4,4 "-dimethoxytrityl, 9-anthryl, 9-(9-phenyl) xanthenyl, 9-phenylthioxanthen base, 9-(9-phenyl-10-oxo) anthryl, 1,3-benzo dithiolane-2-base, and 4,5-bis-(ethoxy carbonyl)-[1,3]-dioxolane-2-base, benzisothiazole base S, S-dioxide.When silyl ether, blocking group for OH can be selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexanyl silylation, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzyl silyl, three-p-Xylol base silyl, triphenyl-silyl, diphenylmethylsilyl, di-t-butyl methyl-silicane base, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1, 1, 3, 3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group) sily oxide-1-base, with fluorine silyl.In the case of the esters, the blocking group of OH can be selected from manthanoate, benzoyl formate, acetic ester, chloracetic acid ester, dichloro-acetic ester, trichloroacetic acid ester, three chloro acetimide esters, trifluoroacetic acid ester, methoxyacetic acid ester, triphenylmethoxy acetic ester, phenylium ester, p-chlorinated benzene ethoxyacetic acid ester, phenylacetate, diphenyl acetic acid ester, 3-Phenpropionate, difluoro chain propionyl, 4-pentenoate, 4-oxy pentanoic acid ester, 4,4-(vinyl dithio) valerate, 5-[3-bis-(4-p-methoxy-phenyl) hydroxymethylphenoxy] levulinate, pivalate, 1-Buddha's warrior attendant acid esters, crotonate, 4-methoxyl group crotonate, benzoic ether, para Toluic Acid's phenyl ester, mesitylene carboxylic acid ester, 4-bromo benzoic ether, 2,5-difluorobenzoic acid ester, p-nitrobenzoyl acid esters, picolinic acid ester, nicotinate, 2-(azido methyl) benzoic ether, 4-azido-butyric ester, (2-azido methyl) phenylacetic acid ester, 2-{ [(trityl sulfo-) oxygen] methyl } benzoic ether, 2-{ [(4-Methoxytrityl sulfo-) oxygen] methyl } benzoic ether, 2-{ [methyl (trityl sulfo-) is amino] methyl } benzoic ether, 2-{{ [(4-Methoxytrityl) sulfo-] methylamino }-methyl } benzoic ether, 2-(allyloxy) phenylacetic acid ester, 2-(isoamyl () dialkylene oxygen ylmethyl) benzoic ether, 6-(acetyl-propionyl yloxymethyl)-3-methoxyl group-2-nitrobenzoyl acid esters, 6-(acetyl-propionyl yloxymethyl)-3-methoxyl group-4-nitrobenzoyl acid esters, 4-benzyloxy butyric ester, 4-trialkyl silica oxyalkyl butyric ester, 4-acetoxyl group-2,2-dimethyl butyrate acid esters, 2,2-dimethyl-4-pentenoate, 2-iodobenzoic acid ester, 4-nitro-4-methyl valerate, o-(two bromomethyl) benzoic ether, 2-formylbenzene sulfonate, 4-(methyl thio methoxyl group) butyric ester, 2-(methyl thio methoxymethyl) benzoic ether, 2-(chloroacetyl oxygen ylmethyl) benzoic ether, 2-[(2-chloroacetyl oxygen base) ethyl] benzoic ether, 2-[2-(benzyloxy) ethyl] benzoic ether, 2-[2-(4-methoxyl group benzyloxy) ethyl] benzoic ether, the chloro-4-methylphenoxyacetate of 2,6-bis-, the chloro-4-of 2,6-bis-(1,1,3,3-tetramethyl butyl) phenylium ester, 2,4-bis-(1,1-methyl-propyl) phenylium ester, chloro diphenyl acetic acid ester, isobutyrate, monosuccinic acid ester, (E)-2-methyl-2-butene acid esters, adjacent (methoxycarbonyl) benzoic ether, α-naphthoicacid ester, nitric ether, alkyl N, N, N ', N '-tetramethyl-phosphorodiamidite and 2-Chlorobenzoic Acid ester.When sulphonate, sulfenic acid ester and-sulfinic acid ester; the blocking group of OH is optional from sulfuric ester, allyl sulphonic acid ester, methane sulfonate, phenmethyl sulphonate, tosylate, 2-[(4-nitrophenyl) ethyl] sulphonate, 2-trifluoromethy benzene sulfonate, 4-monomethoxytrityl sulfenic acid ester, alkyl 2; 4-dinitrophenyl sulfenic acid ester, 2; 2; 5,5-tetramethylpyrrolidi-e-3-ketone-1--sulfinic acid ester, boric acid ester and dimethyl sulphide phosphino-.When carbonic ether, the blocking group of OH can be selected from methyl carbonate, carbonic acid methoxyl group methyl esters, carbonic acid 9-fluorenyl methyl ester, ethyl-carbonate, carbonic acid bromine ethyl ester, carbonic acid 2-(methyl thio methoxyl group) ethyl ester, carbonic acid 2,2,2-tri-chloro ethyl ester, carbonic acid 1,1-dimethyl-2,2,2-tri-chloro ethyl ester, carbonic acid 2-(trimethyl silyl) ethyl ester, carbonic acid 2-[dimethyl (2-menaphthyl) silyl] ethyl ester, carbonic acid 2-(benzenesulfonyl) ethyl ester, carbonic acid 2-(triphenyl phosphorus base) ethyl ester, cis-[4-[[(Methoxytrityl) methylthio group] oxygen] tetrahydrofuran (THF)-3-base] oxygen carbonic ether, isobutyl carbonate butyl ester, t-butyl carbonate, NSC 11801, allyl carbonate, carbonic acid cinnamic ester, carbonic acid alkynes propyl ester, rubigan carbonic ether, p-nitrophenyl carbonate, 4-oxyethyl group-1-naphthyl carbonic ether, 6-bromo-umbelliferone-4-ylmethyl carbonic ether, methyl phenyl carbonate, adjacent nitrobenzyl carbonic ether, p-nitrophenyl methyl carbonic, to mehtoxybenzyl carbonic ether, 3,4-dimethoxy benezene carbonic ether, anthraquinone-2 ylmethyl carbonic ether, carbonic acid 2-dansyl base ethyl ester, carbonic acid 2-(4-nitrophenyl) ethyl ester, carbonic acid 2-(2,4-dinitrophenyl) ethyl ester, carbonic acid 2-(2-nitrophenyl) propyl ester, alkyl carbonate 2-(3,4-methylene-dioxy-6-nitrophenyl) propyl ester, 2-cyano group-1-styroyl carbonic ether, 2-(2-pyridyl) amino-1-styroyl carbonic ether, 2-[N-methyl-N-(2-pyridyl)] amino-1-styroyl carbonic ether, carbonic acid phenacylate, 3 ', 5-dimethoxy st-yrax carbonic ether, dithiocarbonic acid methyl esters and S-phenmethyl thiocarbonic ester.And when carbamate, the blocking group of OH can be selected from dimethylthiocarbamate, N-phenylcarbamate, N-methyl-N-(O-Nitrophenylfluorone) carbamate.These groups mentioned should not be construed as limiting the scope of the invention; because enumerate the citing that they are only the blocking group to OH, other groups with described function known to those skilled in the art are also within protection scope of the present invention.
Term " pharmacy acceptable salt, prodrug " refers to any pharmacy acceptable salt, ester, solvate, hydrate or to any other compound that can provide (directly or indirectly) compound described herein during patient's dispenser.But be understandable that, in non-pharmaceutical, acceptable salt also drops within scope of invention, because they can be used for the preparation of pharmacy acceptable salt.The preparation of salt and prodrug is undertaken by method well known in the prior art.
Such as, the pharmacy acceptable salt of compound provided herein is synthesized by the parent compound comprising alkalescence or acidic moiety by the chemical process of routine.Usually, these salt are such as by making these compounds of free acid or alkali form in water or preparing with stoichiometric suitable alkali or acid-respons in organic solvent or in both mixtures.Usually, preferred non-aqueous media is as ether, vinyl acetic monomer, ethanol, Virahol or acetonitrile.The example of the salt of acid addition comprises: inorganic acid addition salt, such as hydrochloride, hydrobromate, hydriodate, vitriol, nitrate, phosphoric acid salt; Organic acid addition salt, example such as, acetate, trifluoroacetate, maleate, fumarate, Citrate trianion, oxalate, succinate, tartrate, malate, mandelate, methanesulfonates, tosilate.The example of base addition salt comprises: inorganic salt, such as sodium salt, sylvite, calcium salt, ammonium salt; Organic alkali salt, such as quadrol, thanomin, N, N-bis-alkylidene group thanomin, trolamine and alkaline amino acid salt.
Compound of the present invention can be crystallized form, and as free compound or solvate (such as hydrate), these two kinds of forms all within the scope of the invention.The method of solvation is widely known by the people in this area.
As any compound of formula I prodrug all in the scope and essence of this area.Term " prodrug " used in the application is defined herein as a kind of chemical compound, there is the chemically derived replacement as another chemical group or addition in it, to change its any one (medicinal) physical-chemical performance, as solubleness and bioavailability, such as, after being administered to main body, itself produce ester derivative and the ether derivant of the active compound of active compound.The example preparing the known method of the prodrug of given active compound is known to those skilled in the art, such as can at Krogsgaard-Larsen etc., Textbook of Drug design and Discovery (medicinal design and exploitation textbook), Taylor & Francis found in (in April, 2002).
Any compound related to herein is intended to represent this particular compound and some variant or form.Particularly, the compound mentioned herein can have center of asymmetry, therefore exists with different enantiomeric forms.The optical isomer and steric isomer and composition thereof of all compounds related to herein all comprise within the scope of the invention.Therefore, any specific compound related to herein is all intended to represent any one racemoid, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomer forms and composition thereof.Especially, the compound of the present invention of above-mentioned formula I representative, can comprise enantiomer according to its asymmetry or diastereomer.Stereoisomerism around double bond is also possible, and therefore in some cases, molecule can exist with (E)-isomer or (Z)-isomer.If molecule comprises multiple double bond, then each double bond will have its stereoisomerism, and this may be identical or different with the stereoisomerism of other double bonds of molecule.The mixture of individual isomer and isomer falls within the scope of the invention.
In addition, the compound mentioned herein can exist with geometrical isomer (i.e. cis and trans-isomer(ide)), tautomer or atropisomer.Specifically, term tautomer refers to one in two or more compound structure isomer, and it exists with equilibrium state and is converted to another kind from a kind of isomeric form easily.Common change is to being amine-imines, amide-imide, keto-enol, lactan-lactim etc.In addition, any compound mentioned herein is all intended to represent hydrate, solvate, polymorphic and their mixture when these forms exist in media as well.In addition, the compound mentioned herein can isotope-labeled form exist.All geometrical isomers of the compound related to herein, tautomer, atropisomer, hydrate, solvate, polymorphic, isotope labelled form and their mixture, all fall within the scope of the invention.
Describe accurately to provide, some quantitative expressions are not herein with term " about ".Be understandable that, no matter term " about " clearly uses or does not use, the each quantity provided herein means actual set-point, this also means the approximation that relate to these set-point can rationally known by inference according to the ordinary skill of this area, comprises due to the experiment of similar set-point and/or measuring condition and the equivalent value obtained and approximation.
In the compound of general formula I, particularly preferably Y is-CHR
ay-,-CR
ay=CR
by-and-CHR
ay-CR
by=CR
cy-, wherein R
ay, R
byand R
cydefinition as front.
Particularly preferably R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-C
12alkyl.Preferred R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-C
6alkyl, more preferably hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl and comprise the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-and substituted or unsubstituted sec-butyl.The preferred substituents of these groups is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or vicinal hydroxyl groups phenyl, comprise the indyl of 1-, 2-and 3-indoles, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen and methyl are most preferred R
ay, R
byand R
cygroup.Specifically, when Y is-CHR
ay-time, then particularly preferred R
ayit is methyl; When Y is-CR
ay=CR
by-time, then particularly preferably R
ayhydrogen, particularly preferably R
byit is methyl; When Y is-CHR
ay-CR
by=CR
cy-time, then particularly preferably R
ayhydrogen or methyl, particularly preferably R
byhydrogen, particularly preferably R
cyit is methyl.
Particularly preferably R
1, R
2, R
3, R
4and R
5hydrogen and substituted or unsubstituted C
1-C
12alkyl, more preferably R
1, R
2, R
3, R
4and R
5hydrogen and substituted or unsubstituted C
1-C
6alkyl, and to be more preferably be hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl and comprise the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-, substituted or unsubstituted sec-butyl.The preferred substituting group of described group be OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or vicinal hydroxyl groups phenyl, comprise the indyl of 1-, 2-and 3-indyl, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen, methyl, sec.-propyl, the tertiary butyl and phenmethyl are most preferred R
1, R
2, R
3, R
4and R
5group.Specifically, particularly preferred R
1, R
2, R
3, R
4hydrogen.Particularly preferably R
5methyl, sec.-propyl and the tertiary butyl.
Particularly preferably W is NR
7, wherein R
7as defined above.
Particularly preferably R
6nR
8r
9and OR
10, wherein R
8, R
9and R
10as defined above, and be more preferably R
6nR
8r
9.
Particularly preferably R
7and R
8hydrogen, and substituted or unsubstituted C
1-C
12alkyl.More preferably R
7and R
8hydrogen and substituted or unsubstituted C
1-C
6alkyl.To be more preferably be hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen is most preferred.
In another embodiment, particularly preferred, R
7and R
5and connected corresponding atom N forms replacement or unsubstituting heterocycle group together with C atom.In this respect, preferred heterocyclic group is such heterocyclic group, and it comprises one, two or three are selected from the heteroatoms of N, O or S atom, particularly preferably comprises an atom N, and this heterocyclic group has 5 to about 10 annular atomses, particularly preferably has 5,6 or 7 annular atomses.Pyrrolidino group is most preferred.
Particularly preferably be and there is other key one or more in position represented by dashed line.More preferably with R
1and R
2there is an other key between the C atom connected, and with R
3and R
4one or two other key is there is between the C atom connected.In addition, the three-dimensional arrangement of each double bond can (E) or (Z) exist.The mixture of individual isomer and this isomer also falls within the scope of the invention.
In compound, wherein A is
When Y is a)-CHR
ay-,-CHR
ay-CHR
by-,-CR
ay=CR
by-,-C ≡ C-or-CHR
ay-C ≡ C-; Or b)-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-, and with R
3and R
4between the carbon atom connected when there is triple bond, then particularly preferably R
9hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.More preferably hydrogen, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.The alkynyl of the alkyl of preferred replacement, the thiazolinyl of replacement, replacement, the Ene alkynyl base of replacement can exist not only one, but two or more substituting group.Preferred alkyl is that those have the group of 6 to about 10 carbon atoms, more preferably has the group of 7,8 and 9 carbon atoms.Heptyl, octyl group and nonyl are most preferred alkyl groups.On the other hand, preferred alkenyl group is that those have 6 to about 10 carbon atoms, more preferably the group of carbon atom of 7,8 or 9.Pungent-1,6-dialkylene, pungent-1,5-dialkylene, pungent-1,4-dialkylene, pungent-1,3-dialkylene, the ninth of the ten Heavenly Stems-1,7-dialkylene, the ninth of the ten Heavenly Stems-1,6-dialkylene, the ninth of the ten Heavenly Stems-1,5-dialkylene, the ninth of the ten Heavenly Stems-1,4-dialkylene, the ninth of the ten Heavenly Stems-butadienyl, heptan-1,5-dialkylene, heptan-1,4-dialkylene, heptan-butadienyl is most preferred alkenyl group.On the other hand, preferred alkynyl group is that those have the group of 6 to about 10 carbon atoms, more preferably has the group of 7,8 or 9 carbon atoms.Pungent-7-alkynyl, pungent-6 alkynyls, pungent-5-alkynyl, pungent-4-alkynyl, pungent-3-alkynyl, pungent-2-alkynyl, pungent-1-alkynyl, the ninth of the ten Heavenly Stems-8-alkynyl, the ninth of the ten Heavenly Stems-7-alkynyl, the ninth of the ten Heavenly Stems-6-alkynyl, the ninth of the ten Heavenly Stems-5-alkynyl, the ninth of the ten Heavenly Stems-4-alkynyl, the ninth of the ten Heavenly Stems-3-alkynyl, the ninth of the ten Heavenly Stems-2-alkynyl, the ninth of the ten Heavenly Stems-1-alkynyl, heptan-6-alkynyl, heptan-5-alkynyl, heptan-4-alkynyl, heptan-3-alkynyl, heptan-2-alkynyl, heptan-1-alkynyl be most preferred group.On the other hand, preferred Ene alkynyl base has 6 to about 10 carbon atoms, those of more preferably 7,8 or 9 carbon atoms.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.Preferred substituents for described alkyl, thiazolinyl, alkynyl and Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.Above-mentioned thiazolinyl, alkynyl, the preferred substituting group of Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.These alkyl, thiazolinyl, alkynyl and the preferred substituting group of Ene alkynyl base group are halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (TMS) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl, Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, wherein the blocking group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (TMS) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are these alkyl, thiazolinyl, alkynyl and the most preferred substituting group of Ene alkynyl base group.
When Y is-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-, and with R
3and R
4when there is singly-bound or double bond between the carbon atom connected, then R
9substituted or unsubstituted C
4-C
12ene alkynyl base.One, two or more substituting group can be there is in preferred replacement Ene alkynyl base.Preferred Ene alkynyl base group has 6 to about 10 carbon atoms, those of even more preferably 7,8 or 9 carbon atoms.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.The preferred substituents of described Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.The preferred substituting group of above-mentioned Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.The preferred substituting group of these Ene alkynyl base groups is halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl-dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (TMS) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl.Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, the blocking group wherein for OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl-dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are the most preferred substituting groups of these Ene alkynyl base groups.
Particularly preferably R
16hydrogen, OR
aand OCOR
a, wherein R
abe selected from hydrogen and substituted or unsubstituted C
1-C
12alkyl.Particularly preferably R
ahydrogen and substituted or unsubstituted C
1-C
6alkyl; Be more preferably hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen, OH and methoxyl group are most preferred R
16group.
Particularly preferably R
17and R
18hydrogen and substituted or unsubstituted C
1-C
12alkyl.More preferably R
17and R
18hydrogen and substituted or unsubstituted C
1-C
6alkyl.Be more preferably hydrogen.
On the other hand, in compound, A is
Particularly preferably R
9hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, replacement or do not replace C
4-C
12ene alkynyl base and be more preferably hydrogen, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, replacement or do not replace C
4-C
12ene alkynyl base.One, two or more substituting group can be there is in the alkynyl of the alkyl of preferred replacement, the thiazolinyl of replacement, replacement, the Ene alkynyl base of replacement.Preferred alkyl group has 6 to about 10 carbon atoms, those of even more preferably 7,8 or 9 carbon atoms.Heptyl, octyl group and nonyl are most preferred alkyl groups.On the other hand, preferred alkenyl group is that those have 6 to about 10 carbon atoms, more preferably the group of carbon atom of 7,8 or 9.Pungent-1,6-diene, pungent-1,5-diene, pungent-Isosorbide-5-Nitrae-diene, pungent-1,3-diene, the ninth of the ten Heavenly Stems-1,7-diene, the ninth of the ten Heavenly Stems-1,6-diene, the ninth of the ten Heavenly Stems-1,5-diene, the ninth of the ten Heavenly Stems-Isosorbide-5-Nitrae-diene, the ninth of the ten Heavenly Stems-1,3-diene, heptan-1,5-diene, heptan-Isosorbide-5-Nitrae-diene, heptan-1,3-diene be most preferred alkenyl group.On the other hand, preferred alkynyl group is that those have the group of 6 to about 10 carbon atoms, more preferably has 7,8 or 9 carbon atoms.Pungent-7-alkynyl, pungent-6 alkynyls, pungent-5-alkynyl, pungent-4-alkynyl, pungent-3-alkynyl, pungent-2-alkynyl, pungent-1-alkynyl, the ninth of the ten Heavenly Stems-8-alkynyl, the ninth of the ten Heavenly Stems-7-alkynyl, the ninth of the ten Heavenly Stems-6-alkynyl, the ninth of the ten Heavenly Stems-5 alkynyl, the ninth of the ten Heavenly Stems-4-alkynyl, the ninth of the ten Heavenly Stems-3-alkynyl, the ninth of the ten Heavenly Stems-2-alkynyl, the ninth of the ten Heavenly Stems-1-alkynyl, heptan-6-alkynyl, heptan-5-alkynyl, heptan-4-alkynyl, heptan-3-alkynyl, heptan-2-alkynyl, heptan-1-alkynyl be most preferred group.On the other hand, preferred Ene alkynyl base has 6 to about 10 carbon atoms, more preferably has 7,8 or 9 carbon atoms those.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.The preferred substituents of described alkyl, thiazolinyl, alkynyl and Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.Above-mentioned thiazolinyl, alkynyl, the preferred substituting group of Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.These alkyl, thiazolinyl, alkynyl and the preferred substituting group of Ene alkynyl base group are halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl.Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, wherein the blocking group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are these alkyl, thiazolinyl, alkynyl and the most preferred substituting group of Ene alkynyl base group.
Particularly preferably R
16hydrogen, OR
aand OCOR
a, wherein R
abe selected from hydrogen and substituted or unsubstituted C
1-C
12alkyl.Particularly preferably R
ahydrogen and substituted or unsubstituted C
1-C
6alkyl; Be more preferably hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen, OH and methoxyl group are most preferred R
16group.
Particularly preferably R
17and R
18hydrogen and substituted or unsubstituted C
1-C
12alkyl.More preferably R
19hydrogen, substituted or unsubstituted C
1-C
12alkyl and COR
a, wherein R
asubstituted or unsubstituted C
1-C
12alkyl.More preferably R
17and R
18hydrogen and substituted or unsubstituted C
1-C
6alkyl and more preferably R
19hydrogen, substituted or unsubstituted C
1-C
6alkyl and COR
a, wherein R
asubstituted or unsubstituted C
1-C
6alkyl.Particularly preferably R
afor methyl, ethyl, propyl group, sec.-propyl and the butyl comprising the tertiary butyl.More preferably R
17, R
18and R
19for hydrogen.
Particularly preferably, there is one or more other key in position represented by dashed line.More preferably with R
1and R
2there is an other key between the carbon atom connected, with R
3and R
4one or two other key is there is between the carbon atom connected.In addition, the three-dimensional arrangement of each double bond can (E) or (Z) exist.The mixture of individual isomer and this isomer also falls within the scope of the invention.
Specifically, the preferred compound of general formula I is those or its pharmaceutically acceptable salt, tautomer, prodrug or the steric isomer also with general formula I A,
Wherein Y is selected from-CHR
ay-,-CHR
ay-CHR
by-,-CR
ay=CR
by-,-C ≡ C-,-CHR
ay-CHR
by-CHR
cy-,-CHR
ay-CR
by=CR
cy-and-CHR
ay-C ≡ C-;
R
ay, R
byand R
cyall independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
5be selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
6be selected from NR
8r
9, and OR
10;
W is selected from O and NR
7;
R
7be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; Or R
7and R
5and the corresponding atom N to be connected with them and C atom form substituted or unsubstituted heterocyclic group;
R
8and R
9be selected from hydrogen, COR independently of one another
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base, condition is, when Y is-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-and at C
3and C
4between when there is singly-bound or double bond, R
9substituted or unsubstituted C
4-C
12ene alkynyl base; .
R
10be selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
16be selected from hydrogen, OR
a, OCOR
a, OCOOR
a, NR
ar
b, NR
acOR
band NR
ac (=NR
a) NR
ar
b, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; And
R
a, R
ball independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group; And
Each dotted line represents an optional other key.
In the compound of general formula I A, particularly preferably Y is-CHR
ay-,-CR
ay=CR
by-and-CHR
ay-CR
by=CR
cy-, wherein R
ay, R
byand R
cyas defined above.
Particularly preferably R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-C
12alkyl.Preferred R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-C
6alkyl, is more preferably hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl, comprises the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-and substituted or unsubstituted sec-butyl.The preferred substituents of these groups is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or vicinal hydroxyl groups phenyl, comprise the indyl of 1-, 2-and 3-indyl, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen and methyl are most preferred R
ay, R
byand R
cygroup.Specifically, when Y is-CHR
ay-time, then particularly preferred R
ayit is methyl; When Y is-CR
ay=CR
by-time, then particularly preferably R
ayhydrogen, particularly preferably R
byit is methyl; When Y is-CHR
ay-CR
by=CR
cy-time, then particularly preferably R
ayhydrogen or methyl, particularly preferably R
byhydrogen, particularly preferably R
cyit is methyl.
Particularly preferably R
5hydrogen and substituted or unsubstituted C
1-C
12alkyl, more preferably R
5hydrogen and substituted or unsubstituted C
1-C
6alkyl, and to be more preferably be hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl, comprise the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-, substituted or unsubstituted sec-butyl.The preferred substituting group of described group be OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or ortho position hydroxy phenyl, comprise the indyl of 1-, 2-and 3-indyl, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen, methyl, sec.-propyl, the tertiary butyl and phenmethyl are most preferred R
5group, the most preferably R
5methyl, sec.-propyl and the tertiary butyl.
Particularly preferably W is NR
7, wherein R
7as defined above.
Particularly preferably R
6nR
8r
9, wherein R
8, R
9as defined above.
Particularly preferably R
7and R
8hydrogen and substituted or unsubstituted C
1-C
12alkyl.More preferably R
7and R
8hydrogen and substituted or unsubstituted C
1-C
6alkyl; To be more preferably be hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen is most preferred.
In another embodiment, particularly preferably be, R
7and R
5and connected corresponding atom N forms substituted or unsubstituted heterocyclic group together with C atom.In this respect, preferred heterocyclic group be comprise one, two or three are selected from the heteroatoms of N, O or S atom, particularly preferably comprise an atom N, and this heterocyclic group have 5 to about 10 annular atomses, particularly preferably 5,6 or 7 annular atomses.Pyrrolidino group is most preferred.
When Y is a)-CHR
ay-,-CHR
ay-CHR
by-,-CR
ay=CR
by-,-C ≡ C-or-CHR
ay-C ≡ C-; Or b)-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-, and at C
3and C
4between when there is triple bond, then particularly preferably R
9hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.More preferably hydrogen, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.One, two or more substituting group can be there is in the alkynyl of the alkyl of preferred replacement, the thiazolinyl of replacement, replacement, the Ene alkynyl base of replacement.Preferred alkyl those there is the group of 6 to about 10 carbon atoms, more preferably there is the group of 7,8 and 9 carbon atoms.Heptyl, octyl group and nonyl are most preferred alkyl groups.On the other hand, preferred alkenyl group is that those have 6 to about 10 carbon atoms, more preferably has the group of 7,8 or 9 carbon atoms.Pungent-1,6-dialkylene, pungent-1,5-dialkylene, pungent-1,4-dialkylene, pungent-1,3-dialkylene, the ninth of the ten Heavenly Stems-1,7-dialkylene, the ninth of the ten Heavenly Stems-1,6-dialkylene, the ninth of the ten Heavenly Stems-1,5-dialkylene, the ninth of the ten Heavenly Stems-1,4-dialkylene, the ninth of the ten Heavenly Stems-butadienyl, heptan-1,5-dialkylene, heptan-1,4-dialkylene, heptan-butadienyl is most preferred alkenyl group.On the other hand, preferred alkynyl group is that those have the group of 6 to about 10 carbon atoms, more preferably has the group of 7,8 or 9 carbon atoms.Pungent-7-alkynyl, pungent-6 alkynyls, pungent-5-alkynyl, pungent-4-alkynyl, pungent-3-alkynyl, pungent-2-alkynyl, pungent-1-alkynyl, the ninth of the ten Heavenly Stems-8-alkynyl, the ninth of the ten Heavenly Stems-7-alkynyl, the ninth of the ten Heavenly Stems-6-alkynyl, the ninth of the ten Heavenly Stems-5 alkynyl, the ninth of the ten Heavenly Stems-4-alkynyl, the ninth of the ten Heavenly Stems-3-alkynyl, the ninth of the ten Heavenly Stems-2-alkynyl, the ninth of the ten Heavenly Stems-1-alkynyl, heptan-6-alkynyl, heptan-5-alkynyl, heptan-4-alkynyl, heptan-3-alkynyl, heptan-2-alkynyl, heptan-1-alkynyl be most preferred alkynyl group.On the other hand, preferred Ene alkynyl base has 6 to about 10 carbon atoms, more preferably has 7,8 or 9 carbon atoms those.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.The preferred substituents of described alkyl, thiazolinyl, alkynyl and Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.Above-mentioned thiazolinyl, alkynyl, the preferred substituting group of Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.These alkyl, thiazolinyl, alkynyl and the preferred substituting group of Ene alkynyl base group are halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl.Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, wherein the blocking group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, di-t-butyl methyl-silicane base, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are these alkyl, thiazolinyl, alkynyl and the most preferred substituting group of Ene alkynyl base group.
When Y is-CHR
ay-CHR
by-CHR
cy-or-CHR
ay-CR
by=CR
cy-, and at C
3and C
4between when there is singly-bound or double bond, R
9substituted or unsubstituted C
4-C
12ene alkynyl base.One, two or more substituting group can be there is in the Ene alkynyl base of preferred replacement.Preferred Ene alkynyl base group has those of 6 to about 10 carbon atoms, even more preferably has 7,8 or 9 carbon atoms.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.The preferred substituents of described Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.The preferred substituting group of above-mentioned Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.The preferred substituting group of these Ene alkynyl base groups is halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, di-t-butyl methyl-silicane base, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl.Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, wherein the blocking group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, two-tertbutyl methyl silyl, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are these alkyl, thiazolinyl, alkynyl and the most preferred substituting group of Ene alkynyl base group.
Particularly preferably R
16hydrogen, OR
aand OCOR
a, wherein R
abe selected from hydrogen and substituted or unsubstituted C
1-C
12alkyl.Particularly preferably R
ahydrogen and substituted or unsubstituted C
1-C
6alkyl; Be more preferably hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen, OH and methoxyl group are most preferred R
16group.
Particularly preferred, other key one or more is there is in position represented by dashed line.More preferably at C
1and C
2between there is an other key, and/or at C
3and C
4between there is one or two other key, and/or at C
5and C
6between there is an other key.In addition, the three-dimensional arrangement of each double bond can (E) or (Z) exist.The mixture of individual isomer and this isomer also falls within the scope of the invention.
The compound of another kind of particularly preferred general formula I is compound or its pharmacy acceptable salt, tautomer, prodrug or the steric isomer with general formula I B,
Wherein Y is selected from-CHR
ay-,-CHR
ay-CHR
by-,-CR
ay=CR
by-,-C ≡ C-,-CHR
ay-CHR
by-CHR
cy-,-CHR
ay-CR
by=CR
cy-and-CHR
ay-C ≡ C-.
R
ay, R
byand R
cyall independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
5be selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
6be selected from NR
8r
9, and OR
10;
W is selected from O and NR
7;
R
7be selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; Or R
7and R
5and the corresponding atom N to be connected with them and C atom can form substituted or unsubstituted heterocyclic group.
R
8and R
9independently selected from hydrogen, COR
a, COOR
a, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base.
R
10be selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl;
R
16be selected from hydrogen, OR
a, OCOR
a, OCOOR
a, NR
ar
b, NR
acOR
band NR
ac (=NR
a) NR
ar
b, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; And
R
19be selected from hydrogen, COR
a, COOR
a, CONR
ar
b, S (O) R
a, SO
2r
a, P (O) (R
a) OR
b, SiR
ar
br
c, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl; And
R
a, R
b, R
call independently selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group; And
Each dotted line represents an optional other key.
In the compound of general formula I B, particularly preferably Y is-CHR
ay-,-CR
ay=CR
by-and-CHR
ay-CR
by=CR
cy-, wherein R
ay, R
byand R
cyas defined above.
Particularly preferably R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-
12alkyl.Preferred R
ay, R
byand R
cyhydrogen, substituted or unsubstituted C
1-C
6alkyl, is more preferably hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl, comprises the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-, substituted or unsubstituted sec-butyl.The preferred substituents of these groups is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or ortho position hydroxy phenyl, comprise the indyl of 1-, 2-and 3-indyl, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen and methyl are most preferred R
ay, R
byand R
cygroup.Specifically, when Y is-CHR
ay-time, then particularly preferred R
ayit is methyl; When Y is-CR
ay=CR
bytime, then particularly preferably R
ayhydrogen, particularly preferably R
byit is methyl; When Y is-CHR
ay-CR
by=CR
cy-time, then particularly preferably R
ayhydrogen or methyl, particularly preferably R
by, be hydrogen, particularly preferably R
cyit is methyl.
Particularly preferably R
5hydrogen and substituted or unsubstituted C
1-C
12alkyl, more preferably R
5hydrogen and substituted or unsubstituted C
1-C
6alkyl, and to be more preferably be hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl group, substituted or unsubstituted sec.-propyl, comprise the substituted or unsubstituted butyl of the substituted or unsubstituted tertiary butyl, substituted or unsubstituted isobutyl-, substituted or unsubstituted sec-butyl.The preferred substituting group of described group be OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.In above-mentioned group, preferred substituting group is OH, SCH
3, SH, NH
2, NHC (=NH) NH
2, CONH
2, COOH, phenyl, contraposition, a position or ortho position hydroxy phenyl, comprise the indyl of 1-, 2-and 3-indyl, comprise the imidazolyl of 4-, 5-imidazolyl.Hydrogen, methyl, sec.-propyl, the tertiary butyl and benzyl are most preferred R
5group, the most preferably R
5methyl, sec.-propyl and the tertiary butyl.
Particularly preferably W is NR
7, wherein R
7as defined above.
Particularly preferably R
6nR
8r
9, wherein R
8, R
9as defined above.
Particularly preferably R
7and R
8hydrogen and substituted or unsubstituted C
1-C
12alkyl.More preferably R
7and R
8hydrogen and substituted or unsubstituted C
1-C
6alkyl.To be more preferably be hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen is most preferred.
In another embodiment, particularly preferably be, R
7and R
5and connected corresponding atom N forms substituted or unsubstituted heterocyclic group together with C atom.In this respect, preferred heterocyclic group comprises one, two or three are selected from the heteroatoms of N, O or S atom, particularly preferably comprise an atom N, and this heterocyclic group has 5 to about 10 annular atomses, particularly preferably has 5,6 or 7 annular atomses.Pyrrolidino group is most preferred.
Particularly preferably R
9hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.More preferably hydrogen, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted C
4-C
12ene alkynyl base.One, two or more substituting group can be there is in the alkynyl of the alkyl of preferred replacement, the thiazolinyl of replacement, replacement, the Ene alkynyl base of replacement.Preferred alkyl is that those have the group of 6 to about 10 carbon atoms, more preferably has 7,8 and 9 carbon atoms.Heptyl, octyl group and nonyl are most preferred alkyl groups.On the other hand, preferred alkenyl group is that those have the group of 6 to about 10 carbon atoms, more preferably has the group of the carbon atom of 7,8 or 9.Pungent-1,6-dialkylene, pungent-1,5-dialkylene, pungent-1,4-dialkylene, pungent-1,3-dialkylene, the ninth of the ten Heavenly Stems-1,7-dialkylene, the ninth of the ten Heavenly Stems-1,6-dialkylene, the ninth of the ten Heavenly Stems-1,5-dialkylene, the ninth of the ten Heavenly Stems-1,4-dialkylene, the ninth of the ten Heavenly Stems-butadienyl, heptan-1,5-dialkylene, heptan-1,4-dialkylene, heptan-butadienyl is most preferred alkenyl group.On the other hand, preferred alkynyl group is that those have the group of 6 to about 10 carbon atoms, more preferably has the group of 7,8 or 9 carbon atoms.Pungent-7-alkynyl, pungent-6 alkynyls, pungent-5-alkynyl, pungent-4-alkynyl, pungent-3-alkynyl, pungent-2-alkynyl, pungent-1-alkynyl, the ninth of the ten Heavenly Stems-8-alkynyl, the ninth of the ten Heavenly Stems-7-alkynyl, the ninth of the ten Heavenly Stems-6-alkynyl, the ninth of the ten Heavenly Stems-5 alkynyl, the ninth of the ten Heavenly Stems-4-alkynyl, the ninth of the ten Heavenly Stems-3-alkynyl, the ninth of the ten Heavenly Stems-2-alkynyl, the ninth of the ten Heavenly Stems-1-alkynyl, heptan-6-alkynyl, heptan-5-alkynyl, heptan-4-alkynyl, heptan-3-alkynyl, heptan-2-alkynyl, heptan-1-alkynyl be most preferred group.On the other hand, preferred Ene alkynyl base is the group with 6 to about 10 carbon atoms, more preferably has the group of 7,8 or 9 carbon atoms.Pungent-1-alkene-7-alkynyl, pungent-1-alkene-6-alkynyl, pungent-1-alkene-5-alkynyl, pungent-1-alkene-4-alkynyl, pungent-1-alkene-3-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-8-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-7-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-6-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-5-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-4-alkynyl, the ninth of the ten Heavenly Stems-1-alkene-3-alkynyl, heptan-1-alkene-6-alkynyl, heptan-1-alkene-5-alkynyl, heptan-1-alkene-4-alkynyl and heptan-1-alkene-3-alkynyl be most preferred Ene alkynyl base group.The preferred substituents of described alkyl, thiazolinyl, alkynyl and Ene alkynyl base is OR ' ,=O, SR ', SOR ', SO
2r ', NO
2, NHR ', NR ' R ' ,=N-R ', NHCOR ', N (COR ')
2, NHSO
2r ', NR ' C (=NR ') NR ' R ', CN, halogen, COR ', COOR ', OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ', shielded OH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, wherein, R ' group is all independently selected from hydrogen, OH, NO
2, NH
2, SH, CN, halogen, COH, CO-alkyl, COOH, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group.When these groups are substituted itself, substituting group can be selected from above-mentioned inventory.Above-mentioned thiazolinyl, alkynyl, the preferred substituting group of Ene alkynyl base group be halogen, OR ' ,=O, OCOR ', OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein R ' group is all preferably selected from hydrogen, substituted or unsubstituted C
1-C
12alkyl, substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, substituted or unsubstituted aryl.These alkyl, thiazolinyl, alkynyl and the preferred substituting group of Ene alkynyl base group are halogen, OR ',=O, OCONHR ', OCONR ' R ', CONHR ', CONR ' R ' and shielded OH, wherein the protecting group group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, di-t-butyl methyl-silicane base, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl, and wherein each R ' group is more preferably selected from hydrogen, unsubstituted C
1-C
6alkyl, substituted or unsubstituted aryl, Cl, OH ,=O, OCONH
2, OCONH phenyl, with shielded OH, wherein the blocking group of OH is preferably selected from trimethyl silyl, triethylsilyl, triisopropyl silyl, dimethylisopropylsilyl, diethyl isopropyl silyl, dimethylhexylsilyl, 2-norcamphyl dimetylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, three p-Xylol base silyls, triphenyl-silyl, diphenylmethylsilyl, di-t-butyl methyl-silicane base, two (tertiary butyl)-1-pyrenyl methoxysilyl, three (trimethyl silyl) silyl, (2-hydroxystyrene based) dimetylsilyl, (2-hydroxystyrene based) diisopropylsilyl, tertiary butyl butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, 1,1,3,3-tetra isopropyl-3-[2-(triphenylmethoxy) oxyethyl group] sily oxide-1-base, and fluorine silyl are these alkyl, thiazolinyl, alkynyl and the most preferred substituting group of Ene alkynyl base group.
Particularly preferably R
16hydrogen, OR
aand OCOR
a, wherein R
abe selected from hydrogen and substituted or unsubstituted C
1-C
12alkyl.Particularly preferably R
ahydrogen and substituted or unsubstituted C
1-C
6alkyl; Be more preferably hydrogen, methyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Hydrogen, OH and methoxyl group are most preferred R
16group.
Particularly preferably R
19hydrogen and substituted or unsubstituted C
1-C
12alkyl and COR
a, wherein R
abe selected from hydrogen and substituted or unsubstituted C
1-C
12alkyl.More preferably R
19hydrogen and substituted or unsubstituted C
1-C
6alkyl and COR
a, wherein R
afree hydrogen and substituted or unsubstituted C
1-C
6alkyl.Particularly preferably R
amethyl, ethyl, propyl group, sec.-propyl and comprise the butyl of the tertiary butyl.Be more preferably R
19hydrogen.
Particularly preferred, other key one or more is there is in position represented by dashed line.More preferably at C
1and C
2between there is an other key, and/or at C
3and C
4between there is one or two other key, and/or at C
5and C
6between there is an other key.In addition, the three-dimensional arrangement of each double bond can (E) or (Z) exist.The mixture of individual isomer and this isomer also falls within the scope of the invention.
As shown in flow process A, compound of the present invention is by obtaining different sheet connection breaking synthetically.
Flow process A
Wherein R
1, R
2, R
3, R
4, R
5, R
6, A, Y and W be the suitable blocking group of desired group or needs, and J, K, L and M are suitable reactive group or leavings group.
Compound of the present invention obtains by following any one strategy:
1) segment A and B can couple together (i.e. Bodanszky M and Bodanszky A, The Practice of Peptide Synthesis, Springer-Verlag, 1993) according to the standard method in organic chemistry.
2) segment C and segment D can couple together (i.e. R.B.Crabtree according to the standard method in organometallic chemistry, " The Organometallic Chemistry of the Transition Metals ", 2nd Ed., Wiley, Nueva York, 1994).
Segment A, B, C and D can be prepared according to the standard method in organic synthesis independently.
The deprotection of blocking group can carry out (Greene and Wuts, Protective Groups in Organic Synthesis, 3 according to the currently known methods in organic synthesis
rded., Wiley-Interscience; Burke and Danheiser, Handbook of Reagents for Organic Synthesis:Oxidizing andReducing Agents, Wiley; The J.Org.Chem.2005 such as Pla D, 70,8231).
If desired, substituting group can use suitable blocking group, to ensure that active group is not affected.Building-up process is designed to be used in the suitable stage and can be transformed into required substituent precursor substituent.As a part for synthesis, can introduce or remove desaturation or undersaturated ring structure.In order to ensure synthesising target compound, can change parent material and reagent as required.In addition, by the usual method in synthetic organic chemistry known to those skilled in the art, can by the compou nd synthesis analogue obtained.
Above-mentioned synthetic route can change as required, to obtain the mixture of steric compounds and steric isomer.By comprising the different methods of use stereotaxis reagent or passing through to introduce chiral centre in compound in building-up process, specific steric isomer or specific mixture can be synthesized.One or more Stereocenter can be introduced between synthesis phase, also can change the Stereocenter of existence.In addition, once synthesize this compound, by the standard resolution technology that skilled reader is known, just can separation of stereoisomers.
A key character of the compound of above-mentioned general formula I is their biological activity, particularly their cytotoxic activity.
According to the present invention, we provide the new pharmaceutical compositions of the compound of Formula I with cytotoxic activity, and they are as the application of antineoplastic agent.Therefore, present invention also offers a kind of pharmaceutical composition, this pharmaceutical composition comprises compound of the present invention, its pharmacy acceptable salt, tautomer, prodrug or steric isomer and pharmaceutically acceptable carrier.
Term " carrier " means thinner, auxiliary material, vehicle or the vehicle used together with activeconstituents.Suitable pharmaceutical carrier, at " Remington ' s Pharmaceutical Sciences " E.W.Martin, has description in 1995.
The example of pharmaceutical composition comprises solid (tablet, pill, capsule, particle etc.) or liquid (solution, suspensoid or the emulsion) composition of any oral, local application or administered parenterally.
The administration of compound of the present invention or composition is undertaken by any appropriate means, as venoclysis, oral preparations, abdominal injection and intravenous administration.The preferred use transfusion time of maximum 24 hours, more preferably 1-12 hour, most preferably 1-6 hour.The transfusion time that special needs are shorter, can treat without the need to spending the night in hospital like this.But if needed, transfusion can be 12-24 hour or longer.Transfusion can be carried out under the appropriate intervals in 1-4 week.Pharmaceutical composition containing the compounds of this invention is by the lipid of slow release formulation or nanometer ball encapsulation or the load mode transmission by other standards.
The correct dose of compound can change according to the specific position of specific formula, method of application and treatment, host and tumour.Other factors like age, body weight, sex, diet, administration time, drainage rate, host's situation, drug regimen, reaction susceptibility and disease severity all should be considered.Administration can within the scope of maximum tolerance continuously or cyclical administration.
Compound of the present invention can use to provide combined therapy with composition together with other drug.Other medicine can form a part for same combination, or at the same time or different time as independent component administration.
The anti-tumor activity of these compounds includes but not limited to lung cancer, colorectal carcinoma, mammary cancer.
Embodiment
embodiment 1: the synthesis of segment 9
Flow process 1 provides the example that segment 9 is synthesized.
Flow process 1
the synthesis of intermediate 1
To (the 2S using methylene dichloride/dimethyl sulfoxide mixture as solvent (331mL/149mL) of 0 DEG C, 3S)-3, (P.Phukan in two { [(tertiary butyl) dimetylsilyl] the oxygen }-2-methylpent-1-alcoholic solution of 5-, S.Sasmal and M.E.Maier Eur.J.Org.Chem.2003,1733-1740) (50g, 0.14mol) adds Et by dropping funnel
3n (96.1mL, 0.69mol).After 10 minutes, add SO in batches
3pyr (54.8g, 0.34mol), and at 0 DEG C of stirred solution 2h again.Then, with dchloromethane (800mL), with hydrochloric acid (0.5N, 800mL).Separate out organic layer, and through MgSO
4drying, vacuum concentration.Aldehyde 1 (the yield: 90%) of 45g is obtained after column chromatography purification (hexane/EtOAc 100: 0 to 10: 1).
1H NMR(CDCl
3,300MHz)δ:9.79(s,1H),4.30(m,1H),3.65(m,2H),2.51(m,1H),1.69(m,2H),1.04(d,3H,J=6.9Hz),0.85-0.88(m,18H),0.03-0.07(m,12H)。
13C NMR(CDCl
3,75MHz)δ:205.4,69.4,59.6,51.7,37.5,26.1,26.0,18.4,18.2,8.0,-4.3,-4.5,-5.2。
the synthesis of intermediate 2
Ethoxycarbonyl ethylidene triphenylphosphine (113g, 0.31mol) is added, by mixture 60 DEG C of heating more than 17 hours in toluene (625mL) solution of aldehyde 1 (45g, 0.12mol).Then, removal of solvent under reduced pressure, the oil phase using column chromatography (hexane/EtOAc 100: 0 to 10: 1) purifying to obtain, obtains the ester cpds 2 (yield: 96%) of 53.3g.
1H NMR(CDCl
3,300MHz)δ:6.71(dd,1H,J=1.5,10.2Hz),4.19(m,2H),3.77(m,1H),3.66(m,2H),2.61(m,1H),1.85(d,3H,J=1.5Hz),1.68(m,2H),1.30(t,3H,J=7.2Hz),0.98(d,3H,6.9Hz),0.90(m,18H),0.05(m,12H)。
13C NMR(CDCl
3,75MHz)δ:168.3,145.4,126.7,72.2,60.4,59.7,38.4,38.0,25.9,18.2,18.1,14.3,14.3,12.6,-4.4,-4.6,-5.4。
the synthesis of intermediate 3
Under an argon atmosphere, to the ester 2 (46.7g of the cooling of-78 DEG C in 10 minutes, add with toluene (231mL in anhydrous THF solution (525mL) 0.105mol), 0.231mol) as the diisobutylaluminium hydride (DIBAL) of the 1M of solvent, and stir the mixture at-78 DEG C.With MeOH (10mL) cancellation reaction after 4 hours, and add the saturated solution (800mL) of sodium-potassium tartrate, dilute with EtOAc (1000mL).Stir this mixture 2 hours, then separate out organic layer.The other EtOAc (2 × 400mL) of remaining aqueous phase extracts, the organic over anhydrous Na of mixing
2sO
4drying, evaporating solvent.The oil phase that column chromatography (hexane/EtOAc 20: 1 to 10: 1) purifying obtains, obtains the alcohol 3 (yield: 77%) of 32.5g.
1H NMR(CDCl
3,300MHz)δ:5.31(d,1H,J=9.6Hz),3.98(m,2H),3.66(m,3H),2.49(m,1H),1.67(s,3H),1.70-1.62(m,2H),0.91(d,3H,J=6.9Hz),0.88(m,18H),0.03(m,12H)。
13C NMR(CDCl
3,75MHz)δ:133.9,129.8,73.1,69.1,59.9,37.8,37.5,25.9,18.3,18.1,15.9,13.9,-4.4,-4.4,-5.3。
the synthesis of intermediate 4
Under an argon atmosphere, in ether (387mL) solution of alcohol 3 (31.2g, 77.5mmol), MnO is added
2(101g, 1.16mol) mixture stirred at room temperature 2 hours.This mixture filters through silicagel column, and with EtOAc (3L) wash-out, the solution that drying under reduced pressure obtains, obtains the aldehyde 4 (yield: 94%) of 29.1g.
1H NMR(CDCl
3,300MHz)δ:9.37(s,1H),6.44(d,1H,J=9.6Hz),3.82(dd,1H,J=6.3,10.8Hz),3.65(m,2H),2.82(m,1H),1.74(s,3H),1.67(m,2H),1.02(d,3H,J=6.9Hz),0.86(s,18H),0.04-0.01(m,12H).
13C NMR(CDCl
3,75MHz)δ:195.4,157.8,138.3,72.0,59.5,38.7,37.5,25.8,18.2,18.0,14.3,9.4,-4.4,-4.5,-5.4.
the synthesis of intermediate 5
At 0 DEG C to iodomethyl triphenylphosphine iodide (Gilbert Stork, KZ.Tetrahedron letters1989,30 (17), 2173) (96.3g, in anhydrous THF (727mL) suspension 181.7mmol), by dropping funnel, hexamethyldisilazane sodium (NaHMDS) (181.7mL, the 181.7mmol) solution adding 1M in 10 minutes lentamente.Stir 5 minutes again, solution is cooled to-78 DEG C, and add 1 by intubate, 3-dimethyl-3,4,5,6-tetrahydrochysene-2 (1H)-pyrimidine (DMPU) (43.9mL, 363.4mmol), the aldehyde 4 (29.1g, 72.7mol) being dissolved in anhydrous THF (727mL) is added afterwards.Temperature is remained on-78 DEG C, simultaneously stirred reaction mixture 2 hours.Add hexane (1L), the slurry of acquisition passes through diatomite filtration and cleans with extra hexane (3L).Filtrate evaporated under reduced pressure, the oil phase obtained by column chromatography (hexane/EtOAc 100: 0 to 20: 1) purifying, obtains the iodide 5 (yield: 84%) of 32g.
1H NMR(CDCl
3,300MHz)δ:6.73(d,1H,J=8.4Hz),6.09(dd,1H,J=8.4,1.2Hz),5.57(dd,1H,J=9.6,1.2Hz),3.63-3.71(m,3H),2.58(m,1H),1.90(s,3H),1.70(m,2H),0.96(dd,3H,J=6.6,1.2Hz),0.88(s,18H),0.04(m,12H)。
13C NMR(CDCl
3,75MHz)δ:142.3,138.1,131.8,74.6,72.9,59.8,38.1,37.9,26.0,18.3,18.2,15.7,15.7,-4.4,-5.2,-5.2。
the synthesis of intermediate 6
In EtOH (114mL) solution of iodide 5 (12g, 22.9mmol), add pyridinium p-toluenesulfonate (PPTS) (2.01g, 8.0mmol), reaction mixture was stirring at room temperature 25 hours.Then, removal of solvent under reduced pressure, also by the oil phase that column chromatography (hexane/EtOAc 10: 1) purifying obtains, obtains the alcohol 6 (yield: 93%) of 8.7g.
1H NMR(CDCl
3,300MHz)δ:6.69(d,1H,J=8.4Hz),6.12(d,1H,J=8.4Hz),5.47(d,1H,J=9.9Hz),3.67-3.87(m,4H),2.71(m,1H),1.89(s,3H),1.73-1.86(m,2H),1.01(d,3H,J=6.9Hz),0.91(s,9H),0.087-0.115(m,6H)。
13C NMR(CDCl
3,75MHz)δ:142.4,136.4,132.6,75.8,75.2,60.0,38.1,36.4,26.1,18.2,17.1,16.0,-4.1,-4.2。
the synthesis of intermediate 7
To in the solution of the alcohol 6 (8.7g, 21.2mmol) using methylene dichloride/DMSO (50.9mL/22.9mL) mixture as solvent of 0 DEG C, add Et3N (14.8mL, 106mmol) by dropping funnel.After 10 minutes, add SO in batches
3pyr (8.43g, 53.0mol) at 0 DEG C of stirred solution 2h again.Then, with methylene dichloride (800mL) dilution, with hydrochloric acid (0.5N, 50mL) cancellation.Separate out organic layer, and through MgSO
4drying, vacuum concentration.Aldehyde 7 (the yield: 80%) of 6.9g is obtained through column chromatography purification (hexane/EtOAc 10: 1).
1H NMR(CDCl
3,300MHz)δ:9.89(t,1H,J=1.5Hz),6.67(d,1H,J=8.4Hz),6.13(d,1H,J=8.4Hz),5.43(d,1H,J=10.2Hz),3.98(m,1H),2.59-2.69(m,3H),1.85(s,3H),1.01(d,3H,J=6.6Hz),0.86(s,9H),0.06(s,3H),0.03(s,3H)。
13C NMR(CDCl
3,75MHz)δ:201.8,141.9,135.2,133.3,76.3,71.9,49.3,39.3,25.8,18.0,16.7,15.9,-4.4,-4.5。
the synthesis of intermediate 8
To diethyl (methoxyl group [methoxycarbonyl] methyl) phosphoric acid ester (5.51g stirred under-78 DEG C and argon gas atmosphere, 14.45mmol) with hexaoxacyclooctadecane-6-6 (11.5g, in anhydrous THF (390mL) solution 43.34mmol), drip two (trimethyl silyl) potassium amide solution (KHMDS) (43.34mL, 21.67mmol) of 0.5M.After 15 minutes, in 30 minutes, drip the anhydrous THF solution of aldehyde 7 (5.9g, 14.45mmol), and stir 90 minutes in-78 DEG C.Then, with saturated ammonium chloride (NH
4cl) solution (200mL) cancellation reaction, is heated to room temperature, and dilutes with methylene dichloride (1000mL).Organic phase is through anhydrous Na
2sO
4dry also reduction vaporization.Column chromatography purification (hexane/Et
2o 20: 1) obtain pure 4.2g (59%) (E)-8.
1H NMR(CDCl
3,300MHz)δ:6.70(d,1H,J=8.4Hz),6.08(d,1H,J=8.4Hz),5.47(d,1H,J=9.9Hz),5.37(t,1H,J=7.2Hz),3.78(s,3H),3.60(s,3H),3.60(m,1H),2.79(m,1H),2.52-2.67(m,2H),1.83(s,3H),0.99(d,3H,J=6.6Hz),0.89(s,9H),0.05(s,3H),0.04(s,3H)。
13C NMR(CDCl
3,75MHz)δ:163.7,145.9,142.1,137.3,132.1,110.4,75.4,74.8,55.4,51.9,38.1,32.3,25.9,18.1,16.5,15.7,-4.3,-4.5。
the synthesis of intermediate 9
The hydrochloric acid (1.04mL) of 37% is added, stirred reaction mixture 6 hours in MeOH (125mL) solution of room temperature to ester 8 (4.15g, 8.39mmol).Then, NaHCO is used
3saturated aqueous solution (pH 7-8) neutralise mixt and reduction vaporization organic solvent.With the suspension that methylene dichloride (3 × 200mL) extraction obtains, drying is also evaporated.Column chromatography filters (hexane/EtOAc 10: 1 to 2: 1), obtains 2.76g (yield: 94%) lactone 9.
1H NMR(500MHz,CDCl
3)δ:6.68(d,1H,J=9.0Hz),6.20(d,1H,J=8.5Hz),5.63(dd,1H,J=2.5,6.5Hz),5.43(d,1H,J=10.0Hz),4.19(m,1H),3.65(s,3H),2.84(m,1H),2.55(m,1H),2.43(dc,1H,J=3.0,12.0,15.0,18.0Hz),1.87(s,3H),1.16(d,3H,J=6.5Hz)。
13C NMR(125MHz,CDCl
3)δ:161.6,145.2,141.8,134.4,132.7,108.3,81.7,77.4,55.4,37.1,26.6,16.5,16.1。
embodiment 2: the synthesis of segment 21 and 22
Flow process 2 provides the example of synthetic fragment 21 and 22.
Flow process 2
the synthesis of intermediate 11
In room temperature to intermediate 10 (72.3g, add 3-Chloroperbenzoic acid (m-CPBA) (100g in anhydrous methylene chloride (DCM) (918mL) solution 0.39mol) in batches, 0.58mol), mixture stirred at room temperature 18 hours.Use NaHCO
3saturated aqueous solution to quench white depositions, extract with DCM (3 × 250mL) and use NaHCO
3saturated aqueous solution (3 × 250mL) again clean.Merge organic layer, through anhydrous Na
2sO
4dry also vacuum concentration.At purified over silica gel (hexane-EtOAc; 15: 1) oil phase obtained is to provide epoxide as colourless oil phase (64.5g, 82%).To racemic epoxides (30g, (R is added in anhydrous THF (7.5mL) solution 0.15mol), R)-(-)-N, N '-two (3,5-bis--tertiary butyl salicylidene)-1,2-hexanaphthene diamino cobalt (II) [(R, R) Co (II) complex compound] (448mg, 0.74mmol), AcOH (0.14mL) is then added.Solution is cooled to 0 DEG C, and drips water (1.2mL).Make reaction be heated to room temperature and stir 18h.Vacuum concentration volatile matter afterwards, directly by crude product dress on a silica gel column.Use hexane/EtOAc (15: 1 to 12: 1) as the flash chromatography method of elutriant, obtain chiral epoxy compound (+)-11 (13.6g, the productive rate: 46%) as colourless oil phase.
[α]
D=+14.1(c1,CHCl
3).
1H NMR(CDCl
3,300MHz)δ:3.74(t,2H,J=6.3Hz),3.01(m,1H),2.74(t,1H,J=4.6Hz),2.48(dd,1H,J=5.1,3.1Hz),1.70(m,2H),0.87(s,9H),0.04(s,6H)。
13C NMR(CDCl
3,75MHz)δ:60.2,50.2,47.3,36.1,26.1,18.4,-5.2。
the synthesis of intermediate 12
-78 DEG C of concentrated propine (10mL, 0.176mol), and be dissolved in anhydrous THF (165mL).In 30 minutes, drip n-Butyl Lithium (75.1mL, 0.188mol) under a nitrogen, and stir at-78 DEG C another 30 minutes of the white suspension obtained.Drip anhydrous THF (125mL) solution of (+) (R)-2-[2-tertiary butyl dimethyl Si alkane) ethyl] oxyethane 11 (23.7g, 0.117mol), then add BF
3oEt
2(22.1mL, 0.176mol).Stir the mixture 1 hour at-78 DEG C and stir 1 hour again at 0 DEG C.(150mL) cancellation of reaction mixture saturated aqueous ammonium chloride also uses Et
2o (3 × 150mL) extracts.The organic layer merged is through Na
2sO
4drying, filters, concentrated.Flash chromatography method (hexane/EtOAc 10: 1 to 1: 1) provides alcohol 12 (22.7g, productive rate: 80%) as colourless oil phase.
[α]
D=+5.6(c O.1,CHCl
3).
1H NMR(500MHz,CDCl
3)δ:3.75-3.90(m,3H),3.47(d,1H,J=2.7Hz,OH),2.34(m,2H),1.79,(t,3H,J=2.4Hz),1.75(m,2H),0.89(s,9H),0.07(s,6H)。
13C NMR(125MHz,CDCl
3)δ:77.8,75.8,70.7,62.4,37.6,27.6,26.1,18.3,3.7,-5.3,-5.4.
MS(ES)m/z 243.2[M+H]
+,265.2[M+Na]
+。
the synthesis of intermediate 13
At-78 DEG C, to 12 (41.8g under nitrogen atmosphere, 0.173mol) with hexaoxacyclooctadecane-6-6 ether (50.27g, in 30 minutes, added the toluene solution (380mL, 0.190mol) of the KHMDS of 0.5N by dropping funnel in anhydrous THF (1190mL) solution 0.190mol).Stir the mixture 45 minutes in this temperature, then add the anhydrous THF solution of 4-mehtoxybenzyl ammonium chloride (PMBCl) (23.89g, 0.176mol).At-78 DEG C after 2 hours, with saturated aqueous ammonium chloride (600mL) quench mix.Be separated organic layer and use EtOAc (3 × 500mL) thoroughly aqueous phase extracted.Organic layer saturated sodium-chloride water solution after merging cleans, and through anhydrous Na
2sO
4drying, filters, and concentrated, obtain 13 of yellow oil phase, namely it can be used for next step (61.3g, productive rate: 99%) without the need to being further purified.
1H NMR(CDCl
3,300MHz)δ:7.25(d,2H,J=8.7Hz),6.90(d,2H,J=8.7Hz),4.45(m,2H),3.80(s,3H),3.65(m,3H),2.40(m,2H),1.82(m,2H),1.79(t,3H,J=2.4Hz),0.92(s,9H),0.05(s,6H)。
the synthesis of intermediate 14
At 0 DEG C, in dry toluene (2.1L) solution of 13 (61.3g, 0.169mol) under nitrogen atmosphere, add Schwarz reagent (two (cyclopentadienyl) zirconium (IV) chlorine hydride, Cp
2zrHCl) (130.3g, 0.507mol), and at room temperature stirring reaction 5 minutes.Temperature of reaction rose to 50 DEG C through 20 minutes, and stirred 2.5 hours at 50 DEG C.During this period, the color of reaction solution becomes orange.Reaction is cooled to 0 DEG C, and a step adds N-chlorosuccinimide (58.45g, 0.440mol).Stirring 30 minutes is continued, with hexane/EtOAc (95: 5 in room temperature; 500mL) dilute.Through solids removed by filtration, evaporating volatile substances, obtains 14 of yellow oil phase, it can use without the need to being further purified (15.1g, productive rate: 86%).
[α]
D=+20.5(c 1,CHCl
3)。
1H NMR(CDCl
3,300MHz)δ:7.25(d,2H,J=8.7Hz),6.87(d,2H,J=8.7Hz),5.64(td,1H,J=7.8,0.9Hz),4.45(q,2H,J=11.1Hz),3.80(s,3H),3.70(m,2H),3.62(m,1H),2.27(t,2H,J=6.9Hz),2.03(s,3H),1.70(m,2H),0.89(s,9H),0.05(s,6H)。
13C NMR(CDCl
3,75MHz)δ:159.4,130.9,130.7,129.6,124.2,114.0,75.2,71.4,59.8,55.5,37.7,33.8,26.1,21.2,18.5,-5.1。
the synthesis of intermediate 15
At 0 DEG C, to 14 (23g under nitrogen, in anhydrous THF (288mL) solution 0.058mol)), in 20 minutes, drip tetrabutylammonium (TBAF) (115.3mL, 0.115mol) solution (solution reddens).Stirring at room temperature reaction mixture 2 hours, then use saturated aqueous ammonium chloride (200mL) cancellation.Separating layer also uses EtOAc (3 × 150mL) thoroughly aqueous phase extracted.Organic layer after merging is through anhydrous Na
2sO
4drying, filters, concentrated.Flash chromatography method (hexane/EtOAc 4: 1 to 1: 1) obtains 15 (11.9g, productive rates: 73%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.25(d,2H,J=8.7Hz),6.86(d,2H,J=8.7Hz),5.62(t,1H,J=7.8Hz),4.45(m,2H),3.80(s,3H),3.70(m,3H),2.35(m,2H),2.03(s,3H),1.75(m,2H)。
the synthesis of intermediate 16
To alcohol 15 (9.2g, 32.4mmol) He 2,2,6,6-tetramethyl piperidine 1-oxygen base (TEMPO) (515mg, in anhydrous methylene chloride (92mL) solution 3.3mmol), add (diacetoxy iodo) benzene (BAIB) (11.5g, 35.7mmol).At stirring at room temperature reaction mixture 20h, until no longer detect (TLC) to alcohol, then also extract with DCM (3 × 100mL) with saturated aqueous ammonium chloride cancellation.Organic layer after merging is through anhydrous Na
2sO
4dry, filter, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 1), purifying is carried out to residuum, obtain 16 (6.3g, productive rates: 69%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.78(s,1H),7.25(d,2H,J=8.7Hz),6.85(d,2H,J=8.7Hz),5.64(t,1H,J=7.8Hz),4.45(q,2H,J=11.1Hz),4.02(m,1H),3.80(s,3H),2.60(m,2H),2.35(m,2H),2.03(s,3H).
13C NMR(CDCl
3,75MHz)δ:201,159.6,132.1,130.1,129.7,122.8,114.1,73.3,71.5,55.5,48.3,33.5,21.3。
the synthesis of intermediate 17
At room temperature, in anhydrous THF (126mL) suspension of iodo-methyl triphenylphosphine iodide (16.6g, 31mmol), slowly add anhydrous THF (31.27mL, the 31.27mol) solution of the NaHMDS of 1M.Stir after 2 minutes, yellow mixture is cooled to-78 DEG C, then add anhydrous THF (82mL) solution of 16 (6.3g, 22mmol).Reaction mixture stirs 2 hours at-78 DEG C, and stirring at room temperature 5 minutes, with hexane dilution, and passes through
plug filters.The hexane rinsing of this plug, the filtrate after reduction vaporization merges, and by the oil phase that column chromatography (hexane/EtOAC 12: 1 to 8: 1) purifying obtains, obtain 17 (5.6g, productive rates: 62%) of yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:7.25(d,2H,J=8.7Hz),6.85(d,2H,J=8.7Hz),6.25(m,2H)5.64(t,1H,J=7.8Hz),4.42(m,2H),3.80(s,3H),3.55(m,1H),2.40(m,2H),2.25(m,2H),2.03(s,3H)。
the synthesis of intermediate 18
At room temperature under nitrogen atmosphere, in (5g, 12mmol) DCM-water (20: 1, the 98mL) solution of 17,2,3-bis-chloro-5,6-dicyanos-para benzoquinone (DDQ) (3.6g, 16mmol) is added.After 1.5 hours (TLC hexane/EtOAc 4: 1 display does not have parent material), by pouring Et into
2o (200mL) also carrys out cancellation reaction with 1M sodium hydroxide (3 × 50mL) and salt solution (50mL) cleaning.Organic phase is through anhydrous Na
2sO
4dry, filtration, concentrated.The chromatographic separation of aubepine is promoted by being reduced into p-methoxy benzyl alcohol.For this reason, by obtain residue MeOH (98mL) solution in NaBH
4(0.60g, 16mmol) keeps 1 hour at room temperature under nitrogen atmosphere.Then by pouring Et into
2o (100mL) also carrys out cancellation reaction with 1M HCl (40mL) and salt solution (40mL) cleaning.Organic phase is through anhydrous Na
2sO
4dry, filtration, and concentrated.The oil phase obtained is purifying on silica gel (hexane/EtOAc 10: 1 to 4: 1), to obtain secondary alcohol (2.8g, the yield: 80%) of colourless oil phase.
Under 0 DEG C and nitrogen atmosphere, to secondary alcohol (2.8g, 2 are dripped in anhydrous DCM (38mL) solution 10mmol), 6-lutidine (2.28mL, 20mmol), then t-butyldimethylsilyl three fluoro methane sulfonate (TBSOTf) (2.33mL, 12mmol) is added.Stirred reaction mixture 2 hours.At this moment, also extract with DCM (2 × 25mL) with hydrochloric acid (25mL) the cancellation crude product of 0.5M.The saturated NaHCO of organic layer after merging
3the aqueous solution and salt solution cleaning.Organic phase is through Na
2sO
4dry, filter and concentrate.Flash chromatography method (hexane/EtOAc 100: 1 to 20: 1) obtains 18 (3.14g, yields: 80%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:6.25(m,2H)5.64(t,1H,J=7.8Hz),3.82(m,1H),2.38(t,2H,J=6.0Hz),2.20(t,2H,J=6.3Hz),2.03(s,3H),0.86(s,9H),0.05(s,6H)。
13C NMR(CDCl
3,75MHz)δ:137.7,130.9,124.3,84.6,70.6,42.5,36.6,25.9,21.3,18.2。
the synthesis of intermediate 19a
Can repeat to load cuprous iodide (I) (148mg, 0.78mmol), salt of wormwood (1.076g, 7.78mmol) and Boc-tert-LeuCONH in the Schlenk pipe sealed
2(according to Pozdnev, V.F., Tetrahedron Letters 1995,36, the method preparation described in 71 15-71 18) (0.96g, 4.15mmol), vacuumizes and is filled with nitrogen.Add N under a nitrogen, N '-dimethyl quadrol (DMEDA) (0.166mL, 1.55mmol), vinyl iodide 18 (1.04g, 2.59mmol) and dry DMF (15ML).Sealing Schlenk pipe, 90 DEG C of heating 18 hours, then cool to room temperature.The mixture obtained with EtOAc dilution also goes out with shrend.With water cleaning organic layer and through anhydrous Na
2sO
4dry.Removal of solvent under reduced pressure, and by (hexane/EtOAc, 20: 1 to 15: 1) flash chromatography residuum on silica gel.Obtain intermediate 19a (670mg, the productive rate: 53%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.72(d,1H,J=9.9Hz),6.70(t,1H,J=9.6Hz),5.54(t,1H,J=7.8Hz),5.35(d,1H,J=9.0Hz),4.76(q,1H,J=7.8Hz),3.89(d,1H,J=9.0Hz),3.73-3.68(m,1H),2.12(m,4H),1.98(s,3H),1.40(s,9H),0.97(s,9H),0.84(s,9H),0.02(s,3H),0.01(s,3H)。
13C NMR(CDCl
3,75MHz)δ:168.9,156.0131.1,123.9,122.6,108.2,79.9,71.6,62.5,36.5,34.8,33.8,28.1,26.7,25.9,21.2,18.3,-4.3,-4.4。
the synthesis of intermediate 19b
Can repeat to load cuprous iodide (I) (40.4mg, 0.213mmol), salt of wormwood (294mg, 2.13mmol) and Boc-Val-CONH in the Schlenk pipe sealed
2(the method preparation according to describing in Pozdnev, V.F., TetrahedronLetters 1995,36,7115-7118) (230mg, 1.06mmol), vacuumizes and is filled with nitrogen.Add N under a nitrogen, N '-dimethyl quadrol (45 μ L, 0.426mmol), vinyl iodide 18 (283mg, 0.71mmol) and dry DMF (35mL).Sealing Schlenk pipe, 90 DEG C of heating 18 hours, then cool to room temperature.The mixture obtained with EtOAc dilution also goes out with shrend.With water cleaning organic layer and through anhydrous Na
2sO
4dry.Removal of solvent under reduced pressure also passes through (hexane/EtOAc, 7: 1 to 3: 1) flash chromatography residuum on silica gel.Obtain intermediate 19b (270g, the productive rate: 77%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.80(d,1H,J=9.3Hz),6.79-6.73(m,1H),5.58(t,1H,J=7.5Hz),5.02(br s,1H),4.85-4.76(m,1H),3.93(dd,1H,J=8.4,6.0Hz),3.80-3.73(m,1H),2.12-2.22(m,5H),2.02(s,3H),1.45(s,9H),0.98(d,3H,J=6.9Hz),0.93(d,3H,J=6.9Hz),0.89(s,9H),0.07(s,3H),0.06(s,3H)。
the synthesis of intermediate 20a
At ethylene glycol (30mL) solution 15 minutes of the derivative 19a (670mg, 1.33mmol) of 200 DEG C of heating amido protectings.Then by reaction mixture cool to room temperature, and with DCM dilution, be poured into water with salt solution cancellation.Add several 3M NaOH, until solution reaches pH 14, then extract fully with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and vacuum concentration, obtains primary amine 20a (510mg, productive rate: 95%) without the need to being further purified i.e. spendable yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:8.77(d,1H,J=9.9Hz),6.71(t,1H,J=9.6Hz),5.56(t,1H,J=7.8Hz),4.71(m,1H),3.72(m,1H),3.14(s,1H),2.14(m,4H),1.97(s,3H),0.97(s,9H),0.84(s,9H),0.02(s,6H)。
13C NMR(CDCl
3,75MHz)δ:171.2,131.0,124.1,122.5,107.1,71.5,64.3,36.2,34.5,33.8,26.5,26.0,21.2,18.2,-4.4,-4.5。
the synthesis of intermediate 20b
At ethylene glycol (15mL) solution 15 minutes of the derivative 19b (255mg, 0.52mmol) of 200 DEG C of heating amido protectings.Then by reaction mixture cool to room temperature, and with DCM dilution, be poured into water with salt solution cancellation.Add several 3M NaOH, until solution reaches pH 14, then extract fully with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and vacuum concentration, obtains the primary amine 20b (170mg, productive rate 85%) without the need to being further purified i.e. spendable yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:9.27(d,1H,J=10.2Hz),6.76(dd,1H,J=11.1,9.6Hz),5.61(t,1H,J=7.8Hz),4.80-4.72(m,1H),3.81-3.73(m,1H),3.31(d,1H,J=3.6Hz)2.44-2.33(m,1H),2.20-2.16(m,4H),2.03(s,3H),1.59(br s,2H),1.00(d,3H,J=6.9Hz),0.89(s,9H),0.82(d,3H,J=6.9Hz),0.05(s,6H)。
13C NMR(CDCl
3,75MHz)δ:172.1,131.1,124.1,122.5,107.4,71.5,60.2,36.2,33.7,30.8,26.0,21.3,20.0,18.3,16.1,-4.3,-4.4。
the synthesis of intermediate 21a
Under a nitrogen to amine 20a (918mg, in anhydrous DCM/DMF (10: 1,39.6mL) solution 2.27mmol), add (Z)-3-tributylstamlyl vinylformic acid (1028mg, anhydrous DCM solution 2.84mmol), then 0 DEG C of cooling.Diisopropylethylamine (DIPEA) (0.6mL is added in solution, 3.4mmol), 1-hydroxyl-7-azepine benzotriazole (HOAt) (310mg, 2.27mmol), N, N, N ', N '-tetramethyl--O-(7-azepine benzo triazol-1-yl) urea hexafluorophosphate (HATU) (860mg, 2.27mmol), removes cooling bath after 30 minutes.At stirring at room temperature reaction mixture 2h, use saturated NH
4the cancellation of the Cl aqueous solution, and be poured into water, extract with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.The acid amides 21a (1.11g, productive rate 66%) of oil phase is obtained by flash chromatography residuum (hexane/EtOAc, 20: 1 to 15: 1).
1H NMR(CDCl
3,300MHz)δ:7.63(d,1H,J=10.5Hz),6.97(d,1H,J=12.3Hz),6.75(d,1H,J=12.3Hz),6.72(t,1H,J=9.5Hz),6.50(d,1H,J=9.0Hz),5.56(t,1H,J=6.6Hz),4.83(q,1H,J=9.0Hz),4.41(d,1H,J=9.6Hz)3.76(m,1H),2.17(m,4H),2.01(s,3H),1.45(m,6H),1.25(m,8H),1.0(s,9H),0.88(s,9H),0.84(m,13H),0.06(s,6H)。
the synthesis of intermediate 21b
In a nitrogen atmosphere, to amine 20b (170mg, anhydrous DCM/DMF (10: 1 0.437mmol), 7.7mL) in solution, add (Z)-3-tributylstamlyl vinylformic acid (197.2mg, solution 0.546mmol) in anhydrous DCM, then 0 DEG C of cooling.In solution, add DIPEA (0.11mL, 0.655mmol), HOAt (59.4mg, 0.437mmol) and HATU (166mg, 0.437mmol) also removes cooling bath after 30 minutes.At stirring at room temperature reaction mixture 2h, use saturated NH
4the cancellation of the Cl aqueous solution, and be poured into water, extract with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.By flash chromatography residuum (hexane/EtOAc, 20: 1 to 15: 1), obtain the acid amides 21b (250mg of white foam; Productive rate 78%).
1H NMR(CDCl
3,300MHz)δ:7.94(d,1H,J=10.8Hz),7.00(d,1H,J=12.3Hz),6.75(d,1H,J=12.3Hz),6.72(t,1H,J=9.5Hz),6.50(d,1H,J=9.0Hz),5.56(t,J=6.6Hz,1H),4.83(q,1H,J=9.0Hz),4.41(t,1H,J=9.0Hz),3.76(m,1H),2.17(m,4H),2.01(s,3H),1.45(m,7H),1.25(m,8H),0.88(s,9H),0.84(m,19H),0.06(s,6H)。
13C NMR(CDCl
3,75MHz)δ:169.2,166.8,153.8,136.2,131.1,123.9,122.6,108.7,71.6,59.2,36.5,33.7,31.4,29.5,27.6,26.1,21.3,19.5,18.5,14.0,11.8,-4.3,-4.4。
the synthesis of intermediate 22a
At 0 DEG C, to 20a (120mg, 0.30mmol) with propynoic acid (23 μ L, in anhydrous DCM/DMF 10: 1 (4.2mL) solution 0.37mmol), add HATU (113mg, 0.30mmol), HOAt (40mg, 0.30mmol) with DIPEA (0.78 μ L, 0.44mmol).0 DEG C of stirring reaction 30 minutes and at stirring at room temperature 2h.Then, saturated NH is used
4the mixture of Cl aqueous solution process crude product also uses CH
2cl
2extraction.The filtrate H merged
2o cleans.Drying, solvent evaporated under reduced pressure, by column chromatography (ethyl acetate/hexane mixture) purification of crude product, obtains pure compound 22a (50mg, productive rate: 40%).
1H NMR(CDCl
3,300MHz)δ:8.20(d,1H,J=10.2Hz),6.83(d,1H,J=9.6Hz),6.72(t,1H,J=9.3Hz),5.55(t,1H,J=6.9Hz),4.88(q,1H,J=8.7Hz),4.58(d,1H,J=9.6Hz),3.75(m,1H),2.90(s,1H),2.17(m,4H),2.00(s,3H),1.02(s,9H),0.87(s,9H),0.05(s,3H),0.04(s,3H)。
13C NMR(CDCl3,75MHz)δ:167.5,152.1,131.0,124.1,122.3,109.4,77.1,74.8,71.7,60.9,36.5,35.7,33.8,26.7,26.1,21.2,18.3,-4.3,-4.4。
the synthesis of intermediate 22b
At 0 DEG C, to 20b (200mg, 0.51mmol) with propynoic acid (39 μ L, in anhydrous DCM/DMF 10: 1 (8mL) solution 0.64mmol), add HATU (194mg, 0.51mmol), HOAt (69mg, 0.51mmol) with DIPEA (133 μ L, 0.76mmol).0 DEG C of stirring reaction 30 minutes and at stirring at room temperature 2h.Then, saturated NH is used
4the mixture of Cl aqueous solution process crude product also uses CH
2cl
2extraction.The filtrate H merged
2o cleans.Drying, solvent evaporated under reduced pressure, by column chromatography (ethyl acetate/hexane mixture) purification of crude product, obtains pure compound 22b (150mg, productive rate: 67%).
1H NMR(CDCl
3,300MHz)δ:7.02(d,1H,J=11.4Hz),6.75(dd,1H,J=10.8,9.0Hz),6.53(d,1H,J=10.2Hz),5.58(dd,1H,J=9.0,7.8Hz),4.87(q,1H,J=7.8Hz),4.33(dd,1H,J=8.7,6.3Hz),3.84-3.76(m,1H),2.83(s,1H),2.23-2.11(m,5H),2.05-2.03(m,3H),0.99(d,6H,J=6.9Hz),0.89(s,9H),0.08(s,3H),0.06(s,3H)。
embodiment 3: the synthesis of segment 27
Flow process 3 provides the example of the synthesis of segment 27.
Flow process 3
the synthesis of intermediate 23
At 0 DEG C, to iodo-methyl triphenylphosphine iodide (Gilbert Stork, KZ.Tetrahedronletters 1989,30 (17), 2173), in anhydrous THF (50mL) suspension of (6.6g, 12.47mmol), dropping funnel is passed through, hexamethyldisilazane sodium (NaHMDS) (12.5mL, the 12.47mmol) solution of 1M is added lentamente in 10 minutes.After stirring 5 minutes again, solution is cooled to-78 DEG C, then 1 is added by sleeve pipe, 3-dimethyl-3,4,5,6-tetrahydrochysene-2 (1H)-pyrimidone (DMPU) (3.02mL, 24.95mmol), the aldehyde 1 (1.80g, 4.99mmol) be dissolved in anhydrous THF (50mL) is then added.Temperature remains on-78 DEG C, simultaneously stirred reaction mixture 2 hours.Add hexane (200mL) and the slurry obtained through diatomite filtration, clean with other hexane (200mL).Reduction vaporization filtrate, and by the oil phase that column chromatography (hexane/EtOAc 100: 0 to 20: 1) purifying obtains, obtain the iodide 23 (productive rate: 68%) of 1.64g.
1H NMR(CDCl
3,300MHz)δ:6.18-6.09(m,2H),3.79(m,1H),3.67(m,2H),2.57(m,1H),1.75-1.63(m,2H),0.96(d,3H,J=6.9Hz),0.89(m,18H),0.04(m,12H)。
the synthesis of intermediate 24
To in EtOH (5.3mL) solution of iodide 23 (520mg, 1.07mmol), add pyridinium p-toluenesulfonate (PPTS) (94.4mg, 0.38mmol), and stirring at room temperature reaction mixture 25 hours.Then removal of solvent under reduced pressure, the oil phase obtained by column chromatography (hexane/EtOAc 4: 1) purifying, obtains 380mg (productive rate: alcohol 24 87%).
1H NMR(CDCl
3,300MHz)δ:6.20(d,1H,J=7.5Hz),6.08(m,1H),3.87-3.72(m,3H),2.69(m,1H),1.85-1.80(m,1H),1.71-1.65(m,1H),0.99(d,3H,J=6.6Hz),0.90(m,9H),0.09(m,6H)。
the synthesis of intermediate 25
To in anhydrous DCM (10.3mL) solution of the alcohol 24 (380mg, 1.03mmol) of 0 DEG C, add Dai Si-Martin and cross iodine alkane (870mg, 2.05mmol).After 1h, add NaHCO
3saturated aqueous solution (50mL), separates out organic layer, through MgSO
4drying, and vacuum concentration.350mg (productive rate: aldehyde 25 93%) is obtained by column chromatography (hexane/EtOAc 1: 1) purifying.
1H NMR(CDCl
3,300MHz)δ:9.82(t,1H,J=2.1Hz),6.26(dd,1H,J=0.6,7.5Hz),6.05(dd,1H,J=1.5,9.0Hz),4.14(m,1H),2.68(m,1H),2.58(m,2H),1.01(d,3H,J=6.6Hz),0.87(m,9H),0.07(s,3H),0.03(s,3H)。
the synthesis of intermediate 26
At argon gas atmosphere and-78 DEG C, to diethyl (methoxyl group [methoxyl group phosphinylidyne] methyl) phosphoric acid ester (362mg stirred, 1.42mmol) with hexaoxacyclooctadecane-6-6 (754mg, in anhydrous THF (27mL) solution 2.85mmol), drip two (trimethyl silyl) potassium amide solution (KHMDS) (2.85mL, 1.42mmol) of 0.5M.Over the course of 15 mins, dripped anhydrous THF (14mL) solution of aldehyde 25 (350mg, 0.95mmol) through 30 minutes, and stir 90 minutes at-78 DEG C.Then, saturated NH is used
4cl solution (20mL) cancellation is reacted, and is heated to room temperature and dilutes with methylene dichloride (50mL).Dry organic phase (anhydrous Na
2sO
4), reduction vaporization.By column chromatography (hexane/Et
2o 20: 1) purifying, obtain (E)-26 of pure 370mg (86%).
1H NMR(CDCl
3,300MHz)δ:6.12(d,1H,J=7.2Hz),6.03(m,1H),5.32(t,1H,J=7.5Hz),3.78(s,3H),3.77-3.70(m,1H),3.63(s,3H),2.69(m,2H),2.58(m,1H),0.97(d,3H,J=6.6Hz),0.88(s,9H),0.04(s,6H)。
the synthesis of intermediate 27
In MeOH (3.15mL) solution of room temperature to ester 26 (95mg, 0.21mmol), add the HCl (26 μ L) of 37%, and stirred reaction mixture 6 hours.Then saturated NaHCO is used
3(pH 7-8) aqueous solution neutralise mixt, reduction vaporization organic solvent.With the suspension that methylene dichloride (4 × 20mL) extraction obtains, drying is also evaporated.Filtered by column chromatography (hexane/EtOAc 10: 1 to 2: 1), obtain 210mg (productive rate: lactone 27 84%).
1H NMR(CDCl
3,300MHz)δ:6.32(dd,1H,J=0.6,7.5Hz),6.08(dd,1H,J=1.5,9.3Hz),5.62(dd,1H,J=3.0,6.3Hz),4.28(m,1H),3.63(s,3H),2.84(m,1H),2.54(m,1H),2.34(m,1H),1.13(d,3H,J=6.6Hz)。
embodiment 4: the synthesis of segment 30
Flow process 4 provides the example of the synthesis of segment 30.
Flow process 4
the synthesis of intermediate 28
Under 0 DEG C and nitrogen, to L-Boc-Terleu (300mg, anhydrous DCM (13mL) 1.3mmol) and dicyclohexylcarbodiimide (DCC) (295mg, in mixture 1.43mmol), add 3-butenol (0.3ml, 3.9mmol) with dimethyl aminopyridine (DMAP) (15.9mg, 0.13mmol).Reaction mixture stirred 5 minutes at 0 DEG C, stirring at room temperature 4 hours.Reduction vaporization organic solvent also by the solid that column chromatography (hexane/EtOAc 10: 1) purifying obtains, obtains ester 28 (300mg, productive rate: 81%).
1H NMR(CDCl
3,300MHz)δ:5.82-5.71(m,1H),5.14-5.06(m,2H),4.24-4.12(m,2H),4.08(d,1H,J=9.8Hz),2.41(q,2H,J=6.7Hz),1.43(s,9H),0.96(s,9H)。
the synthesis of intermediate 29
In room temperature, HCl-MeOH (3.6ml) solution of the 1M of stirring ester 28 (180mg, 0.63mmol) 24 hours.Reduction vaporization organic solvent, to be diluted in acquisition solid in DCM and to use H
2o cleans, through anhydrous Na
2sO
4the dry organic phase obtained, filters and evaporating solvent, obtains 29 (productive rates 100%) of 116mg.
1H NMR(CDCl
3,300MHz)δ:5.85-5.72(m,1H),5.15-5.06(m,2H),4.16(t,2H,J=6.7Hz),3.15(s,1H),4.44-4.37(m,2H),0.96(s,9H)。
the synthesis of intermediate 30
Under 0 DEG C and argon gas, to 29 (168mg, 0.9mmol) with (Z)-3-tributylstamlyl vinylformic acid (393mg, anhydrous DCM/DMF (10: 1 1.2mmol), 14mL) in solution, add DIPEA (0.24ml, 1.4mmol), HOAt (123.3mg, 0.9mmol) with HATU (345mg, 0.9mmol).After 2 hours, removing cooling bath, and stirring at room temperature reaction mixture 1 hour, use saturated NH
4the cancellation of the Cl aqueous solution, and be poured into water, extract with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.By flash chromatography (hexane/EtOAc, 15: 1 to 10: 1) purifying residuum, obtain 30 (340mg, productive rates: 72%).
1H NMR(CDCl
3,300MHz)δ:7.01(d,1H,J=12.3Hz),6.75(d,1H,J=12.3Hz),6.03(d,1H,J=9.73Hz),5.84-5.69(m,1H),5.14-5.05(m,2H),4.60(d,1H,J=9.76Hz),4.19-4.14(m,2H),2.40(q,2H,J=6.70Hz),1.48-1.40(m,6H),1.31-1.19(m,6H),0.96(s,9H),0.93-0.83(m,15H)。
embodiment 5: the synthesis of segment 37
Flow process 5 provides the synthesis of segment 37.
Flow process 5
the synthesis of intermediate 31
In room temperature by alcohol 12 (2.88g, 11.9mmol), DMF (14mL) the solution stirring overnight of t-butyldiphenylsilyl muriate (4.39mL, 16.89mmol) and 4-(dimethylamino) pyridine (43.6mg).Dilute with water mixture also uses Et
2o extracts, and cleans organic phase with salt solution, through anhydrous Na
2sO
4dry, filter and concentrate.Flash chromatography (hexane/EtOAc, 95: 1) obtains the silicomethane ester 31 (5.3g, 93%) of colourless liquid.
1H NMR(300MHz,CDCl
3)δ:7.70-7.66(m,4H),7.40-7.34(m,6H),3.99-3.95(m,1H),3.70-3.62(m,2H),2.23-2.22(m,2H),1.84-1.81(m,2H),1.69(t,3H,J=2.7Hz),1.05(s,9H),0.84(s,9H),0.01(s,6H)。
13C NMR(CDCl
3,75MHz)δ:136.1,134.6,129.7,127.8,77.8,76.2,69.9,60.1,39.6,27.5,27.2,26.2,19.6,18.5,3.7,-5.1。
the synthesis of intermediate 32
PPTS (837.7mg, 3.33mmol) is disposable to be joined in ethanol (80mL) solution of 31 (4g, 8.33mmol).At stirring at room temperature reaction mixture 7h, then concentrate.Residuum is diluted in DCM, and with saturated NaHCO
3aqueous cleaning.Extraction organic layer, through anhydrous Na
2sO
4drying, filters and concentrates.Flash chromatography (hexane/EtOAc, 95: 1), obtains silicomethane ester 32 (2.12g, the productive rate: 69%) of colourless liquid.
1H NMR(500MHz,CDCl
3)δ:7.71-7.63(m,4H),7.45-7.26(m,6H),4,14-4.01(m,2H),3.80-3.71(m,1H),2.31-2.28(m,2H),1.94-1.80(m,2H),1.79(t,3H,J=2.4Hz),1.07(s,9H)。
the synthesis of intermediate 33
(diacetoxy iodo) benzene (BAIB) (1.93g, 6.00mmol) join alcohol 32 (2.0g, 5.46mmol) He 2,2,6, in anhydrous methylene chloride (27mL) solution of 6-tetramethyl piperidine-1-oxygen base (TEMPO) (85mg, 0.55mmol).Stirring at room temperature reaction mixture 18h, until alcohol (TLC) no longer detected, then uses saturated NH
4the aqueous solution cancellation of Cl is also with DCM (3 × 500mL) extraction.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.Residuum, by flash chromatography (hexane/EtOAc, 20: 1 to 10: 1) purifying, obtains 33 (1.64g, productive rates: 82%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.72(s,1H),7.71-7.63(m,4H),7.45-7.26(m,6H),4.29(m,1H),2.65(m,2H),2.33(m,2H),1.70(s,3H),1.04(s,9H)。
the synthesis of intermediate 34
At room temperature, to iodo-methyl triphenylphosphine iodide (3.14g; In anhydrous THF (60mL) suspension 6.04mmol), add THF (6.0mL) solution of the NaHMDS of 1M lentamente.Stir after 2 minutes, yellow mixture is cooled to-78 DEG C, then add anhydrous THF (35mL) solution of 33 (1.57g, 4.31mmol).-78 DEG C of stirred reaction mixture 2h, and stirring at room temperature 5 minutes, are filtered by plug of celite with hexane dilution.With hexane cleaning plug, the filtrate that reduction vaporization merges, the oil phase obtained by column chromatography (hexane/EtOAc, 50: 1) purifying, obtains 34 (1.31g, productive rates: 62%) of yellow oil phase.
1H NMR(500MHz,CDCl
3)δ:7.70-7.66(m,4H),7.44-7.34(m,6H),6.27-6.24(m,2H),3.99-3.95(m,1H),2.47-2.41(m,2H),2.27-2.23(m,2H),1.71(t,3H,J=2.7Hz),1.07(s,9H)。
the synthesis of intermediate 35
Can repeat to load cuprous iodide (I) (85.1mg, 0.447mmol), salt of wormwood (0.618g, 4.47mmol) and Boc-tert-LeuCONH in the Schlenk pipe sealed
2(the method preparation according to describing in Pozdnev, V.F., Tetrahedron Letters 1995,36,7115-7118) (0.514g, 2.23mmol), vacuumizes and is filled with argon gas.Add N under argon gas, N '-dimethyl quadrol (DMEDA) (0.095mL, 0.89mmol), vinyl iodide 34 (0.727g, 1.49mmol) and dry DMF (11mL).Sealing Schlenk pipe, 90 DEG C of heating 18 hours, and cool to room temperature.The mixture obtained with EtOAc dilution also goes out with shrend.With water cleaning organic layer and through anhydrous Na
2sO
4dry.Removal of solvent under reduced pressure, and by flash chromatography (hexane/EtOAc, 20: 1 to 15: 1) the purifying residuum on silica gel.Obtain intermediate 35 (388g, the productive rate: 44%) of oil phase.
1H NMR(300MHz,CDCl
3)δ:7.70-7.66(m,4H),7.53(d,1H,J=10.5Hz),7.43-7.26(m,6H),6.73(t,1H,J=9.6Hz),5.29(m,1H),4.79(m,1H),3.85-3.81(m,2H),2.39-2.30(m,1H),2.27-2.21(m,3H),1.88(s,3H),1.43(s,9H),1.06(s,9H),0.97(s,9H)。
the synthesis of intermediate 36
At ethylene glycol (17mL) solution 15 minutes of the derivative 35 (288mg, 0.487mmol) of 200 DEG C of heating amido protectings.Then by reaction mixture cool to room temperature, and with DCM dilution, be poured into water with salt solution cancellation.Add several 3M NaOH, until solution reaches pH 14, then extract fully with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and vacuum concentration, obtains primary amine 36 (165mg, productive rate: 69%) without the need to being further purified i.e. spendable yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:8.46(d,1H,J=11.1Hz),7.71-7.63(m,4H),7.45-7.26(m,6H),6.76(t,1H,J=10.2Hz),4.77(q,1H,J=10.2Hz),3.89(m,1H),3.06(s,1H),2.30(m,2H),2.24(m,2H),1.70(s,3H),1.05(s,9H),0.98(s,9H)。
the synthesis of intermediate 37
Under an argon atmosphere to amine 36 (221mg, in anhydrous DCM/DMF (4: 1,5mL) solution 0.450mmol), add (Z)-3-tributylstamlyl vinylformic acid (195mg, anhydrous DCM solution 0.54mmol), then 0 DEG C of cooling.DIPEA (0.094mL, 0.54mmol) is added, HOAt (73.5mg, 0.54mmol) and HATU (205mg, 0.54mmol) and remove cooling bath after 30 minutes in solution.At stirring at room temperature reaction mixture 2h, use saturated NH
4the cancellation of the Cl aqueous solution, and be poured into water, extract with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.By flash chromatography residuum (hexane/EtOAc, 20: 1 to 15: 1), obtain acid amides 37a (288mg, the productive rate: 77%) of oil phase.
1H NMR(300MHz,CDCl
3)δ:7.70-7.66(m,4H),7.61(d,1H,J=10.2Hz),7.42-7.38(m,6H),7.02(d,1H,J=12.0Hz),6.77-6-70(m,2H),6.28(d,1H,J=9.6Hz),4.82(q,1H,J=8.4Hz),4.36(d,1H,J=9.6Hz),3.89-3-86(m,1H),2.39-2.24(m,4H),1.94(s,3H),1.50-1.41(m,6H),1.30-1-23(m,6H),1.07(s,9H),0.92(s,9H),0.92-0.84(m,15H)。
embodiment 6: the synthesis of segment 40
Flow process 6 provides the synthesis of segment 40
Flow process 6
the synthesis of intermediate 38
Under room temperature and argon gas atmosphere, chloro-for 2,3-bis-5,6-dicyano-p-benzoquinone (DDQ) (8.70g, 38mmol) are joined 17 (12g; Methylene dichloride-H 30mmol)
2in O (20: 1) (236mL) solution, after 1: 30h (TLC hexane/EtOAc 4: 1 display does not have parent material), by pouring Et into
2o (400mL) also carrys out cancellation reaction with 1M sodium hydroxide (3 × 200mL) and salt solution (200mL) cleaning.Organic phase is through anhydrous Na
2sO
4dry, filtration, and concentrated.The chromatographic separation of aubepine is promoted by being reduced into p-methoxy benzyl alcohol.For this reason, by obtain residue MeOH (236mL) solution in NaBH
4(1.5g, 38mmol) keeps 1 hour under room temperature and argon gas atmosphere.Then by pouring Et into
2o (400mL) also carrys out cancellation reaction with 1M HCl (200mL) and salt solution (200mL) cleaning.Organic phase is through anhydrous Na
2sO
4dry, filtration, and concentrated.The oil phase obtained is purifying on silica gel (hexane/EtOAc 10: 1 to 4: 1), to obtain secondary alcohol (6g, the yield: 73%) of colourless oil phase.
Under room temperature and argon gas atmosphere, to secondary alcohol (6g; Add imidazoles (3.3g in dry DMF (25mL) solution 21mmol) in batches, 48.6mmol), then t-butyldiphenylsilyl chlorine (TBDPSCl) (7.6mL is added, 29.3mmol) with DMAP (77mg, 0.63mmol).Overnightly to stir the mixture, at this moment, use Et with water (30mL) cancellation crude product
2o (3 × 30mL) extracts.Organic layers with water after merging and salt solution fully clean.Organic phase is through Na
2sO
4dry, filter and concentrate.38 (9.6g, 92%) of colourless oil phase are obtained by flash chromatography method (hexane/EtOAc 100: 1 to 30: 1).
1H NMR(CDCl
3,300MHz)δ:7.67(m,4H),7.45-7.37(m,6H),6.25(m,2H),5.51(t,1H,J=7.8Hz),3.89(m,1H),2.30(t,2H,J=5.5Hz),2.14(t,2H,J=6.4Hz),1.85(s,3H),1.07(s,9H)。
the synthesis of intermediate 39
Can repeat to load cuprous iodide (I) (1.05g, 5.54mmol), salt of wormwood (7.65g, 55.4mmol) and Boc-tert-LeuCONH in the Schlenk pipe sealed
2(the method preparation according to describing in Pozdnev, V.F., Tetrahedron Letters 1995,36,7115-7118) (6.8g, 29.6mmol), vacuumizes and is filled with argon gas.Add N under argon gas, N '-dimethyl quadrol (DMEDA) (1.18mL, 11.1mmol), vinyl iodide 38 (9.7g, 18.5mmol) and dry DMF (92mL).Sealing Schlenk pipe, 90 DEG C of heating 18 hours, then cool to room temperature.The mixture obtained with EtOAc dilution also goes out with shrend.With water cleaning organic layer and through anhydrous Na
2sO
4dry.Removal of solvent under reduced pressure also passes through flash chromatography (hexane/EtOAc, 20: 1 to 15: 1) the purifying residuum on silica gel.Obtain compound 39 (5.8g, the productive rate: 51%) of white solid.
1H NMR(CDCl
3,300MHz)δ:7.67(m,4H),7.47-7.37(m,6H),7.02(d,1H,J=10.2Hz),6.67(t,1H,J=9.4Hz),5.51(t,1H,J=7.3Hz),5.23(d,1H,J=8.4Hz),4.72(q,1H,J=8.1Hz),3.81(m,2H),2.18-2.04(m,4H),1.86(s,3H),1.42(s,9H),1.05(s,9H),0.97(s,9H)。
the synthesis of compound 40
At ethylene glycol (140mL) solution 15 minutes of the derivative 39 (4.75g, 7.6mmol) of 200 DEG C of heating amido protectings.Then by reaction mixture cool to room temperature, and with dchloromethane, be poured into water with salt solution cancellation.Add several 3M NaOH, until solution reaches pH 14, then extract fully with methylene dichloride.Merge organic phase washed with water cleaning and through anhydrous Na
2sO
4drying, filters and concentrating under reduced pressure, obtains primary amine 40 (3.8g, productive rate: 95%) without the need to being further purified i.e. spendable yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:8.66(d,1H,J=10.5Hz),7.66(m,4H),7.47-7.33(m,6H),6.71(t,1H,J=9.3Hz),5.53(t,1H,J=8.3Hz),4.72(q,1H,J=8.4Hz),3.83(m,1H),3.19(s,1H),2.22-2.05(m,4H),1.83(s,3H),1.05(s,9H),0.99(s,9H)。
embodiment 7: the synthesis of segment 45
Flow process 7 provides the example that segment 45 is synthesized.
Flow process 7
the synthesis of intermediate 41
At 0 DEG C to anhydrous CrCl
2anhydrous THF (10mL) solution of aldehyde 1 (0.995g, 2.76mmol) and iodoform (2.17g, 5.52mmol) is added in anhydrous THF (30mL) solution of (2.03g, 16.55mmol).After stirring 4 hours at 23 DEG C, use Et
2o dilution mixture thing, and pass through diatomite filtration.Concentrated filtrate obtains residuum, by flash chromatography method at purified over silica gel (hexanes/ch, 50: 1 to 5: 1) this residuum, obtains ethene iodine 41 (0.79g, the productive rate: 57%) of faint yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:6.58(dd,1H,J=14.5,6.7Hz),5.98(dd,1H,J=14.5,1.3Hz),3.76-3.70(m,1H),3.67-3.59(m,2H),2.37-2.32(m,1H),1.62-1.53(m,2H),0.96(d,3H,J=7.2Hz),0.89(m,18H),0.04(m,12H)。
the synthesis of intermediate 42
To in EtOH (15mL) solution of iodide 41 (786mg, 1.58mmol), add pyridinium p-toluenesulfonate (PPTS) (139mg, 0.55mmol).Stirring at room temperature reaction mixture 25 hours.Then removal of solvent under reduced pressure, and by the oil phase that column chromatography (hexane/EtOAc 4: 1) purifying obtains, obtain 379.7mg (productive rate: the 63%) alcohol 42 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:6.56(dd,1H,J=14.5,6.7Hz),6.01(dd,1H,J=14.5,1.3Hz),3.78-3.3.69(m,3H),2.45-2.39(m,1H),1.87-1.83(m,1H),1.71-1.59(m,2H),1.00(d,3H,J=6.6Hz),0.90(s,9H),0.09(s,3H),0.07(s,3H)。
the synthesis of intermediate 43
To in anhydrous DCM (10mL) solution of the alcohol 42 (389mg, 1.01mmol) of 0 DEG C, add Dai Si-Martin and cross iodine alkane (Dess-Martin periodinane) (644mg, 1.52mmol).Stir 1 hour at 0 DEG C and after 30 minutes, use saturated NaHCO 23 DEG C of stirrings
3aqueous solution cancellation reaction mixture.Pour out organic layer, and through anhydrous Na
2sO
4drying, and concentrating under reduced pressure.By column chromatography (hexane/EtOAc 20: 1 to 2: 1) purifying, obtain 349.3mg (productive rate: the 90%) aldehyde 43 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.77(t,1H,J=2.1Hz),6.52(dd,1H,J=14.7,7.5Hz),6.05(dd,1H,J=14.7,1.2Hz),4.12-4.07(m,1H),2.52-2.47(m,2H),2.2.43-2.36(m,1H),0.98(d,3H,J=7.2Hz),0.87(s,9H),0.07(s,3H),0.03(s,3H)。
the synthesis of intermediate 44
Diethyl (methoxyl group [methoxycarbonyl] methyl) phosphoric acid ester (348.4mg stirred under the argon gas atmosphere of-78 DEG C, 1.37mmol) with hexaoxacyclooctadecane-6-6 (722.3mg, in anhydrous THF (13mL) solution 2.73mmol), drip the toluene solution (2.74mL, 1.37mmol) of two (trimethyl silyl) potassium amide (KHMDS) of 0.5M.After 15 minutes, in 30 minutes, drip anhydrous THF (9mL) solution of aldehyde 43 (349.4mg, 0.91mmol), and stir 90 minutes in-78 DEG C.Then, with saturated ammonium chloride (MH
4cl) solution (20mL) cancellation reaction, is heated to room temperature, and dilutes with methylene dichloride (50mL).Dry organic phase is (through anhydrous Na
2sO
4) and reduction vaporization.Column chromatography (hexane/Et
2o 30: 1 to 5: 1) purifying, obtain 410mg (99%) as E/Z mixture (
1the regioselectivity > 5: 1 that H NMR determines) 44.
1h NMR (CDCl
3, 300MHz) and about (2,7)-44 δ: 6.51 (dd, 1H, J=14.4,7.8Hz), 5.97 (dd, 1H, J=14.4,1.2Hz), 5.29 (t, 1H, J=7.7Hz), 3.82 (s, 3H), 3.77-3.70 (m, 1H), 3.60 (s, 3H), 2.65-2.61 (m, 2H), 2.39-2.21 (m, 1H), 1.00 (d, 3H, J=6.9Hz), 0.89 (s, 9H), 0.04 (s, 6H).
the synthesis of intermediate 45
In MeOH (13.5mL) solution of room temperature to ester 44 (410.9mg, 0.90mmol), add the hydrochloric acid (160 μ L) of 37%, reaction mixture stirs 6 hours.Then, NaHCO is used
3saturated aqueous solution (pH 7-8) neutralise mixt, and reduction vaporization organic solvent.With the suspension that methylene dichloride (4 × 20mL) extraction obtains, drying is also evaporated.By column chromatography (hexane/EtOAc 10: 1 to 2: 1) purification of crude product, obtain 192mg (yield: the lactone 45 of white solid 69%).
1H NMR(CDCl
3,300MHz)δ:6.32(dd,1H,J=14.7,8.4Hz),6.21(dd,1H,J=14.7,1.2Hz),5.62(dd,1H,J=6.6,2.7Hz),4.27-4.19(m,1H),3.64(s,3H),2.61-2.54(m,1H),2.43-2.34(m,2H),1.14(d,3H,J=6.9Hz).MS(ES)[m/z]=331.1[M+Na]
+。
embodiment 8: the synthesis of segment 51
Flow process 8 provides the example that segment 51 is synthesized.
Flow process 8
the synthesis of intermediate 46
The anhydrous DCM of triphenylphosphine (1.38g, 52.69mmol) (50mL) solution is dripped in 0 DEG C of anhydrous methylene chloride to carbon tetrabromide (8.74g, 26.35mmol) (26mL) solution.Dark yellow solution is cooled to-78 DEG C of anhydrous DCM (13mL) solution also adding aldehyde 1 (4.75g, 13.2mmol) fast.The mixture obtained is stirred at-78 DEG C (30 points) and 0 DEG C (10 minutes).Use Et
2o diluting reaction, then cleans with salt solution.Use Et
2o aqueous layer extracted, merges organic layer, drying, filtration reduction vaporization.Flash chromatography method (hexanes/ch 10: 1) purifying, obtains 4.37g (productive rate: the dibromoalkene of colourless oil phase 66%).At-78 DEG C, in anhydrous THF (80mL) solution of two bromo alkene, drip the hexane solution (7.03mL) of the n-Butyl Lithium of 2.5M.Reactant is heated to-25 DEG C and stirs 1 hour.Reaction is cooled gets back to-78 DEG C, drips anhydrous THF (9mL) solution of methyl-iodide (0.55mL, 8.79mmol).The mixture of acquisition is heated to room temperature, and stirs 1 hour again.With saturated NH
4the cancellation of the Cl aqueous solution is reacted, and then uses Et
2o dilutes.Organic layer is dry, filtration also reduction vaporization.Flash chromatography (hexanes/ch, 50: 1 to 5: 1) purifying, obtains 2.77mg (yield: the 89%) alkynes 46 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:3.74-3.66(m,3H),2.49-2.46(m,1H),1.83-1.72(m,2H),1.78(s,3H),1.08(d,3H,J=7.2Hz),0.89(m,18H),0.07(s,3H),0.06(s,3H),0.05(s,6H)。
the synthesis of intermediate 47
To 46 (200mg under 23 DEG C and argon gas, in dry toluene (7mL) solution 0.56mmol), add two (cyclopentadienyl) zirconium (IV) hydrochloride (432.3mg, 1.68mmol), and 50 DEG C of stirring reactions 1 hour.During this period, reaction soln becomes orange.Reactant is cooled to 23 DEG C, and once adds iodine (284.3mg, 1.12mmol).Room temperature with constant stirs 30 minutes and with hexane diluting reaction thing, passes through diatomite filtration.Concentrated filtrate, obtains residuum, by this residuum of flash chromatography with hexanes/ch (10: 1 to 1: 2) wash-out, provides ethene iodine 47 (140.4mg, the productive rate: 49%) of faint yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:6.07(dd,1H,J=9.9,1.5Hz),3.72-3.67(m,1H),3.65-3.61(t,2H,J=6.6Hz),2.53-2.47(m,1H),2.37(s,3H),1.68-1.61(m,2H),0.92(d,3H,J=6.6Hz),0.89(m,18H),0.05(m,12H)。
the synthesis of intermediate 48
To in EtOH (2mL) solution of iodide 47 (140.4mg, 0.27mmol), add pyridinium p-toluenesulfonate (PPTS) (24mg, 0.09mmol), and stirring at room temperature reaction mixture 25 hours.Then removal of solvent under reduced pressure, the oil phase obtained by column chromatography (hexane/EtOAc 4: 1) purifying, obtains 90.3mg (productive rate: the alcohol 48 of colourless oil phase 83%).
1H NMR(CDCl
3,300MHz)δ:6.01(dd,1H,J=9.9,1.5Hz),3.78-3.67(m,3H),2.62-2.55(m,1H),2.39(s,3H),2.00-1.98(m,1H),1.80-1.62(m,2H),0.96(d,3H,J=6.6Hz),0.89(s,9H),0.09(s,3H),0.08(s,3H)。
the synthesis of intermediate 49
To in anhydrous DCM (2mL) solution of the alcohol 48 (87mg, 0.22mmol) of 0 DEG C, add Dai Si-Martin and cross iodine alkane (140mg, 0.33mmol).Stir 1h at 0 DEG C and after 30 minutes, use saturated NaHCO 23 DEG C of stirrings
3aqueous solution cancellation reaction mixture.Pour out organic layer, through Na
2sO
4drying, and concentrating under reduced pressure.By column chromatography (hexane/EtOAc 20: 1 to 2: 1) purifying, obtain 76.6mg (productive rate: the 86%) aldehyde 49 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.79(t,1H,J=2.4Hz),5.98(dd,1H,J=9.9,1.5Hz),4.02-3.97(m,1H),2.57-2.51(m,3H),2.38(s,3H),0.97(d,3H,J=6.6Hz),0.87(s,9H),0.08(s,3H),0.04(s,3H)。
13C NMR(CDCl
3,75MHz)δ:201.5,143.5,95.1,71.3,49.3,41.9,28.3,26.0,18.2,15.8,-4.2,-4.4。
the synthesis of intermediate 50
To diethyl (methoxyl group [methoxycarbonyl] methyl) phosphoric acid ester (73.7mg stirred under-78 DEG C and argon gas atmosphere, 0.29mmol) with hexaoxacyclooctadecane-6-6 (153.4mg, in anhydrous THF (3mL) solution 0.58mmol), drip toluene (0.58mL, the 0.29mmol) solution of two (trimethyl silyl) potassium amide (KHMDS) of 0.5M.After 15 minutes, in 10 minutes, drip anhydrous THF (2mL) solution of aldehyde 49 (76.6mg, 0.19mmol), and stir 90 minutes in-78 DEG C.Then, with saturated ammonium chloride (NH
4cl) aqueous solution cancellation reaction, is heated to room temperature, and with dchloromethane.Dry organic phase is (through anhydrous Na
2sO
4) and reduction vaporization.Column chromatography purification (hexane/Et
2o 30: 1 to 5: 1), obtain 89.0mg (100% productive rate) as water white oil phase mixture 50 mixture E/Z (
1h NMR measure regioselectivity > 2.5: 1) 50.
1h NMR (CDCl
3, 300MHz) and about (2E, 7E)-50 δ: 6.28 (d, 1H, J=9.0Hz), 5.33 (t, 1H, J=9.0Hz), 3.84 (s, 3H), 3.61-3.57 (m, 1H), 3.61 (s, 3H), 2.77-2.70 (m, 1H), 2.64-2.55 (m, 1H), 2.49-2.37 (m, 1H), 2.30 (s, 3H), 0.96 (d, 3H, J=6.6Hz), 0.89 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H).
the synthesis of intermediate 51
In MeOH (3mL) solution of room temperature to ester 50 (90.8mg, 0.19mmol), add 37% aqueous hydrochloric acid (34 μ L), reaction mixture stirs 6 hours.Then, NaHCO is used
3saturated aqueous solution neutralise mixt (pH 7-8) and reduction vaporization organic solvent.With the suspension that dichloromethane extraction obtains, drying is also evaporated.Column chromatography (hexane/EtOAc 10: 1 to 2: 1) purification of crude product, obtains 34mg (yield: the 50%) lactone 51 of white solid.
1H NMR(CDCl
3,300MHz)δ:5.99(dd,1H,J=9.9,1.2Hz),5.62(dd,1H,J=5.1,4.2Hz),4.19-4.11(m,1H),3.64(s,3H),2.78-2.70(m,1H),2.41(s,3H),2.42-2.37(m,2H),1.11(d,3H,J=6.6Hz)。
embodiment 9: the synthesis of segment 56
Flow process 9 provides the example that segment 56 is synthesized.
Flow process 9
the synthesis of intermediate 52
By the heptane of the diisopropylamide lithium of 1.8M/THF/ ethylbenzene (8.96mL, 16.13mmol) solution dilution in the anhydrous THF of 88mL.After being cooled to-78 DEG C, add trimethyl silyl diazomethane (8.06mL, 2M THF solution, 16.13mmol), the mixture that stirring obtains 30 minutes.Add anhydrous THF (35mL) solution of 4 (4.377g, 10.75mmol), at-78 DEG C of Keep agitation 1h and at 23 DEG C of stirring 2h.Reaction mixture is joined in icy water, and uses Et
2o extracts.Organic layer (anhydrous Na after dry merging
2sO
4) and except desolventizing.By flash chromatography residuum, obtain 2.38g (productive rate: 55%) yellow oil phase 52.
1H NMR(CDCl
3,300MHz)δ:5.86(d,1H,J=9.9Hz),3.73-3.63(m,3H),2.74(s,1H),2.58-2.50(m,1H),1.80(s,3H),1.70-1.63(m,2H),0.93(d,3H,J=6.6Hz),0.88(m,18H),0.04(m,12H)。
13C NMR (CDCl
3,75MHz)δ:143.3,116.3,87.1,73.7,72.8,60.0,38.6,38.0,26.1,26.1,18.5,18.3,17.4,15.3,-4.2,-5.1。
the synthesis of intermediate 53
To in EtOH (50mL) solution of 52 (2.05g, 5.17mmol), add pyridinium p-toluenesulfonate (PPTS) (511.7mg, 2.04mmol), stirring at room temperature reaction mixture 25 hours.Then removal of solvent under reduced pressure, and by the oil phase that column chromatography (hexane/EtOAc 4: 1) purifying obtains, obtain 1.055g (productive rate: the 72%) alcohol 53 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:5.76(d,1H,J=9.9Hz),3.73-3.63(m,3H),2.79(s,1H),2.64-2.59(m,1H),2.24(bs,1H),1.80(s,3H),1.70-1.60(m,2H),0.95(d,3H,J=6.9Hz),0.88(s,9H),0.08(s,3H),0.06(s,3H)。
the synthesis of intermediate 54
To in anhydrous DCM (5mL) solution of the alcohol 53 (140mg, 0.48mmol) of 0 DEG C, add Dai Si-Martin and cross iodine alkane (308.5mg, 0.73mmol).Stir 30 minutes at 0 DEG C and after 60 minutes, use saturated NaHCO 23 DEG C of stirrings
3aqueous solution cancellation reaction mixture.Analyse organic layer, through anhydrous Na
2sO
4drying, and vacuum concentration.By column chromatography (hexanes/ch 5: 1 to 1: 1) purifying, obtain 100mg (productive rate: the 73%) aldehyde 54 of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.79(t,1H,J=2.4Hz),5.72(d,1H,J=10.2Hz),4.02-3.96(m,1H),2.77(s,1H),2.64-2.53(m,3H),1.80(s,3H),0.98(d,3H,J=6.9Hz),0.87(s,9H),0.08(s,3H),0.04(s,3H)。
13C NMR(CDCl
3,75MHz)δ:201.7,141.2,117.9,86.6,74.5,71.8,49.4,39.7,26.0,18.2,17.6,16.2,-4.3,-4.4。
the synthesis of intermediate 55
Under-78 DEG C and argon gas atmosphere, to diethyl (methoxyl group [methoxycarbonyl] methyl) phosphoric acid ester (768.6mg stirred, 3.02mmol) with hexaoxacyclooctadecane-6-6 (1.60g, in anhydrous THF (30mL) solution 6.06mmol), drip toluene (6.1mL, the 3.05mmol) solution of two (trimethyl silyl) potassium amide (KHMDS) of 0.5M.After 15 minutes, in 10 minutes, drip anhydrous THF (20mL) solution of aldehyde 54 (578mg, 2.02mmol), and stir 90 minutes in-78 DEG C.Then, with saturated ammonium chloride (MH
4cl) aqueous solution cancellation reaction, is heated to room temperature, and with dchloromethane.Dry organic phase is (through anhydrous Na
2sO
4) and reduction vaporization.Column chromatography purification (hexane/Et
2o 30: 1 to 5: 1), obtain pure 839.4mg (> 100% productive rate) water white oil phase mixture E/Z (
1the regioselectivity > 4: 1 that H NMR determines) 55.
1h NMR (CDCl
3, 300MHz) and about (2E, 7E)-55 δ: 5.73 (d, 1H, J=9.9Hz), 5.33 (dd, 1H, J=7.8,6.9Hz), 3.80 (s, 3H), 3.61-3.57 (m, 1H), 3.59 (s, 3H), 2.77-2.68 (m, 1H), 2.73 (bs, 1H), 2.58-2.44 (m, 2H), 1.72 (bs, 3H), 0.95 (d, 3H, J=6.6Hz), 0.85 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H).
the synthesis of intermediate 56
In room temperature, in MeOH (30mL) solution of ester 55 (839.4mg, 2.29mmol), add 37% aqueous hydrochloric acid (766 μ L, 9.16mmol), reaction mixture stirs 4 hours.Then, NaHCO is used
3saturated aqueous solution (pH 7-8) neutralization and reduction vaporization organic solvent.With the suspension that dichloromethane extraction obtains, drying is also evaporated.By column chromatography (hexane/EtOAc 10: 1 to 1: 3) purification of crude product, obtain 312.7mg (yield: the 62%) lactone 56 of white solid.
1H NMR(CDCl
3,300MHz)δ:5.72(dd,1H,J=10.2,1.8Hz),5.60(dd,1H,J=5.1,4.2Hz),4.20-4.10(m,1H),3.64(s,3H),2.85-2.2.77(m,1H),2.81(s,1H),2.41-2.36(m,2H),1.84(s,3H),1.13(d,3H,J=6.9Hz).
13CNMR(CDCl
3,125MHz)δ:161.3,145.1,138.6,118.9,108.0,85.9,81.3,74.8,55.4,37.2,26.2,17.5,16.2.MS(ES)[m/z]=243.2[M+Na]
+。
embodiment 10: the synthesis of segment 62
Flow process 10 provides the synthesis example of segment 62.
Flow process 10
the synthesis of intermediate 57
Find time containing 31 (4.73g, 9.85mmol), quinoline (0.582mL, 4.92mmol) and Lin Dela (Lindlar) catalyzer (2.18g) mixture ethyl acetate solution flask and be filled with H
2.At H
2(1atm) in stirring at room temperature reaction mixture 2h under, then filtered by diatomaceous plug.This plug ethyl acetate is cleaned, and the filtrate after merging with 0.1%HCl cleaning.Organic layer is through anhydrous Na
2sO
4drying, filters and concentrates, and obtains intermediate 57 (4.27g, productive rate: 90%) without the need to being further purified i.e. spendable colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.70-7.67(m,4H),7.44-7.36(m,6H),5.48(m,1H),5.36-5.27(m,1H),3.95-3.87(m,1H),3.71-3.55(m,2H),2.16(dd,2H,J=6.9,6.3Hz),1.73-1.66(m,2H),1.41(dd,3H,J=6.6,1.2Hz),1.05(s,9H),0.84(s,9H),-0.02(s,6H)。
13C NMR(CDCl
3,75MHz)δ:136.2,134.8,129.8,127.8,126.4,125.8,70.9,60.4,39.6,34.8,27.3,26.2,19.7,18.5,13.1,-5.1。
the synthesis of intermediate 58
PPTS (837.7mg, 3.33mmol) once joins in ethanol (80mL) solution of 57 (4g, 8.33mmol).At stirring at room temperature reaction mixture 7h, then concentrate.Residuum is diluted with DCM, and with saturated NaHCO
3aqueous cleaning.Extraction organic layer, through anhydrous Na
2sO
4drying, filters and concentrates.Flash chromatography (hexane/EtOAc, 95: 1) obtains the silyl ether 58 (2.12g, 69%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.73-7.69(m,4H),7.44-7.36(m,6H),5.44-5.38(m,1H),5.21-5.17(m,1H),4.01-3.94(m,1H),3.84-3.76(m,1H),3.69-3.64(m,1H),2.32-2.14(m,2H),1.89-1.78(m,1H),1.70-1.60(m,1H),1.37(d,3H,J=6.9Hz),1.07(s,9H)。
13C NMR(CDCl
3,75MHz)δ:136.2,134.1,130.0,127.8,126.3,125.9,72.3,60.1,37.7,34.3,27.2,19.5,13.0。
the synthesis of intermediate 59
To in the 25mL DCM solution of alcohol 58 (2.05g, 5.56mmol) and TEMPO (86.87mg, 0.56mmol), add BAIB (1.97g, 6.11mmol).At stirring at room temperature reaction mixture 16-18h, until alcohol (TLC) no longer detected, then extract with DCM with saturated aqueous ammonium chloride cancellation.Organic phase after merging is through anhydrous Na
2sO
4dry, filter, concentrated.By flash chromatography method (hexane/EtOAc 5: 1 to 1: 2) to residuum purifying, obtain 59 (1.733mg, productive rates: 79%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.72(t,1H,J=2.7Hz),7.74-7.67(m,4H),7.48-7.37(m,6H),5.56-5.45(m,1H),5.32-5.23(m,1H),4.29-4.20(m,1H),2.51-2.48(m,2H),2.31-2.27(m,2H),1.43(dd,3H,J=6.9,1.5Hz),1.06(s,9H)。
13C NMR(CDCl
3,75MHz)δ:202.3,136.1,134.0,130.1,127.9,127.4,125.1,69.4,50.1,35.1,27.2,19.5,13.1。
the synthesis of intermediate 60
In room temperature, in anhydrous THF (60mL) suspension of iodo-methyl triphenyl phosphonium iodide phosphine (3.32g, 6.38mmol), slowly add the anhydrous THF solution of the 1M NaHMDS (6.38mmol) of 6.83mL.Stir after 2 minutes, yellow mixture is cooled to-78 DEG C, then add anhydrous THF (40mL) solution of 59 (1.67g, 4.56mmol).Reaction mixture stirs 90 minutes at-78 DEG C, and stirring at room temperature 5 minutes, with hexane dilution, and by plug diatomite/SiO
2filter.This plug hexane/EtOAc (10: 1 to 5: 1) rinsing, obtains compound 60 (2g, the productive rate: 89%) without the need to being further purified i.e. spendable colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.70-7.66(m,4H),7.45-7.34(m,6H),6.21-6.31(m,2H),5.49-5.43(m,1H),5.35-5.27(m,1H),3.94-3.75(m,1H),2.30-2.27(m,2H),2.24-2.04(m,2H),1.43(d,3H,J=6.6Hz),1.06(s,9H)。
13C NMR(CDCl
3,75MHz)δ:138.2,136.2,134.3,129.9,127.8,126.4,126.0,84.1,71.9,41.6,34.5,27.2,19.6,13.2。
the synthesis of intermediate 61
Can repeat to load cuprous iodide (I) (232.4mg, 1.22mmol), salt of wormwood (1.688g, 12.23mmol) and Boc-tert-LeuCONH in the Schlenk pipe sealed
2(2.474g, 6.12mmol), vacuumizes and is filled with argon gas.Add N under argon gas, N '-dimethyl quadrol (0.26mL, 2.45mmol), vinyl iodide 60 (2g, 4.08mmol) and dry DMF (35ML).Sealing Schlenk pipe, 90 DEG C of heating 18 hours, and cool to room temperature.The mixture obtained with EtOAc dilution also goes out with shrend.With water cleaning organic layer and through anhydrous Na
2sO
4dry.Removal of solvent under reduced pressure is also passed through at flash chromatography on silica gel (hexane/EtOAc, 20: 1 to 15: 1) purifying residuum.Obtain intermediate 61 (1.06g, the productive rate: 44%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.70-7.67(m,4H),7.43-7.35(m,6H),7.13(d,1H,J=10.5Hz),6.67(dd,1H,J=10.2,9.6Hz),5.56-5.45(m,1H),5.36-5.28(m,2H),4.86-4.78(m,2H),3.88-3.77(m,1H),2.26-2.04(m,4H),1.44(d,3H,J=6.9Hz),1.43(s,9H),1.06(s,9H),0.96(s,9H)。
the synthesis of intermediate 62
At ethylene glycol (50mL) the solution 10-20 minute of the derivative 61 (847mg, 1.43mmol) of 200 DEG C of heating amido protectings.Then by reaction mixture cool to room temperature, and with DCM dilution, be poured into water with salt solution cancellation.Add several 3M NaOH, until solution reaches pH 14, then extract fully with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and vacuum concentration, by flash chromatography (hexane/EtOAc 10: 1 to 1: 2) purifying, obtains primary amine 62 (435mg, the productive rate: 62%) of white foam.
1H NMR(CDCl
3,300MHz)δ:8.50(d,1H,J=10.8Hz),7.70-7.66(m,4H),7.45-7.33(m,6H),6.67(dd,1H,J=11.1,9.3Hz),5.48-5.40(m,1H),5.36-5.28(m,1H),4.79(dd,1H,J=16.2,7.5Hz),3.87-3.79(m,1H),3.08(s,1H),2.22-2.14(m,4H),1.43(d,3H,J=6.9Hz),1.05(s,9H),0.97(s,9H)。
13C NMR(CDCl
3,75MHz)δ:171.0,136.1,134.5,129.8,127.8,126.3,126.2,122.1,107.6,72.6,64.4,34.0,34.4,32.8,27.2,26.9,19.6,13.2。
embodiment 11: the synthesis of segment 63
Flow process 11 provides the example that segment 63 is synthesized.
Flow process 11
the synthesis of intermediate 63
Under an argon atmosphere, (Z)-3-tributylstamlyl vinylformic acid (505.6mg is added in anhydrous DCM/DMF (4: 1, the 12.5mL) solution of amine 62 (575mg, 1.17mmol), anhydrous DCM solution 1.4mmol), then 0 DEG C of cooling.In solution, add DIPEA (0.243mL, 1.76mol), 7-hydroxybenzotriazole (HOBt) (189.2mg, 1.4mmol), HATU (532.28mg, 1.4mmol), remove cooling bath after 30 minutes.At stirring at room temperature reaction mixture 2h, use saturated NH
4the cancellation of the Cl aqueous solution, is poured into water, extracts with DCM.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.By flash chromatography residuum (hexane/EtOAc, 20: 1 to 15: 1), obtain the amine 63 (780.4mg of white foam; Productive rate 77%).
1H NMR(CDCl
3,300MHz)δ:7.70-7.68(m,4H),7.43-7.36(m,6H),7.02(d,1H,J=12.3Hz),7.00(d,1H,J=10.8Hz),6.75(d,1H,J=12.3Hz),6.66(t,1H,J=9.3Hz),6.26(d,1H,J=9.6Hz),5.57-5.34(m,1H),5.38-5.28(m,1H),4.83(dd,1H,J=16.5,7.8Hz),4.31(d,1H,J=9.6Hz),3.89-3.82(m,1H),2.26-2.02(m,4H),1.50-1.42(m,6H),1.43(d,3H,J=6.9Hz),1.33-1.20(m,6H),1.06(s,9H),0.96(s,9H),0.95-0.83(m,15H)。
13C-RMN(CDCl
3,75MHz)δ:168.0,166.2,153.8,136.3,136.1,134.3,130.0,127.8,126.7,126.0,121.6,109.0,72.6,60.7,35.7,34.0,32.7,29.5,27.7,27.2,26.7,19.5,14.0,13.2,11.8。
embodiment 12
Flow process 12 provides the synthesis of several compound of the present invention.
Flow process 12
the synthesis of intermediate 64a
Under-20 DEG C and nitrogen, to the DMF/Et of iodo compound 9 (11mg, 0.033mmol)
3pd (Ph is added in N (0.25ml and 0.05ml) solution
3p)
2cl
2(2.3mg, 0.0033mmol) and CuI (1.9mg, 0.01mmol).Then add compound 22a (15mg, 0.03mmol, in 0.1ml DMF), and between-20 DEG C to room temperature stirred reaction mixture 3 hours.Use H
2o cancellation crude product is also extracted with ethyl acetate.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (ethyl acetate/hexane mixture) purifying, obtain pure compound 64a (10mg, productive rate: 46%).
1H NMR(CDCl
3,300MHz)δ:7.75(d,1H,J=10.5Hz),6.70(t,1H,J=10.2Hz),6.50(d,1H J=9.3Hz),6.38(d,1H,J=12.3Hz),5.60(m,3H),5.45(d,1H,J=12.0Hz),4.87(q,1H,J=8.1Hz),4.37(d,1H,J=9.3Hz),4.21(m,1H),3.77(m,1H),3.64(s,3H),2.87(m,1H),2.40(m,2H),2.20(m,4H),2.09(s,3H),2.01(s,3H),1.15(d,3H,J=6.6Hz),1.02(s,9H),0.89(s,9H),0.07(s,3H),0.05(s,3H)。
midbody compound 64b
At-20 DEG C, to the DMF/Et of 9 (40mg, 0.113mmol)
3pd (Ph is added in N solution (1ml and 0.19ml)
3p)
2cl
2(7.9mg, 0.113mmol) and CuI (6.5mg, 0.034mmol).Then add 22b (50mg, 0.113mmol, in 0.4ml DMF), and between-20 DEG C to room temperature stirred reaction mixture 3 hours.Use H
2o cancellation crude mixture is also extracted with ethyl acetate.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (ethyl acetate/hexane mixture) purifying, obtain pure 64b (40mg, productive rate 54%).
1H NMR(CDCl
3,300MHz)δ:7.77(d,1H,J=11.4Hz),6.75(t,1H,J=10.2Hz),6.41-6.36(m,2H),5.64-5.56(m,3H),5.46(d,1H,J=11.7Hz),4.86(q,1H,J=8.1Hz),4.31(dd,1H,J=8.4;6.6Hz),4.25-4.16(m,1H),3.84-3.76(m,1H),3.65(s,3H),2.92-2.81(m,1H),2.44-2.39(m,2H),2.22-2.12(m,5H),2.10(s,3H),2.03(s,3H),1.16(d,3H,J=6.6Hz),0.99(dd,6H,J=9.3;6.9Hz),0.89(s,9H),0.0080(s,3H),0.0064(s,3H)。
the synthesis of compound 65a
Under room temperature and nitrogen, in anhydrous THF (0.5mL) solution of 64a (15mg, 0.022mmol), add THF (0.044mL, the 0.044mmol) solution of 1M TBAF.Stirring at room temperature reaction mixture 18 hours, then extract with EtOAc with saturated aqueous ammonium chloride cancellation.Organic phase after merging is through anhydrous Na
2sO
4dry, filter, concentrated.By flash chromatography method (hexane/EtOAc 3: 1 to 1: 2) purifying residuum, obtain alcohol 65a (5mg, productive rate: 42%).
1H NMR(CDCl
3,300MHz)δ:8.78(d,1H,J=9.6Hz),6.77(t,1H,J=9.0Hz),6.57(d,1H J=9.0Hz),6.38(d,1H,J=12.3Hz),5.60(m,3H),5.45(d,1H,J=12.0Hz),4.90(q,1H,J=8.7Hz),4.29(d,1H,J=9.6Hz),4.23(m,1H),3.80(m,1H),3.65(s,3H),2.86(m,1H),2.66(bs,1H),2.40(m,2H),2.21(m,4H),2.07(s,3H),2.04(s,3H),1.15(d,3H,J=6.6Hz),1.02(s,9H)。
the synthesis of compound 65b
In room temperature, in anhydrous THF (0.9ml) solution of 64b (40mg, 0.06mmol) under nitrogen, add THF (0.12ml, the 0.067mmol) solution of 1M TBAF.Stirring at room temperature reactant 16 hours, then use CH with saturated aqueous ammonium chloride cancellation
2cl
2extraction.Organic phase drying (anhydrous Na
2sO
4) and filtration under diminished pressure.Flash chromatography method (ethyl acetate/hexane) purifying, obtains pure 65b (15mg, productive rate: 45%).
1H NMR(CDCl
3,300MHz)δ:8.95(d,1H,J=10.2Hz),6.77(t,1H,J=9.3Hz),6.60(d,1H,J=9.0Hz),6.38(d,1H,J=12.6Hz),5.64-5.60(m,3H),5.45(d,1H,J=12.0Hz),4.88(q,1H,J=8.4Hz),4.34(dd,1H,J=8.7;7.2Hz),4.27-4.20(m,1H),3.82-3.74(m,1H),3.65(s,3H),2.92-2.82(m,1H),2.45-2.38(m,2H),2.11-2.04(m,5H),1.57-1.45(m,6H),1.28-1.23(m,3H),1.15(d,6H,J=6.6Hz)。
the synthesis of compound 66a
In room temperature, in anhydrous DCM (0.45mL) solution of 65a (3.5mg, 0.0062mmol), add trichloroacetyl isocyanate (TCAI) (1 μ l, 0.0075mmol).Stirring at room temperature reactant 30 minutes, then add neutral alumina (100mg).Stir the mixture 30 minutes, be then immersed in aluminum oxide pad.The mixture of DCM/MeOH 50: 1 is used to wash out product.Filtrate evaporated in vacuo, obtains crude product, and crude product, by column chromatography (hexane/EtOAc 2: 1 to 1: 2) purifying, obtains compound 66a (2.5mg, productive rate 70%).
1H NMR(CDCl
3,500MHz)δ:8.72(d,1H,J=10.5Hz),6.84(t,1H,J=9.0Hz),6.66(d,1H J=10.0Hz),6.38(d,1H,J=12.0Hz),5.60(m,3H),5.46(d,1H,J=12.0Hz),4.82(q,1H,J=8.0Hz),4.42(m,2H),4.22(m,1H),3.65(s,3H),2.88(m,1H),2.44-2.32(m,6H),2.10(s,3H),2.06(s,3H),1.15(d,3H,J=7.0Hz),1.05(s,9H).
MS(ES)(m/z)604.2[M+1]
+,626.2(M+Na
+)。
the synthesis of compound 66b
In room temperature, to the CH of 65b (32mg, 0.06mmol)
2cl
2(4.2ml) trichloroacetyl isocyanate (TCAI) (8.5 μ l, 0.072mmol) is added in solution.React 30 minutes in stirring at room temperature, then add neutral alumina (450mg) and stir 30 minutes more simultaneously.Use CH
2cl
2the mixture of/MeOH 1: 1, through alumina filter reaction mixture, after the evaporation of decompression filtrate, by column chromatography (hexane/EtOAc mixture) purified product, obtains pure 66b (12mg, productive rate 35%).
1H NMR(CDCl
3,300MHz)δ:8.90(d,1H,J=10.8Hz),6.84(t,1H,J=9.0Hz),6.74(d,1H,J=8.7Hz),6.38(d,1H,J=12.0Hz),5.64-5.58(m,3H),5.45(d,1H,J=12.0Hz),5.38(br s,2H),4.86-4.78(m,1H),4.44-4.39(m,2H),4.27-4.19(m,1H),3.65(s,3H),2.96-2.84(m,1H),2.51-2.39(m,2H),2.37-2.30(m,5H),2.18-2.04(m,6H),1.15(d,3H,J=6.6Hz),1.00-0.96(m,6H)。
Embodiment 13
Flow process 13 provides the synthesis of several compound of the present invention.
Flow process 13
the synthesis of compound 67
At 0 DEG C, to alkenylstannane 21a (50mg, 0.07mmol) with iodide (24.8mg, in 1-Methyl-2-Pyrrolidone (NMP) (1mL) solution 0.08mmol), add thiophene carboxylic acid's copper (CuTC) (19.2mg, 0.1mmol).0 DEG C of stirring reaction 45 minutes and stirring at room temperature 20 minutes.Then, filter crude mixture by the plug of neutral alumina, clean with EtOAc/ ether 50: 50, and clean the filtrate merged with HCl0.5N (3 × 5mL).Dry organic solution is also evaporated, and obtains crude product, by column chromatography (hexane/EtOAc 10: 1 to 6: 1) purifying, obtains triolefin 67 (19mg, the productive rate: 44%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.73(d,1H,J=10.5Hz),7.41(dd,1H,J=11.7,11.1Hz),6.77-6.68(m,2H),6.37(d,1H,J=9.3Hz),5.74(d,1H,J=11.4Hz),5.61-5.52(m,3H),4.87-4.79(m,1H),4.37(d,1H,J=9.3Hz),4.21-4.14(m,1H),3.79-3.72(m,1H),3.64(s,3H),3.09-2.99(m,1H),2.39-2.35(m,2H),2.20-2.10(m,4H),2.01(s,3H),1.16(d,3H,J=6.6Hz),1.03(s,9H),0.88(s,9H),0.07(s,3H),0.05(s,3H)。
the synthesis of compound 68
Under room temperature and nitrogen, in anhydrous THF (0.42mL) solution of 67 (18mg, 0.03mmol), add THF (0.05mL, the 0.05mmol) solution of 1M TBAF.Stirring at room temperature reaction mixture 18 hours, then use saturated NH
4the cancellation of the Cl aqueous solution also extracts with EtOAc.Through anhydrous Na
2sO
4dry merge after organic phase, filtration, concentrated.By flash chromatography method (hexane/EtOAc 3: 1 to 1: 2) purifying residuum, obtain alcohol 68 (16mg, the productive rate: 80%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:8.90(d,1H,J=10.5Hz),7.42(dd,1H,J=11.7,11.1Hz),6.78-6.69(m,2H),6.59(d,1H,J=9.3Hz),5.75(d,1H,J=11.4Hz),5.64-5.53(m,3H),4.88-4.80(m,1H),4.37(d,1H,J=9.3Hz),4.22-4.15(m,1H),3.77-3.69(m,1H),3.64(s,3H),3.11-3.01(m,1H),2.39-2.35(m,2H),2.24-2.14(m,4H),2.03(s,3H),1.16(d,3H,J=6.6Hz),1.03(s,9H)。
the synthesis of compound 69
In room temperature, in anhydrous DCM (0.3mL) solution of 68 (15mg, 0.02mmol), add trichloroacetyl isocyanate (TCAI) (4.1 μ l, 0.64mmol).Stirring at room temperature reactant 30 minutes, then add neutral alumina (450mg).Stir the mixture 30 minutes, be then immersed in aluminum oxide pad.DCM/MeOH 50: 1 is used to wash out product.Filtrate evaporated in vacuo, obtains crude product, and crude product, by column chromatography (hexane/EtOAc 3: 1 to 2: 1) purifying, obtains compound 69 (14mg, productive rate: 86%).
1H NMR(CDCl
3,300MHz)δ:8.89(d,1H,J=10.5Hz),7.45(m,1H),6.87-6-71(m,2H),6.53(d,1H,J=9.6Hz),5.75(m,2H),5.60-5.57(m,2H),4.81(m,1H),4.40-4.37(m,2H),4.19(dd,1H,J=9.3,9.5Hz),3.66(s,3H),3.06(m,1H),2.40-2.30(m,5H),2.15-2.08(m,1H),2.07(s,3H),1.17(d,3H,J=4.2Hz),1.04(s,9H).
13C NMR(CDCl
3,75.5MHz)δ:168.1,165.9,161.4,157.7,145.2,138.3,135.2,132.0,125.9,124.5,122.3,121.8,108.1,105.2,81.4,75.1,60.7,55.4,36.1,35.0,32.9,30.8,26.7,26.3,21.0,17.0。
embodiment 14
Flow process 14 provides the synthesis of several compound of the present invention.
Flow process 14
the synthesis of compound 70
At 0 DEG C, to alkenylstannane 37 (94mg, 0.112mmol) He 9 (47mg, in 1-Methyl-2-Pyrrolidone (NMP) (1.1mL) solution 0.135mmol), add thiophene carboxylic acid's copper (CuTC) (32.2mg, 0.168mmol).0 DEG C of reaction stirred 45 minutes and stirring at room temperature 20 minutes.Then, filter crude mixture by the plug of neutral alumina, clean with EtOAc/ ether 50: 50, and clean the filtrate merged with HCl 0.5N (3 × 15mL).Drying also evaporates organic solution to obtain crude product, by column chromatography (hexane/EtOAc 2: 1 to 1: 1) purifying, obtains triolefin 70 (81.4mg, the productive rate: 79%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.74(d,1H,J=10.5Hz),7.66-7.64(m,4H),7.44-7.38(m,6H),7.22(dd,1H,J=12.3,11.4Hz),6.86(dd,1H,J=11.7,11.4Hz),6.70(dd,1H,J=9.9,9.3Hz),6.40(d,1H,J=9.3Hz),6.17(d,1H,J=11.4Hz),5.66(d,1H,J=11.4Hz),5.60(dd,1H,J=5.4,3.9Hz),5.26(d,1H,J=10.2Hz),4.84-4.76(m,1H),4.3(d,1H,J=9.3Hz),4.20-4.16(m,1H),3.88-3.80(m,1H),3.64(s,3H),2.89-2.77(m,1H),2.41-2.33(m,3H),2.28-2.20(m,3H),1.91(s,3H),1.82(s,3H),1.13(d,3H,J=6.9Hz),1.02(s,9H),0.86(s,9H)。
the synthesis of compound 71
Under room temperature and nitrogen, in anhydrous THF (7.5mL) solution of 70 (77.2mg, 0.106mmol), add THF (0.2mL, the 0.2mmol) solution of 1M TBAF.Stirring at room temperature reactant 18 hours, then use saturated NH
4the cancellation of the Cl aqueous solution also extracts with EtOAc.Through anhydrous Na
2sO
4organic phase after dry merging, filters, concentrated.Flash chromatography method (hexane/EtOAc 1: 2) purifying residuum, obtains alcohol 71 (25mg, the productive rate: 44%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:8.79(d,1H,J=9.6Hz),7.28-7.22(m,1H),6.85(t,1H,J=11.7Hz),6.73(t,1H,J=9.6Hz),6.58(d,1H,J=8.7Hz),6.12(d,1H,J=11.4Hz),5.68-5.61(m,2H),5.26(d,1H,J=9.9Hz),4.86(q,1H,J=8.1Hz),4.38(d,1H,J=9.3Hz),4.20-4.18(m,1H),3.78-3.76(m,1H),3.64(s,3H),3.10(br s,1H),2.86-2.79(m,1H),2.41-2.14(m,6H),1.82(s,6H),1.14(d,3H,J=6.6Hz),1.02(s,9H)。
the synthesis of compound 72
At 0 DEG C, in anhydrous DCM (3.1mL) solution of 71 (21.6mg, 0.0443mmol), add trichloroacetyl isocyanate (TCAI) (6.4 μ l, 0.053mmol).0 DEG C of reaction stirred 30 minutes, then add neutral alumina.Stir the mixture 5-30 minute, then immerses in aluminum oxide pad.The mixture of DCM/MeOH 50: 1 is used to wash out product.Filtrate evaporated in vacuo, obtains crude product, and crude product is by column chromatography (hexane/EtOAc 1: 2) purifying.Obtain compound 72 (19.1mg, the productive rate: 76%) of white solid.
1H NMR(CDCl
3,500MHz)δ:8.61(d,1H,J=11.1Hz),7.27(t,1H,J=11.4Hz),6.92-6.78(m,2H),6.52(d,1H,J=9.3Hz),6.15(d,1H,J=11.4Hz),5.69(d,1H,J=11.4Hz),5.62-5.61(m,1H),5.45(br s,2H),5.28(d,1H,J=9.6Hz),4.87-4.78(m,1H),4.53-4.45(m,1H),4.42(d,1H,J=9.6Hz),4.25-4.20(m,1H),3.64(s,3H),2.87-2.80(m,1H),2.44-2.17(m,6H),1.81(s,6H),1.16(d,3H,J=6.5Hz),1.04(s,9H)。
embodiment 15
Flow process 15 provides the synthesis of compound 73.
Flow process 15
the synthesis of compound 73
At 0 DEG C, in NMP (0.8mL) solution of 30 (40mg, 0.076mmol) and 9 (31mg, 0.09mmol), add thiophene carboxylic acid's copper (CuTC, 22mg, 0.11mmol).0 DEG C of reaction stirred 45 minutes and stirring at room temperature 1 hour.Then, filter crude mixture by the plug of neutral alumina, with EtOAc/ ether 50: 50 (20mL) cleaning, and clean the filtrate merged with HCl 0.5N (3 × 10mL).After dry also solvent evaporated under reduced pressure, by column chromatography (ethyl acetate/hexane 5: 1 to 2: 1) purification of crude product, obtain 73 pure (6mg, productive rates: 17%).
1H NMR(CDCl
3,300MHz)δ:7.27(t,1H,J=I 1.46Hz),6.90(t,1H,J=11.52Hz),6.16(d,1H,J=11.7),6.03(d,1H,J=9.55Hz),5.84-5.70(m,1H),5.67-5.60(m,2H),5.28(d,1H,J=10.66Hz),5.14-5.06(m,2H),4.53(d,1H,J=9.41Hz),4.22-4.10(m,3H),3.65(s,3H),2.91-2.81(m,1H),2.47-2.34(m,4H),1.84(s,3H),1.16(d,3H,J=6.65Hz),0.99(s,9H)。
embodiment 16
Flow process 16 provides the synthesis of several compound of the present invention.
Flow process 16
the synthesis of compound 74
At 0 DEG C, to 40 (2.7g, 5.12mmol) with propynoic acid (0.41mL, N-(3-dimethylaminopropyl)-N '-ethyl-carbodiimide hydrochloride EDC (1.23g, 6.4mmol) is added in anhydrous DCM (51mL) solution 6.66mmol).0 DEG C of reaction stirred 30 minutes, and stirring at room temperature 2 hours.Then, to go out crude mixture use dichloromethane extraction with shrend.Use H
2the filtrate that O cleaning merges.In drying and after solvent evaporated under reduced pressure, by column chromatography (EtOAc/ hexanes mixtures) purification of crude product, obtain pure compound 74 (2.25g, the productive rate: 85%) of white solid.
1H NMR(CDCl
3,300MHz)δ:7.66(m,4H),7.47-7.36(m,6H),6.96(d,1H,J=10.5Hz),6.66(d,1H,J=9.2Hz),6.62(t,1H,J=8.9Hz),5.52(t,1H,J=7.4Hz),4.79(q,1H,J=8.6Hz),4.27(d,1H,J=9.4Hz),3.83(m,1H),2.82(s,1H),2.19-2.04(m,4H),1.87(s,3H),1.05(s,9H),0.99(s,9H)。
the synthesis of intermediate 75
Under argon gas, by propynoic acid (45 μ L, 0.726mmol), amine 62 (275mg, anhydrous DCM (5.6mL) solution 0.56mmol) is cooled to 0 DEG C, and add N-(3-dimethylaminopropyl)-N '-ethyl-carbodiimide hydrochloride EDC (134mg, 0.7mmol).0 DEG C of stirred reaction mixture 10 minutes, 23 DEG C were stirred 3 hours, go out and use dichloromethane extraction with shrend.Dry (anhydrous Na
2sO
4) organic layer that merges, filter and concentrate.By flash chromatography (EtOAc/ hexane 1: 10 to 3: 1) purifying residuum, obtain 75 (260mg, productive rates: 85%) of colourless foam solid.
1H NMR(CDCl
3,300MHz)δ:7.69-7.67(m,4H),7.44-7.36(m,6H),7.08(d,1H,J=10.2Hz),6.67-6.61(m,2H),5.53-5.45(m,1H),5.35-5.26(m,1H),4.92-4.84(m,1H),4.26(d,1H,J=9.6Hz),3.89-3.82(m,1H),2.80(s,1H),2.26-2.05(m,4H),1.44(d,3H,J=7.8Hz),1.05(s,9H),0.97(s,9H)。
the synthesis of intermediate 76
Under 0 DEG C and nitrogen, in anhydrous THF (5mL) solution of 75 (244.3mg, 0.45mmol), add THF (0.54mL, the 0.54mmol) solution of 1M TBAF.Stirring at room temperature reactant 3 hours, then use saturated NH
4the cancellation of the Cl aqueous solution, and extract with EtOAc.Organic layer after merging is through anhydrous Na
2sO
4dry, filter and concentrate.Flash chromatography (hexane/EtOAc 4: 1 to 1: 2) purifying residuum, obtains alcohol 76 (94.1mg, the productive rate: 69%) of faint yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:9.02(d,1H,J=9.9Hz),7.09(d,1H,J=9.3Hz),6.74(t,1H,J=9.9Hz),5.65-5.57(m,1H),5.43-5.35(m,1H),4.93-4.85(m,1H),4.44(d,1H,J=9.3Hz),3.78-3.70(m,1H),2.87(s,1H),2.32-2.12(m,4H),1.61(d,3H,J=6.6Hz),1.02(s,9H).
13C NMR(CDCl
3,75MHz)δ:167.7,152.4,127.7,126.0,123.5,109.4,77.3,74.9,72.1,61.3,35.4,34.7,33.2,26.8,13.3。
the synthesis of intermediate 77
In room temperature, in anhydrous DCM (1.6mL) solution of 76 (48.6mg, 0.159mmol), add trichloroacetyl isocyanate (TCAI) (23.0 μ l, 0.19mmol).Stirring at room temperature reactant 30 minutes, then add neutral alumina (250mg).Stir the mixture 60 minutes, then immerse in aluminum oxide pad.The mixture of methylene dichloride/MeOH 50: 1 is used to wash out product.Reduction vaporization filtrate, obtains crude product, and crude product obtains compound 77 (43mg, the productive rate: 77%) of white solid by column chromatography (hexane/EtOAc 3: 1 to 1: 100) purifying.
1H NMR(CDCl
3,300MHz)δ:9.02(d,1H,J=10.5Hz),7.12(bs,1H),7.04(d,1H,J=9.6Hz),6.98(bs,1H),6.80(t,1H,J=9.7Hz),5.63-5.53(m,1H),5.42-5.33(m,1H),4.86(q,1H,J=8.3Hz),4.48-4.30(m,1H),4.39(d,1H,J=9.6Hz),2.87(s,1H),2.46-2.43(m,1H),2.35-2.30(m,2H),2.18-2.11(m,1H),1.61(d,3H,J=6.0Hz),1.00(s,9H)。
the synthesis of compound 78
Under room temperature and nitrogen, in Diisopropylamine (4.3mL) solution of iodo compound 9 (300mg, 0.86mmol), add Pd (Ph
3p)
4(20mg, 0.017mmol) and CuI (6.4mg, 0.034mmol).Then add compound 74 (500mg, 0.86mmol) in batches, and stirring at room temperature reaction mixture 2 hours.Use H
2o cancellation crude product also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (hexane/EtOAc 3: 1 to 1: 1) purifying, obtain compound 78 (580mg, the productive rate: 85%) of pure yellow solid.
1H NMR(CDCl
3,300MHz)δ:7.67(m,4H),7.48-7.37(m,6H),7.75(d,1H,J=10.5Hz),6.65(t,1H,J=10.1Hz),6.46(d,1H J=9.2Hz),6.38(d,1H,J=12.0Hz),5.64-5.48(m,3H),5.43(d,1H,J=12.1Hz),4.78(q,1H,J=7.7Hz),4.28(d,1H,J=9.3Hz),4.20(m,1H),3.82(m,1H),3.65(s,3H),2.86(m,1H),2.40(m,2H),2.14(m,4H),2.09(s,3H),1.86(s,3H),1.15(d,3H,J=6.6Hz),1.05(s,9H),0.99(s,9H)。
the synthesis of compound 79
At 23 DEG C, in DIPA (1.6mL) solution of 9 (113mg, 0.325mmol), add Pd (Ph
3p)
4(7mg, 0.006mmol) and CuI (2.5mg, 0.013mmol).Then 75 (195mg, 0.358mmol) are added, and 23 DEG C of reaction stirred 3 hours.Use H
2o cancellation crude mixture also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (EtOAc/ hexane 1: 3 to 1: 1) purifying residuum, obtain compound 79 (180mg, the productive rate: 70%) of colourless foam solid.
1H NMR(CDCl
3,300MHz)δ:7.67-7.64(m,4H),7.60(d,1H,J=10.8Hz),7.46-7.35(m,6H),6.66(t,1H,J=9.6Hz),6.59(dd,1H,J=9.9Hz),6.31(d,1H,J=12.6Hz),5.62-5.54(m,2H),5.42-5.37(m,1H),5.32(d,1H,J=12.0Hz),5.30-5.23(m,1H),4.92-4.84(m,1H),4.42(d,1H,J=9.6Hz),4.23-4.15(m,1H),3.86-3.78(m,1H),3.63(s,3H),2.88-2.80(m,1H),2.41-2.36(m,2H),2.22-2.11(m,4H),2.06(s,3H),1.39(d,3H,J=6.9Hz),1.13(d,3H,J=6.6Hz),1.03(s,9H),0.96(s,9H)。
13c NMR (CDCl
3, 75MHz) and δ: 167.5,161.7,153.3,148.2,145.4,138.2,136.1,135.7,134.4,129.9,127.8,127.8,126.5,126.1,121.6,109.5,108.5,103.1,88.2,85.1,81.7,72.6,60.8,55.6,37.2,35.6,34.1,32.6,27.2,26.7,26.6,19.5,16.4,15.5, a 13.1. (Csp
2no-fix).
the synthesis of compound 80
At 23 DEG C, in DIPA (0.6ml) solution of 9 (52mg, 0.15mmol), add Pd (Ph
3p)
4(3.5mg, 0.003mmol) and CuI (1.14mg, 0.006mmol).Then the solution be made up of the DIPA of 0.4mL and 75 (45.5mg, 0.15mmol) is added, and 23 DEG C of reaction stirred 120 minutes.Use H
2o cancellation crude mixture also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (methylene dichloride/MeOH 100: 1 to 20: 1) purifying residuum, obtain 80 (59.5mg, productive rates: 75%%) of pure colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:8.94(d,1H,J=9.9Hz),6.75(t,1H,J=9.3Hz),6.69(d,1H,J=9.0Hz),6.37(d,1H,J=12.0Hz),5.68-5.57(m,3H),5.44(d,1H,J=12.0Hz),5.43-5.35(m,1H),4.95-4.87(m,1H),4.34(d,1H,J=9.3Hz),4.24-4.17(m,1H),3.76(m,1H),3.64(s,3H),2.91-2.78(m,1H),2.63(bs,1H),2.43-2.38(m,2H),2.32-2.11(m,4H),2.07(s,3H),1.62(d,3H,J=6.6Hz),1.14(d,3H,J=6.6Hz),1.01(s,9H)。
13C NMR(CDCl
3,125MHz)δ:167.5,161.5,153.2,147.9,145.1,137.8,135.4,127.8,125.5,123.6,109.0,108.3,103.0,88.0,84.7,81.4,72.0,61.1,55.4,37.0,35.2,34.5,32.8,26.6,26.4,16.2,15.3,13.0。
MS(ES)[m/z]=549.2[M+Na]
+。
the synthesis of compound 81
At 23 DEG C, in DIPA (0.6ml) solution of 9 (43mg, 0.123mmol), add Pd (Ph
3p)
4(2.8mg, 0.0025mmol) and CuI (1.0mg, 0.005mmol).Then the solution be made up of the DIPA of 0.4ml and 77 (43mg, 0.123mmol) is added, and 23 DEG C of reaction stirred 120 minutes.Use H
2o cancellation crude mixture also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (methylene dichloride/MeOH 100: 1 to 20: 1) purifying residuum, obtain 81 (38mg, productive rates: 54%) of pure colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:9.00(d,1H,J=10.8Hz),6.81(t,1H,J=9.6Hz),6.73(d,1H,J=9.6Hz),6.38(d,1H,J=12.0Hz),5.63-5.56(m,5H),5.45(d,1H,J=11.7Hz),5.43-5.36(m,1H),4.90-4.81(m,1H),4.40(d,1H,J=9.3Hz),4.40-4.33(m,1H),4.24-4.17(m,1H),3.64(s,3H),2.90-2.82(m,1H),2.42-2.31(m,5H),2.18-2.09(m,1H),2.09(s,3H),1.62(d,3H,J=6.6Hz),1.15(d,3H,J=6.6Hz),1.01(s,9H)。
embodiment 17
Flow process 17 provides the synthesis of several compound of the present invention.
Flow process 17
the synthesis of compound 82
At 0 DEG C, to alkenylstannane 21a (1.1g, 1.47mmol) He 9 (0.62g, in 1-Methyl-2-Pyrrolidone (NMP) (14.7mL) solution 1.77mmol), add thiophene carboxylic acid's copper (CuTC) (422mg, 2.2mmol).0 DEG C of reaction stirred 45 minutes and stirring at room temperature 20 minutes.Then, filter crude mixture by the plug of neutral alumina, clean with EtOAc/ ether 50: 50, and clean the filtrate merged with HCl 0.5N (3 × 15mL).Dry organic solution is also evaporated, and obtains crude product, by column chromatography (hexane/EtOAc 5: 1 to 1: 1) purification of crude product, obtains triolefin 82 (0.66g, the productive rate: 66%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.89(d,1H,J=10.8Hz),7.22(dd,1H,J=12.3,11.4Hz),6.86(dd,1H,J=11.7,11.4Hz),6.70(dd,1H,J=9.9,9.3Hz),6.35(d,1H,J=9.3Hz),6.13(d,1H,J=11.4Hz),5.66(d,1H,J=11.4Hz),5.60(dd,1H,J=5.4,3.9Hz),5.55(br t,1H,J=7.8Hz),5.26(d,1H,J=10.2Hz),4.84-4.76(m,1H),4.3(d,1H,J=9.3Hz),4.20-4.16(m,1H),3.77-3.69(m,1H),3.63(s,3H),2.89-2.77(m,1H),2.41-2.33(m,2H),2.19-2.13(m,4H),2.00(s,3H),1.82(s,3H),1.13(d,3H,J=6.9Hz),1.02(s,9H),0.86(s,9H),0.4(s,3H),0.03(s,3H)。
13C NMR(CDCl
3,75MHz)δ:168.5,166.4,161.8,145.4,140.3,137.3,134.4,134.3,131.0,124.3,124.1,122.4,121.2,108.7,108.4,82.0,71.6,60.6,55.6,37.5,36.5,35.1,33.8,26.5,26.0,21.3,18.3,17.4,16.9,-4.3,-4.4。
the synthesis of compound 83
Under room temperature and nitrogen, in anhydrous THF (6mL) solution of 82 (275mg, 0.41mmol), add the THF solution (0.82mL, 0.82mmol) of 1M TBAF.Stirring at room temperature reaction response thing 18 hours, then extract with EtOAc with saturated aqueous ammonium chloride cancellation.Through anhydrous Na
2sO
4the dry organic phase merged, filters, concentrated.By flash chromatography method (hexane/EtOAc 3: 1 to 1: 2) purifying residuum, obtain alcohol 83 (175g, the productive rate: 76%) of white solid.
1H NMR(CDCl
3,300MHz)δ:9.00(d,1H,J=10.2Hz),7.25(dd,1H,J=12.0,11.4Hz),6.86(dd,1H,J=11.7,11.4Hz),6.72(dd,1H,J=9.6,8.7Hz),6.68(d,1H,J=8.7Hz),6.13(d,1H,J=11.7Hz),5.68(d,1H,J=11.4Hz),5.63-5.58(m,2H),5.27(d,1H,J=10.2Hz),4.85-4.76(m,1H),4.42(d,1H,J=9.3Hz),4.25-4.17(m,1H),3.70-3.69(m,1H),3.63(s,3H),3.48(br s,1H),2.89-2.75(m,1H),2.42-2.36(m,2H),2.22-2.11(m,4H),2.04(s,3H),1.82(s,3H),1.14(d,3H,J=6.6Hz),1.03(s,9H)。
the synthesis of compound 84
At 0 DEG C, in anhydrous DCM (7.5mL) solution of 83 (300mg, 0.53mmol), add trichloroacetyl isocyanate (TCAI) (76 μ l, 0.64mmol).0 DEG C of reaction stirred 30 minutes, then add neutral alumina.Stir the mixture 5-30 minute and immerse in aluminum oxide pad.DCM/MeOH 50: 1 is used to wash out product.Filtrate evaporated in vacuo, obtains crude product, by column chromatography (hexane/EtOAc 2: 1 to 1: 2) purification of crude product, obtains compound 84 ((0.26g, the productive rate: 81%) of white solid.
1H NMR(CDCl
3,300MHz)δ:8.78(d,1H,J=10.8Hz),7.30(dd,1H,J=11.6,11.6Hz),6.91(dd,1H,J=11.6,11.6Hz),6.84(br dd,1H,J=10.8,9.7Hz),6.51(d,1H,J=9.5Hz),6.17(d,1H,J=11.6Hz),5.70(d,1H,J=11.6Hz),5.63(dd,1H,J=6.5,2.6Hz),5.61(br t,1H,J=6.8Hz),5.29(d,1H,J=9.8Hz),4.80(m,1H),4.41(m,1H),4.41(d,1H,J=9.5Hz),4.24(ddd,1H,J=11.5,7.1,4.1Hz),3.66(s,3H),2.85(ddq,1H,J=9.8,7.1,6.7Hz),2.46(m,1H),2.45(ddd,1H,J=17.3,11.5,2.6Hz),2.37(ddd,1H,J=17.3,6.5,4.1Hz),2.33(m,2H),2.09(ddd,1H,J=14.1,8.4,8.1Hz),2.06(s,3H),1.82(s,3H),1.15(d,3H,J=6.7Hz),1.04(s,9H)。
13C NMR(CDCl
3,75MHz)δ:168.2,166.3,161.6,157.2,145.2,140.2,137.6,134.1,133.7,132.0,124.6,124.5,122.4,120.7,108.2,105.0,81.9,74.9,60.8,55.4,37.1,34.7,33.0,30.7,26.7,26.1,21.0,17.1,16.3。
the synthesis of compound 85
Under an argon atmosphere, to the compound 84 (10mg of-78 DEG C of coolings, toluene solution (the 0.02mL of 1M diisobutylaluminium hydride (DIBAL) is added in anhydrous methylene chloride (0.3mL) solution 0.016mmol), 0.02mol), and stir the mixture at-78 DEG C.React with saturated aqueous ammonium chloride solution cancellation after 2 hours and use methylene dichloride (2mL) to dilute.This mixture of stirring at room temperature 0.5 hour, then separates out organic layer.The other methylene dichloride (2 × 4mL) of remaining aqueous phase extracts, the dry organic layer (anhydrous Na merged
2sO
4) and evaporating solvent.Column chromatography (hexane/EtOAc 2: 1 to 1: 2) purification of crude product, obtains compound 85 (5mg, the yield: 50%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:8.57(d,1H,J=10.9Hz),7.19(t,1H,J=11.3Hz),6.92(t,1H,J=11.4Hz),6.82(t,1H,J=9.3Hz),6.38(d,1H,J=9.5Hz),6.18(d,1H,J=11.5Hz),5.64(d,1H,J=11.2Hz),5.60(m,1H),5.35(d,1H,J=10.0Hz),5.27(d,1H,J=3.1Hz),4.81(m,2H),4.46(m,1H),4.40(d,1H,J=9.5Hz),3.85(m,1H),3.57(s,3H),3.21(d,1H,J=3.1Hz),2.61(m,1H),2.46-2.29(m,3H),2.14-2.08(m,3H),2.06(s,3H),1.81(s,3H),1.08(d,3H,J=6.7Hz),1.05(s,9H)。
Embodiment 18
Flow process 18 provides the synthesis of several compound of the present invention.
Flow process 18
the synthesis of compound 86
At 0 DEG C, in NMP (9mL) solution of alkenylstannane 63 (780.4mg, 0.904mmol) and 9 (377.4mg, 1.085mmol), add thiophene carboxylic acid's copper (258.5mg, 1.36mmol).0 DEG C of reaction stirred 45 minutes and stirring at room temperature 20 minutes.Then, filter crude mixture by the plug of neutral alumina, clean with EtOAc/ ether 50: 50, and clean the filtrate merged with HCl 0.5N (3 × 10mL).Dry organic solution is also evaporated, and obtains crude product, by column chromatography (hexane/EtOAc 5: 1 to 1: 1) purification of crude product, obtains triolefin 86 (459.7g, the productive rate: 66%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:7.66-7.64(m,4H),7.43-7.32(m,7H),7.23(t,1H,J=11.7Hz),6.85(t,1H,J=11.7Hz),6.62(dd,1H,J=10.5,9.3Hz),6.41(d,1H,J=9.3Hz),6.11(d,1H,J=11.7Hz),5.66(d,1H,J=11.4Hz),5.60(dd,1H,J=5.7,5.1Hz),5.49-5.41(m,1H),5.32-5.27(m,1H),5.25(d,1H,J=9.9Hz),4.83-4.75(m,1H),4.32(d,1H,J=9.3Hz),4.22-4.15(m,1H),3.83-3.78(m,1H),3.62(s,3H),2.86-2.78(m,1H),2.40-2.35(m,2H),2.20-2.04(m,4H),1.81(s,3H),1.40(d,3H,J=6.9Hz),1.13(d,3H,J=6.9Hz),1.03(s,9H),0.97(s,9H)。
13C NMR(CDCl
3,75MHz)δ:168.3,166.3,161.8,145.4,140.2,137.3,136.1,134.8,134.4,134.3,129.9,127.8,126.4,126.1,124.4,121.7,121.2,108.4,109.1,82.0,72.6,60.6,55.6,37.5,35.2,32.7,31.1,27.2,26.8,26.5,19.5,17.4,16.9,13.1。
the synthesis of compound 87
Under room temperature and nitrogen, in anhydrous THF (7.5mL) solution of 86 (586mg, 0.76mmol), add THF (1.53mL, the 2mmol) solution of 1M TBAF.Stirring at room temperature reaction response thing 18 hours, then extract with EtOAc with saturated aqueous ammonium chloride cancellation.Through anhydrous Na
2sO
4the dry organic phase merged, filters, concentrated.By flash chromatography method (hexane/EtOAc 3: 1 to 1: 2) purifying residuum, obtain alcohol 87 (320mg, the productive rate: 80%) of white solid.
1H NMR(CDCl
3,300MHz)δ:8.95(d,1H,J=10.2Hz),7.25(t,1H,J=12.0Hz),6.85(t,1H,J=11.7Hz),6.73(t,1H,J=9.6Hz),6.57(d,1H,J=8.7Hz),6.12(d,1H,J=11.4Hz),5.67(d,1H,J=11.4Hz),5.61(dd,1H,J=5.4,3.9Hz),5.63-5.58(m,1H),5.44-5.35(m,1H),5.26(d,1H,J=9.9Hz),4.86(q,1H,J=8.1Hz),4.38(d,1H,J=9.3Hz),4.24-4.16(m,1H),3.81-3.71(m,1H),3.64(s,3H),2.96-2.92(m,1H),2.86-2.79(m,1H),2.41-2.37(m,2H),2.28-2.14(m,4H),1.82(s,3H),1.61(d,3H,J=6.6Hz),1.14(d,3H,J=6.6Hz),1.02(s,9H).
13C NMR(CDCl
3,75MHz)δ:168.7,166.6,161.8,145.4,140.3,137.5,134.4,134.3,127.7,126.0,124.4,123.7,121.1,108.9,108.4,82.0,72.1,60.9,55.7,37.6,35.0,34.8,33.2,26.9,26.5,17.4,16.9,13.3。
the synthesis of compound 88
At 0 DEG C, in anhydrous DCM (1mL) solution of 87 (56mg, 0.105mmol), add trichloroacetyl isocyanate (15 μ L, 0.126mmol).0 DEG C of reaction stirred 30 minutes, then add neutral alumina.Stir the mixture 5-30 minute, then immerses in aluminum oxide pad.By DCM/MeOH 50: 1 mixture wash products.Filtrate evaporated in vacuo, obtains crude product, by column chromatography (hexane/EtOAc3: 1 to 1: 2) purification of crude product, obtains compound 88 (57.6mg, the productive rate: 96%) of oil phase.
1H NMR(CDCl
3,300MHz)δ:8.69(d,1H,J=10.4Hz),7.31(dd,1H,J=11.6,11.6Hz),6.90(dd,1H,J=11.6,11.6Hz),6.82(ddd,1H,J=10.4,9.1,0.9Hz),6.53(d,1H,J=9.6Hz),6.15(d,1H,J=11.6Hz),5.72(br d,1H,J=11.6Hz),5.63(dd,1H,J=6.6,2.7Hz),5.60(m,1H),5.40(m,1H),5.29(d,1H,J=9.9Hz),4.82(m,1H),4.45(m,1H),4.44(d,1H,J=9.6Hz),4.25(ddd,1H,J=11.3,7.0,4.0Hz),3.66(s,3H),2.85(ddq,1H,J=9.9,7.0,6.7Hz),2.46(m,1H),2.44(m,1H),2.39(m,1H),2.35(m,2H),2.12(ddd,1H,J=14.1,8.0,8.0Hz),1.82(s,3H),1.63(dd,3H,J=6.8,1.0Hz),1.15(d,3H,J=6.7Hz),1.04(s,9H).
13C NMR(CDCl
3,75MHz)δ:168.2,166.3,161.6,157.6,145.2,140.2,137.5,134.1,133.8,127.1,124.9,124.4,124.2,120.8,108.2,105.8,81.9,75.6,60.7,55.4,37.1,34.8,31.4,30.9,26.7,26.1,17.1,16.4,13.0。
the synthesis of compound 89
Under an argon atmosphere, to the compound 88 (15mg of-78 DEG C of coolings, toluene (the 0.03mL of the diisobutylaluminium hydride (DIBAL) of 1M is added in anhydrous methylene chloride solution (0.5mL) 0.0262mmol), 0.034mol) solution, and stir the mixture at-78 DEG C.NH is used after 2 hours
4the saturated aqueous solution cancellation reaction of Cl, and dilute with methylene dichloride (2mL).This mixture of stirring at room temperature 0.5 hour, then separates out organic layer.With the extraction of other toluene dichloride (2 × 4mL) containing water surplus, the dry organic layer (anhydrous Na merged
2sO
4) and evaporating solvent, obtain compound 89 (12mg, the yield: 80%) without the need to being further purified.
1H NMR(CDCl
3,500MHz)δ:8.67(d,1H,J=10.7Hz),7.17(m,1H),6.92(t,1H,J=11.4Hz),6.81(t,1H,J=9.6Hz),6.44(d,1H,J=9.5Hz),6.18(d,1H,J=11.5Hz),5.65(d,1H,J=11.4Hz),5.59(m,1H),5.40(m,1H),5.35(d,1H,J=10.0Hz),5.27(s,1H),4.83(q,1H,J=8.3Hz),4.80(m,1H),4.46(m,1H),4.40(d,1H,J=9.6Hz),3.85(m,1H),3.57(s,3H),3.27(s,1H),2.61(m,1H),2.42(m,2H),2.15-1.99(m,4H),1.83(s,3H),1.63(d,3H,J=6.7Hz),1.08(d,3H,J=6.6Hz),1.04(s,9H)。
embodiment 19
Flow process 19 provides the synthesis of several compound of the present invention.
Flow process 19
the synthesis of intermediate 90a
By (E)-penta-2-alkene-4-acetylenic acid (52mg, 0.54mmol), amine 62 (232mg, anhydrous DCM (5mL) solution 0.47mmol) is cooled at 0 DEG C under argon gas, and add N-(3-dimethylaminopropyl)-N '-ethyl-carbodiimide hydrochloride EDC (100mg, 0.52mmol).0 DEG C of stirred reaction mixture 10 minutes, and stir 90 minutes at 23 DEG C.Use saturated NH
4the cancellation of the Cl aqueous solution, and use dichloromethane extraction.Dry organic layer (the anhydrous Na merged
2sO
4), filtering and concentrate, obtaining 90a (223mg, the productive rate: 83%) of the colourless foam solid without the need to being further purified.
1H NMR(CDCl
3,300MHz)δ:7.69-7.67(m,4H),7.44-7.36(m,6H),7.11(d,1H,J=10.8Hz),6.72-6.60(m,2H),6.42(d,1H J=8.1Hz),6.41(d,1HJ=15.6Hz),5.54-5.45(m,1H),5.36-5.27(m,1H),4.89-4.81(m,1H),4.30(d,1H,J=9.3Hz),3.89-3.79(m,1H),3.25(bs,1H),2.25-2.02(m,4H),1.45(d,3H,J=6.3Hz),1.05(s,9H),0.97(s,9H).
MS(ES)[m/z]=593.3[M+Na]
+。
13C NMR(CDCl
3,125MHz)δ:167.7,164.1,135.8,134.4,134.1,129.7,129.7,127.6,127.6,126.4,125.8,121.4,121.1,109.2,84.6,80.5,72.3,60.7,35.3,33.8,32.4,29.7,27.0,26.5,19.3,12.9。
the synthesis of intermediate 90b
Under 0 DEG C and nitrogen, to amine 20a (96.04mg, 0.24mmol) and (E)-penta-2-alkene-4-acetylenic acid (27.4mg, in anhydrous methylene chloride/DMF (10: 1,3.3mL) solution 0.28mmol), add DIPEA (0.049mL, 0.28mmol), HOAt (38.11mg, 0.28mmol) with HATU (106.4mg, 0.28mmol), remove cooling bath after 30 minutes.At stirring at room temperature reaction mixture 2h, with the cancellation of the saturated NH4Cl aqueous solution, and be poured into water, use dichloromethane extraction.The organic phase merged is through anhydrous Na
2sO
4drying, filters and concentrates.By flash chromatography (hexane/EtOAc, 20: 1 to 10: 1) purifying residuum, obtain 90b (81.9mg, the productive rate: 71%) of white foam.
1H NMR(CDCl
3,300MHz)δ:7.91(d,1H,J=10.2Hz),6.74-6.63(m,3H),6.48(d,1H,J=15.6Hz),5.58-5.53(m,1H),4.89-4.81(m,1H),4.48(d,1H,J=9.3Hz),3.77-3.73(m,1H),3.25(d,1H,J=9.3Hz),2.18-2.09(m,4H),2.01(s,3H),1.02(s,9H),0.87(s,9H),0.06(s,3H),0.04(s,3H).
13C NMR(CDCl
3,75MHz)δ:168.3,164.4,134.7,131.7,133.9,122.5,121.3,109.1,84.8,80.8,71.6,61.0,36.5,35.4,33.8,26.8,26.0,21.2,18.3,-4.3,-4.4。
the synthesis of compound 91a
At 23 DEG C, in DIPA (1.6ml) solution of 45 (56.2mg, 0.182mmol), add Pd (Ph
3p)
4(15.7mg, 0.014mmol) and CuI (5.2mg, 0.028mmol).Then the solution be made up of 0.4mL DIPA and 90a (114.6mg, 0.200mmol) is added, and 23 DEG C of reaction stirred 90 minutes.Use H
2o cancellation crude mixture also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By flash chromatography method (EtOAc/ hexane 1: 4 to 6: 1) purifying residuum, obtain compound 91a (96mg, the productive rate: 70%) of pure colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.68-7.66(m,4H),7.46-7.35(m,6H),7.11(d,1H,J=10.8Hz),6.81(dd,1H,J=15.3,2.1Hz),6.30(dd,1H,J=10.2,9.3Hz),6.32(d,1H,J=9.3Hz),6.25(d,1H,J=15.3Hz),6.156.32(dd,1H,J=15.9,8.4Hz),5.74(d,1H,J=15.9Hz),5.62(dd,1H,J=6.3,3.0Hz),5.54-5.46(m,1H),5.30-5.27(m,1H),4.84-4.82(m,1H),4.30(d,1H,J=9.3Hz),4.28-4.21(m,1H),3.86-3.82(m,1H),3.65(s,3H),2.68-2.62(m,1H),2.43-2.36(m,2H),2.22-2.04(m,4H),1.43(d,3H,J=6.6Hz),1.18(d,3H,J=6.9Hz),1.04(s,9H),0.96(s,9H)。
13C NMR(CDCl
3,125MHz)δ:167.7,164.3,161.3,145.5,145.2,135.2,134.1,131.8,129.8,129.7,127.6,127.6,126.4,125.8,122.2,121.4,111.3,109.1,108.0,95.1,86.7,80.8,72.3,60.7,55.4,41.5,35.2,33.8,32.4,29.7,27.0,26.5,25.9,19.3,15.5,12.9。
the synthesis of compound 91b
At 23 DEG C, in the DIPA solution (0.5ml) of 45 (30.2mg, 0.098mmol), add Pd (Ph
3p)
4(8mg, 0.007mmol) and CuI (3mg, 0.014mmol).Then the solution be made up of 0.5ml DIPA and 90b (47.6mg, 0.098mmol) is added, and 23 DEG C of stirring reactions 90 minutes.Use H
2o cancellation crude product also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By flash chromatography method (EtOAc/ hexane 1: 4 to 1: 1) purifying residuum, obtain the compound 91b (41.2mg, 64% productive rate) of pure colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.70(d,1H,J=10.2Hz),6.82(dd,1H,J=15.3,2.4Hz),6.72(t,1H,J=9.5Hz),6.28(d,1H,J=9.0Hz),6.25(d,1H,J=15.3Hz),6.15(dd,1H,J=15.9,8.1Hz),5.74(d,1H,J=15.9Hz),5.63(dd,1H,J=6.3,3.0Hz),5.62-5.55(m,1H),4.89-4.81(m,1H),4.38(d,1H,J=9.6Hz),4.30-4.23(m,1H),3.79-3.75(m,1H),3.65(s,3H),2.69-2.61(m,1H),2.44-2.32(m,2H),2.20-2.14(m,4H),2.02(s,3H),1.18(d,3H,J=6.6Hz),1.02(s,9H),0.87(s,9H),0.07(s,3H),0.05(s,3H)。
13C NMR (CDCl
3,75MHz)δ:168.1,164.6,161.5,145.7,145.4,132.1,131.2,123.9,122.4,111.5,108.9,108.2,95.4,86.9,81.0,71.7,61.0,55.7,41.7,36.5,35.4,33.8,29.9,26.8,26.2,26.1,21.3,18.3,15.7,-4.3,-4.4。
the synthesis of compound 91c
At 23 DEG C, in DIPA (1.6mL) solution of 27 (58mg, 0.188mmol), add Pd (Ph
3p)
4(16.3mg, 0.014mmol) and CuI (5.3mg, 0.028mmol).Then the solution be made up of 0.4ml DIPA and 90a (118.2mg, 0.207mmol) is added, and 23 DEG C of reaction stirred 90 minutes.Use H
2o cancellation crude product also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By flash chromatography method (EtOAc/ hexane 1: 4 to 6: 1) purifying residuum, obtain 91c (92mg, the productive rate: 65%) of pure colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.68-7.66(m,4H),7.46-7.35(m,6H),7.15(d,1H,J=10.5Hz),6.85(dd,1H,J=15.3,2.1Hz),6.64(dd,1H,J=10.5,9.3Hz),6.39(d,1H,J=9.0Hz),6.30(d,1H,J=15.3Hz),5.88(t,1H,J=10.5Hz),5.71(dd,1H,J=10.5,2.1Hz),5.69-5.61(m,1H),5.53-5.47(m,1H),5.35-5.30(m,1H),4.88-4.80(m,1H),4.31(d,1H,J=9.6Hz),4.28-4.19(m,1H),3.87-3.82(m,1H),3.65(s,3H),3.14-3.06(m,1H),2.58-2.47(m,1H),2.41-2.32(m,1H),2.23-2.04(m,4H),1.43(d,3H,J=6.6Hz),1.18(d,3H,J=6.9Hz),1.05(s,9H),0.98(s,9H)。
13C NMR(CDCl
3,300MHz)δ:167.9,164.5,161.7,145.5,145.4,136.1,134.3,132.4,130.0,129.9,127.9,127.8,126.7,126.1,122.2,121.6,110.7,109.4,108.4,93.2,91.8,81.0,72.6,61.0,55.6,39.6,35.4,34.0,32.7,29.8,27.2,26.8,23.5,19.5,15.8,13.2。
the synthesis of compound 91d
At-20 DEG C, in DIPEA (4mL) solution of 27 (26.2mg, 0.085mmol), add Pd (Ph
3p)
2cl
2(6mg, 0.0085mmol) and CuI (5mg, 0.025mmol).Then 90b (45mg, 0.094mmol) is added, and 23 DEG C of reaction stirred 90 minutes.Use H
2o cancellation crude mixture also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (EtOAc/ hexane 1: 10 to 2: 1) purifying residuum, obtain 91d (44.5mg, the productive rate: 79%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.75(d,1H,J=11.1Hz),6.81(dd,1H,J=15.6,2.4Hz),6.68(t,1H,J=9.3Hz),6.37(d,1H,J=9.3Hz),6.34(d,1H,J=11.7Hz),5.87(t,1H,J=10.8Hz),5.70(dd,1H,J=10.8,2.4Hz),5.62-5.57(m,2H),4.85(q,1H,J=8.1Hz),4.41(d,1H,J=9.3Hz),4.28-4.18(m,1H),3.81-3.72(m,1H),3.64(s,3H),3.16-3.06(m,1H),2.56-2.46(m,1H),2.40-2.32(m,1H),2.26-2.13(m,4H),2.04(s,3H),1.17(d,3H,J=6.6Hz),1.03(s,9H),0.87(s,9H),0.07(s,3H),0.05(s,3H)。
the synthesis of compound 92a
Under 0 DEG C and nitrogen, in anhydrous THF (2mL) solution of 91a (78.2mg, 0.104mmol), add THF (0.2mL, the 0.208mmol) solution of the TBAF of 1M.Stirring at room temperature reactant 3 hours, then use saturated aqueous ammonium chloride cancellation, and extract with EtOAc.Organic layer after merging is through anhydrous Na
2sO
4drying, filters, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 2) purifying residuum, obtain alcohol 92a (17.9mg, the productive rate: 34%) of faint yellow oil phase.
1H NMR(CDCl
3,500MHz)δ:8.89(d,1H,J=10.0Hz),6.80(dd,1H,J=15.0,2.0Hz),6.75(dd,1H,J=10.0,9.0Hz),6.50(d,1H,J=9.5Hz),6.28(d,1H,J=15.5Hz),6.14(dd,1H,J=15.5,8.0Hz),5.74(dd,1H,J=16.0,2.5Hz),5.68-65(m,1H),5.63(dd,1H,J=6.5,2.5Hz),5.42-5.39(m,1H),4.92-4.90(m,1H),4.37(d,1H,J=9.0Hz),4.28-4.23(m,1H),3.79-3.73(m,1H),3.65(s,3H),2.67-2.62(m,1H),2.47-2.37(m,2H),2.34-2.15(m,4H),1.64(d,3H,J=7.0Hz),1.18(d,3H,J=6.5Hz),1.01(s,9H)。
the synthesis of compound 92b
Under 0 DEG C and nitrogen, to 91b (41.2mg, 0.061mmol)) anhydrous THF (1mL) solution in, add THF (0.12mL, the 0.122mmol) solution of the TBAF of 1M.Stirring at room temperature reactant 18 hours, then use saturated aqueous ammonium chloride cancellation, and extract with EtOAc.Organic phase after merging is through anhydrous Na
2sO
4drying, filters, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 2) purifying residuum, obtain alcohol 92b (14.7mg, the productive rate: 65%) of faint yellow oil phase.
1H NMR(CDCl
3,500MHz)δ:8.85(d,1H,J=10.2Hz),6.84-6.73(m,2H),6.61(d,1H,J=9.3Hz),6.27(d,1H,J=15.6Hz),6.15(dd,1H,J=15.9,8.4Hz),5.75(d,1H,J=15.9Hz),5.63-5.60(m,2H),4.92-4.84(m,1H),4.41(d,1H,J=9.3Hz),4.29-4.23(m,1H),3.79-3.76(m,1H),3.65(s,3H),3.10(bs,1H),2.69-2.61(m,1H),2.46-2.37(m,2H),2.20-2.14(m,4H),2.04(s,3H),1.18(d,3H,J=6.9Hz),1.02(s,9H)。
the synthesis of compound 92c
Under 0 DEG C and nitrogen, in anhydrous THF (2mL) solution of 91c (71.5mg, 0.095mmol), add THF (0.19mL, the 0.19mmol) solution of the TBAF of 1M.Stirring at room temperature reactant 4 hours, then use saturated NH
4the cancellation of the Cl aqueous solution, and extract with EtOAc.Organic phase after merging is through anhydrous Na
2sO
4drying, filters, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 2) purifying residuum, obtain alcohol 92c (18.1mg, the productive rate: 37%) of faint yellow oil phase.
1H NMR(CDCl
3,300MHz)δ:8.94(d,1H,J=9.6Hz),6.83(dd,1H,J=15.3,2.1Hz),6.75(t,1H J=9.6Hz),6.57(d,1H,J=9.6Hz),6.32(d,1H,J=15.3Hz),5.88(d,1H,J=10.2Hz),5.74-5.70(m,1H),5.67-5.62m,2H),5.44-5.36(m,1H),4.95-4.86(m,1H),4.38(d,1H,J=9.3Hz),4.28-4.23(m,1H),3.77-3.73(m,1H),3.65(s,3H),3.14-3.06(m,1H),2.59-2.11(m,6H),1.63(d,3H,J=6.9Hz),1.19(d,3H,J=6.6Hz),1.02(s,9H)。
the synthesis of compound 92d
Under room temperature and nitrogen, in anhydrous THF (0.6mL) solution of 91d (40mg, 0.06mmol), add THF (0.12mL, the 0.12mmol) solution of the TBAF of 1M.Stirring at room temperature reactant 18 hours, then use saturated NH
4the cancellation of the Cl aqueous solution, and extract with EtOAc.Organic phase after merging is through anhydrous Na
2sO
4drying, filters, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 2) purifying residuum, obtain alcohol 92d (20mg, the productive rate: 61%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:8.90(d,1H,J=9.9Hz),6.82(dd,1H,J=15.6,2.4Hz),6.74(t,1H,J=9.6Hz),6.66(d,1H,J=9.3Hz),6.33(d,1H,J=9.3Hz),5.88(t,1H,J=10.5Hz),5.71(dd,1H,J=10.8,2.4Hz),5.64-5.59(m,2H),4.84(q,1H,J=7.8Hz),4.40(d,1H,J=9.3Hz),4.28-4.20(m,1H),3.72(m,1H),3.64(s,3H),3.13-3.06(m,2H),2.58-2.47(m,1H),2.41-2.33(m,1H),2.31-2.15(m,4H),2.05(s,3H),1.18(d,3H,J=6.9Hz),1.02(s,9H)。
embodiment 20
Flow process 20 provides the synthesis of following compound of the present invention.
Flow process 20
the synthesis of compound 93
At 23 DEG C, in anhydrous DCM (0.2mL) solution of 92d (6.5mg, 0.012mmol), add trichloroacetyl isocyanate (TCAI) (1.7 μ l, 0.014mmol).Stirring at room temperature reactant 30 minutes, then add neutral alumina (120mg).Stir the mixture 30 minutes, then immerse in aluminum oxide pad.The mixture of methylene dichloride/MeOH 50: 1 is used to wash out product.Reduction vaporization filtrate, obtains crude product, and crude product, by column chromatography (methylene dichloride/MeOH 100: 1 to 40: 1) purifying, obtains the compound 93 (3mg, productive rate 42%) of white solid.
1H NMR(CDCl
3,300MHz)δ:8.83(d,1H,J=10.5Hz),6.89-6.81(m,2H),6.62(d,1H,J=9.9Hz),6.32(d,1H,J=15.3Hz),5.87(t,1H,J=9.0Hz),5.73(dd,1H,J=10.5,2.4Hz),5.65-5.57(m,2H),5.38(bs,2H),4.84-4.76(m,1H),4.48(d,1H,J=9.3Hz),4.40-4.33(m,1H),4.28-4.21(m,1H),3.66(s,3H),3.19-3.10(m,1H),2.58-2.42(m,3H),2.35-2.30(m,2H),2.14-2.06(m,1H),2.08(s,3H),1.20(d,3H,J=6.6Hz),1.03(s,9H)。
13C NMR(CDCl
3,125MHz)δ:167.9,164.3,161.4,157.6,145.1,145.0132.3,132.0,124.5,122.3,121.9,110.6,108.3,104.9,92.9,91.7,80.8,75.1,61.2,55.5,39.3,35.0,32.9,30.9,26.7,26.4,21.0,15.9。
MS(ES)[m/z]=590.2[M+H]
+。
embodiment 21
Flow process 21 provides the synthesis of several compound of the present invention.
Flow process 21
the synthesis of intermediate 94
Under argon gas, by (Z)-iodo vinylformic acid (365mg, 1.84mmol) (as Takeuchi, R.Tanabe, K., Tanaka, S.J.Org.Chem.2000,65, in 1558-1561 describe and preparation), amine 62 (700mg, anhydrous DCM (12mL) solution 1.42mmol) is cooled to 0 DEG C, and adds N-(3-dimethylaminopropyl)-N '-ethyl-carbodiimide hydrochloride EDC (340.8mg, 1.78mmol).0 DEG C of stirred reaction mixture 10 minutes, then to stir 3 hours at 23 DEG C, use dichloromethane extraction with the cancellation of the saturated NaCl aqueous solution.Dry (anhydrous Na
2sO
4) organic layer that merges, filter and concentrate.By flash chromatography (EtOAc/ hexane 1: 10 to 1: 1) purifying residuum, obtain 94 (675mg, productive rates: 71%) of colourless foam solid.
1H NMR(CDCl
3,300MHz)δ:7.69-7.66(m,4H),7.44-7.36(m,6H),7.24(d,1H,J=9.6Hz),7.06(d,1H,J=9.3Hz),6.90(d,1H J=9.0Hz),6.68-6.61(m,2H),5.55-5.43(m,1H),5.35-5.26(m,1H),4.89-4.81(m,1H),4.38(d,1H,J=9.3Hz),3.88-3.80(m,1H),2.23-2.06(m,4H),1.43(d,3H,J=6.9Hz),1.05(s,9H),1.01(s,9H)。
13C NMR(CDCl
3,125MHz)δ:167.4,164.3,135.8,134.1,133.0,129.7,129.6,127.6,127.5,126.4,125.8,121.4,109.1,88.3,72.3,60.4,35.1,33.8,32.5,27.0,26.7,19.3,12.9.MS(ES)[m/z]=695.2[M+Na]
+。
the synthesis of compound 95
At 23 DEG C, in DIPA (5.5ml) solution of 94 (304.4mg, 0.45mmol), add Pd (Ph
3p)
4(39.3mg, 0.034mmol) and CuI (12.9mg, 0.068mmol).Then 56 (100mg, 0.45mmol) are added, and 23 DEG C of reaction stirred 45 minutes.Extract with EtOAc with H2O cancellation crude product.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By flash chromatography (EtOAc/ hexane 1: 4 to 3: 1) purifying residuum, obtain 95 (300mg, productive rates: 87%) of pure colourless foam solid.
1H NMR(CDCl
3,300MHz)δ:7.82(d,1H,J=9.3Hz),7.68-7.65(m,4H),7.46-7.29(m,7H),6.62(dd,1H,J=10.2,9.3Hz),6.14(d,1H,J=12.3Hz),6.08(dd,1H,J=10.5,9.3Hz),6.05(d,1H,J=12.3Hz),5.60(dd,1H,J=6.3,3.0Hz),5.52-5.43(m,1H),5.33-5.25(m,1H),4.85-4.77(m,1H),4.44(d,1H,J=9.3Hz),4.24-4.23(m,1H),3.88-3.80(m,1H),3.64(s,3H),2.91-2.79(m,1H),2.54-2.34(m,2H),2.23-2.04(m,4H),1.92(s,3H),1.42(d,3H,J=6.9Hz),1.13(d,3H,J=6.6Hz),1.04(s,9H),0.99(s,9H)。
13C NMR(CDCl
3,125MHz)δ:167.9,164.6,161.7,145.5,136.1,134.3,132.5,129.9,127.8,126.7,126.1,121.7,118.9,116.4,108.9,108.4,104.5,98.8,82.8,81.6,72.6,60.9,55.7,38.0,35.5,34.0,32.7,27.2,26.9,26.5,19.5,17.3,16.5,13.1。
the synthesis of compound 96
Under 0 DEG C and nitrogen, in anhydrous THF (3.3mL) solution of 95 (250mg, 0.326mmol), add the THF solution of 1M TBAF (0.65mL, 0.65mmol).Stirring at room temperature reactant 3 hours, then use saturated NH
4the cancellation of the Cl aqueous solution, extracts with EtOAc.Organic phase after merging is through anhydrous Na
2sO
4drying, filters, concentrated.By flash chromatography method (hexane/EtOAc 4: 1 to 1: 3) purifying residuum, obtain alcohol 96 (150mg, the productive rate: 87%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:8.76(d,1H,J=9.9Hz),7.83(d,1H,J=9.0Hz),6.74(t,1H,J=9.3Hz),6.17(d,1H,J=12.0Hz),6.15-6.09(m,1H),6.07(d,1H,J=12.0Hz),5.74-5.60(m,1H),5.61(dd,1H,J=6.3,3.0Hz),5.44-5.37(m,1H),4.94-4.85(m,1H),4.41(d,1H,J=9.3Hz),4.25-4.17(m,1H),3.76(m,1H),3.65(s,3H),2.92-2.80(m,1H),2.55-2.11(m,6H),1.93(s,3H),1.62(d,3H,J=6.6Hz),1.14(d,3H,J=6.6Hz),1.01(s,9H)。
embodiment 22
Flow process 22 provides the synthesis of several compound of the present invention.
Flow process 22
the synthesis of intermediate 97
At 0 DEG C, in anhydrous DCM (3.8ml) solution of 40 (200mg, 0.38mmol) and 4-pentynoic acid (48mg, 0.49mmol), add EDC (91mg, 0.47mmol).0 DEG C of reaction stirred 30 minutes and at stirring at room temperature 2h.Then, also extract with methylene dichloride (3 × 5mL) with water hydrolysis crude mixture.After drying and solvent evaporated under reduced pressure, by column chromatography (hexane/EtOAc 6: 1) purification of crude product, obtain pure compound 97 (105mg, the productive rate: 47%) of colourless oil phase.
1H NMR(CDCl
3,300MHz)δ:7.66(m,4H),7.43(m,6H),7.14(d,1H,J=10.6Hz),6.65(t,1H,J=9.3Hz),6.40(d,1H,J=9.1Hz),5.52(t,1H,J=7.2Hz),4.75(q,1H,J=7.6Hz),4.29(d,1H,J=9.2Hz),3.81(m,1H),2.63-2.40(m,4H),2.19-2.03(m,5H),1.86(s,3H),1.05(s,9H),0.98(s,9H)。
the synthesis of compound 98
Under room temperature and nitrogen, in Diisopropylamine (0.75mL) solution of iodo compound 9 (52mg, 0.148mmol), add Pd (Ph
3p)
4(2.3mg, 0.002mmol) and CuI (1.0mg, 0.005mmol).Then compound 97 (90mg, 0.148mmol) is added in batches, and stirring at room temperature reaction mixture 2 hours.Use H
2o cancellation crude product also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (hexane/EtOAc 3: 1 to 1: 2) purifying, obtain pure compound 98 (105mg, the productive rate: 86%) of white solid.
1H NMR(CDCl
3,300MHz)δ:7.66(m,4H),7.41(m,6H),7.26(d,1H,J=10.6Hz),6.64(t,1H,J=10.1Hz),6.42(d,1H J=9.3Hz),6.06(d,1H,J=12.0Hz),5.61(m,1H),5.48(m,2H),5.35(d,1H,J=11.8Hz),4.74(q,1H,J=8.3Hz),4.28(d,1H,J=9.2Hz),4.16(m,1H),3.81(m,1H),3.64(s,3H),2.81(m,1H),2.66(m,2H),2.47-2.36(m,4H),2.18-2.06(m,4H),2.04(s,3H),1.85(s,3H),1.12(d,3H,J=6.6Hz),1.04(s,9H),0.98(s,9H)。
the synthesis of compound 99
Under room temperature and nitrogen, in anhydrous THF (1.5mL) solution of 98 (75mg, 0.09mmol), add THF (0.18mL, the 0.18mmol) solution of the TBAF of 1M.Stirring at room temperature reactant 4 hours, then use saturated NH
4the cancellation of the Cl aqueous solution, and extract with EtOAc.Organic phase after merging is through anhydrous Na
2sO
4drying, filters, concentrated.Flash chromatography method (hexane/EtOAc 3: 1 to 1: 3) purifying residuum, obtains alcohol 99 (35mg, the productive rate: 67%) of white solid.
1H NMR(CDCl
3,300MHz)δ:8.92(d,1H,J=10.1Hz),6.74(t,1H,J=9.5Hz),6.67(d,1H,J=9.1Hz),6.06(d,1H,J=12.0Hz),5.62(m,2H),5.47(d,1H,J=9.8Hz),5.34(d,1H,J=11.9Hz),4.84(q,1H,J=8.5Hz),4.32(d,1H,J=9.1Hz),4.18(m,1H),3.73(m,1H),3.64(s,3H),3.20(d,1H,J=4.0Hz),2.82(m,1H),2.66(m,2H),2.49-2.36(m,4H),2.24-2.14(m,4H),2.05(s,3H),2.02(s,3H),1.12(d,3H,J=6.6Hz),1.00(s,9H)。
13C NMR(CDCl
3,75MHz)δ:171.3,168.4,161.7,145.1,142.1,135.5,134.4,131.7,123.6,123.4,108.4,108.2,106.1,94.3,81.8,80.2,71.4,60.9,36.7,36.1,35.3,34.5,33.0,29.6,26.5,26.3,21.0,16.4,16.1,15.5。
the synthesis of compound 100
In room temperature, in anhydrous DCM (3.15mL) solution of 99 (30mg, 0.05mmol), add trichloroacetyl isocyanate (TCAI) (6 μ l, 0.06mmol).Stirring at room temperature reactant 30 minutes, then add neutral alumina (375mg).Stir the mixture 1 hour, then immerse in aluminum oxide pad.The mixture of methylene dichloride/MeOH 50: 1 is used to wash out product.Reduction vaporization filtrate, obtains crude product, and crude product, by column chromatography (hexane/EtOAc) purifying, obtains compound 100 (26mg, the productive rate: 82%) of white solid.
1H NMR(CDCl
3,300MHz)δ:8.87(d,1H,J=10.7Hz),6.81(t,1H,J=9.8Hz),6.62(d,1H,J=9.5Hz),6.06(d,1H,J=12.0Hz),5.75(bs,2H),5.61(m,2H),5.45(d,1H,J=10.1Hz),5.35(d,1H,J=11.9Hz),4.80(q,1H,J=8.4Hz),4.37(m,1H),4.33(d,1H,J=9.3Hz),4.18(m,1H),3.64(s,3H),2.83(m,1H),2.66(m,2H),2.50-2.27(m,8H),2.05(s,3H),2.03(s,3H),1.12(d,3H,J=6.6Hz),0.99(s,9H)。
embodiment 23
Flow process 23 provides the synthesis of several compound of the present invention.
Flow process 23
the synthesis of compound 101
Under room temperature and nitrogen, in Diisopropylamine (1.1mL) solution of iodo compound 51 (70mg, 0.217mmol), add Pd (Ph
3p)
4(5mg, 0.004mmol) and CuI (1.7mg, 0.008mmol).Then compound 97 (132mg, 0.217mmol) is added in batches, and stirring at room temperature reaction mixture 2 hours.Use H
2o cancellation crude product also extracts with EtOAc.Dry organic phase (anhydrous Na
2sO
4) and reduction vaporization.By column chromatography (hexane/EtOAc 3: 1 to 1: 2) purifying, obtain pure compound 101 (80mg, the productive rate: 50%) of white solid.
1H NMR(CDCl
3,300MHz)δ:7.66(m,4H),7.41(m,6H),7.25(d,1H,J=10.6Hz),6.65(t,1H,J=10.1Hz),6.44(d,1H J=9.3Hz),5.63-5.48(m,3H),4.78(q,1H,J=8.3Hz),4.32(d,1H,J=9.2Hz),4.14(m,1H),3.81(m,1H),3.64(s,3H),2.81(m,1H),2.62(m,2H),2.46-2.33(m,4H),2.18-2.05(m,4H),2.02(s,3H),1.85(s,3H),1.12(d,3H,J=6.6Hz),1.04(s,9H),0.98(s,9H)。
embodiment 24: for detecting the biological assay of anti-tumor activity
The object of this mensuration is vitro inhibition cytoactive (postponing or stop the ability of growth of tumour cell) or the cellular cytoxicity activity (killing the ability of tumour cell) of assessing sample to be detected.
Clone
Title | N°ATCC | Classification | Tissue | Sex character |
A549 | CCL-185 | People | Lung | Lung cancer (NSCLC) |
HT29 | HTB-38 | People | Colon | Colon and rectum gland cancer |
MDA-MB-231 | HTB-26 | People | Breast | Mammary cancer |
Use the cellular cytoxicity activity evaluation of SBR colorimetric analysis
A kind of analysis of the colorimetric type using Sulforhodamine B (SRB) to react has been used to the growth of quantitative measurment cell and viability (according to J.Natl.Cancer Inst.1990 such as Skehan P, the technology described in 82,1107-1112).
This mensuration form employs cell cultures microplate (the Methods in cell science such as Faircloth, 1988,11 (4), 201-205 in SBS-standard-96 hole; Mosmann et al, Journal ofImmunological.Methods, 1983,65 (1-2), 55-63).All clones being derived from inhomogeneity human body cancer in this research all obtain from American type culture collection (ATCC).
Cell is at 37 DEG C, 5%CO
2with remain under 98% humidity in the Modified Eagle Medium (DMEM) of Dulbecco, be added with the foetal calf serum (FBS) of 10%, 2mM L-glutaminate, 100U/mL penicillin and 100U/mL Streptomycin sulphate.For this test, use tryptic digestion from point converging collecting cell culture, and before counting and plating Eddy diffusion in fresh substratum.
Every decile 150 μ L, cell is with every hole 5 × 10
3individual cell is seeded in the droplet plate in 96 holes, and makes to be attached to plate 18 hours on the surface in without the substratum of medicine.A contrast (untreated) plate (as described below) of fixing each clone is for time zero reference value.Then, joined in the culture of 10 a series of dilutions of every decile 50 μ L by test sample, concentration is from 10 to 0.00262 μ g/mL.After within 48 hours, exposing, evaluate antitumous effect: speak briefly by SRB method, cell PBS cleaning twice, fixes 15 minutes, rinsing twice in PBS in 1% glutaraldehyde solution, and in the SRB solution of room temperature 0.4% painted 30 minutes.Then with 1% acetic acid solution cleaning cell repeatedly and dry air.Then in three (methylol) aminomethane (trizma base) solution of 10mM, extract SRB, in automatic spectrophotometric plate reader, measure the absorbancy at 490nm place.Cell survival number is expressed as the percentage ratio of compared with control cells growth.The final effect of tested sample is evaluated by using NCI algorithm (Boyd MR and Paull KD.Drug Dev.Res.1995,34,91-104).
Use the mean value ± SD of triplicate culture, automatically generate dose-response curve by nonlinear regression analysis.Three basic parameters (NCI algorithm) are calculated: GI by automatic interpolation
50=produce 50% growth inhibiting concentration; The complete growth-inhibiting of TGI=(T suppression cell effect) and LC
50the concentration (cytotoxic effect) that=generation 50% clean cell kills.
Table 1 lists the biologically active data about compound of the present invention.
Table 1 toxicity test-activity data (mol)
Table 1. (Continued)
Table 1 (Continued)
Table 1 (Continued)
Table 1 (Continued)
Table 1 (Continued)
Claims (9)
1. the compound of general formula I or its pharmacy acceptable salt, tautomer or steric isomer,
Wherein, Y is-CHR
ay-CR
by=CR
cy-;
R
ay, R
byand R
cybe selected from hydrogen and unsubstituted C independently of one another
1-C
6alkyl;
R
1, R
2, R
3and R
4each hydrogen naturally; R
5unsubstituted C
1-C
6alkyl;
R
6nR
8r
9;
A is
W is NR
7;
R
7hydrogen;
R
8hydrogen;
The key that each represented by dotted arrows is optionally other and there is other key one or more in position represented by dashed line, but when and R
1and R
2when there is a triple bond between the carbon atom connected, R
1and R
2be non-existent, and work as and R
3and R
4when there is a triple bond between the carbon atom connected, R
3and R
4non-existent; And
R
9be selected from substituted or unsubstituted C
2-C
12thiazolinyl, substituted or unsubstituted C
2-C
12alkynyl, and substituted or unsubstituted C
4-C
12ene alkynyl base, wherein said optional substituting group is selected from halogen atom and OR ', and wherein R ' is hydrogen, silyl-protecting groups or CONR ' ' R ' ', and wherein each R ' ' is identical or different and is H or C
1-C
6alkyl;
R
16be selected from OR
a, wherein R
abe selected from hydrogen and unsubstituted C
1-C
6alkyl;
R
17and R
18hydrogen; With
R
19hydrogen.
2. compound according to claim 1, wherein, R
16be selected from OH and methoxyl group.
3. the compound according to any one of claim 1-2, wherein, with R
16and R
17the key that between the carbon atom connected, existence one is other.
4. the compound according to any one of claim 1-2, wherein, R
ay, R
byand R
cyindependently selected from hydrogen and methyl.
5. the compound according to any one of claim 1-2, wherein, R
5be selected from methyl, sec.-propyl and the tertiary butyl.
6. the compound according to any one of claim 1-2, wherein with R
1and R
2there is an other key between the carbon atom connected, and with R
3and R
4one or two other key is there is between the carbon atom connected.
7. a compound according to claim 1, or its pharmacy acceptable salt, tautomer or steric isomer, described compound has following structural formula:
8. a pharmaceutical composition, described pharmaceutical composition contains: according to compound or its pharmacy acceptable salt, tautomer or the steric isomer of aforementioned any one claim, and pharmaceutically acceptable carrier.
9. the compound according to any one of claim 1-7 or the application in the medicine preparing Therapeutic cancer of its pharmacy acceptable salt, tautomer or steric isomer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07123882 | 2007-12-20 | ||
EP07123882.8 | 2007-12-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880121840.6A Division CN101903367B (en) | 2007-12-20 | 2008-12-19 | Antineoplastic compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102190643A CN102190643A (en) | 2011-09-21 |
CN102190643B true CN102190643B (en) | 2015-02-25 |
Family
ID=40580474
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880121840.6A Active CN101903367B (en) | 2007-12-20 | 2008-12-19 | Antineoplastic compound |
CN2011100568656A Pending CN102174058A (en) | 2007-12-20 | 2008-12-19 | Antitumoral compounds |
CN201110073931.0A Active CN102190643B (en) | 2007-12-20 | 2008-12-19 | Antitumoral compounds |
CN2008801218410A Active CN101903337B (en) | 2007-12-20 | 2008-12-19 | Antitumoral compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880121840.6A Active CN101903367B (en) | 2007-12-20 | 2008-12-19 | Antineoplastic compound |
CN2011100568656A Pending CN102174058A (en) | 2007-12-20 | 2008-12-19 | Antitumoral compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801218410A Active CN101903337B (en) | 2007-12-20 | 2008-12-19 | Antitumoral compounds |
Country Status (27)
Country | Link |
---|---|
US (4) | US8710264B2 (en) |
EP (3) | EP2597091B1 (en) |
JP (3) | JP5529038B2 (en) |
KR (3) | KR101639772B1 (en) |
CN (4) | CN101903367B (en) |
AT (1) | ATE549313T1 (en) |
AU (2) | AU2008341670B2 (en) |
BR (2) | BRPI0821116B8 (en) |
CA (2) | CA2715203C (en) |
CY (1) | CY1117245T1 (en) |
DK (2) | DK2231633T3 (en) |
ES (3) | ES2384420T3 (en) |
HK (3) | HK1147990A1 (en) |
HR (2) | HRP20120464T1 (en) |
IL (3) | IL206397A (en) |
MX (2) | MX2010006796A (en) |
MY (3) | MY148651A (en) |
NZ (3) | NZ597526A (en) |
PL (2) | PL2231590T3 (en) |
PT (2) | PT2231590E (en) |
RS (2) | RS52343B (en) |
RU (3) | RU2528393C9 (en) |
SG (2) | SG170778A1 (en) |
SI (2) | SI2231590T1 (en) |
UA (3) | UA104281C2 (en) |
WO (2) | WO2009080769A1 (en) |
ZA (3) | ZA201004017B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010006796A (en) | 2007-12-20 | 2010-10-26 | Pharma Mar Sa | Antitumoral compounds. |
WO2013103155A1 (en) * | 2012-01-05 | 2013-07-11 | Kao Corporation | Agent for reduction of sensory irritation |
MA38588B1 (en) | 2013-04-16 | 2018-04-30 | Idorsia Pharmaceuticals Ltd | Bi-aromatic antibacterial derivatives |
GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
CN108467378A (en) * | 2017-02-23 | 2018-08-31 | 复旦大学 | A kind of dihydropyran ketone compound and its preparation method and application |
JOP20190254A1 (en) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | Antitumoral compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117894A1 (en) * | 2004-06-03 | 2005-12-15 | Kosan Biosciences Incorporated | Leptomycin compounds |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US4855086A (en) * | 1982-10-15 | 1989-08-08 | Burroughs Wellcome Co. | Novel pesticides, preparation and use |
JPS61109717A (en) | 1984-11-02 | 1986-05-28 | Teruhiko Beppu | Antitumor agent |
WO1992012140A1 (en) * | 1990-12-28 | 1992-07-23 | Georgia Tech Research Corporation | Peptides ketoamides, ketoacids, and ketoesters |
JPH0539283A (en) | 1991-01-31 | 1993-02-19 | Suntory Ltd | New substance, s-59917a, and its production |
ZA938019B (en) | 1992-11-13 | 1995-04-28 | Upjohn Co | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses |
US5523456A (en) * | 1994-09-29 | 1996-06-04 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5681847A (en) * | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
US5834506A (en) | 1996-11-01 | 1998-11-10 | Warner-Lambert Company | Dihydropyrones with improved antiviral activity |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
KR20010085780A (en) | 1998-09-11 | 2001-09-07 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | HIV Protease Inhibitors |
US6380400B1 (en) | 1998-09-11 | 2002-04-30 | Victor Fedij | Methods of making dihydropyrone HIV protease inhibitors |
CA2401104A1 (en) * | 2000-04-04 | 2001-10-11 | Novartis Ag | Method for treating cells resistant to antineoplastic agents |
NZ535578A (en) * | 2002-03-04 | 2008-03-28 | Merck Hdac Res Llc | Methods of inducing terminal differentiation |
BRPI0412843A (en) * | 2003-07-25 | 2006-09-26 | Novartis Ag | substituted lactams and their use as anticancer agents |
RU2006142690A (en) * | 2004-06-03 | 2008-06-10 | Козан Байосайенсиз Инкорпорейтед (Us) | LEPTOMYCIN COMPOUNDS |
WO2007014423A1 (en) * | 2005-08-02 | 2007-02-08 | Medvet Science Pty, Ltd. | Exercise apparatus |
ATE522514T1 (en) * | 2006-06-16 | 2011-09-15 | Pharma Mar Sa | DIHYDROPYRAN-2-ONE COMPOUNDS WITH ANTI-TUMOR EFFECT |
MX2010006796A (en) | 2007-12-20 | 2010-10-26 | Pharma Mar Sa | Antitumoral compounds. |
-
2008
- 2008-12-19 MX MX2010006796A patent/MX2010006796A/en active IP Right Grant
- 2008-12-19 NZ NZ597526A patent/NZ597526A/en unknown
- 2008-12-19 RU RU2013112003/04A patent/RU2528393C9/en active
- 2008-12-19 DK DK08864895.1T patent/DK2231633T3/en active
- 2008-12-19 PT PT08865009T patent/PT2231590E/en unknown
- 2008-12-19 MX MX2010006795A patent/MX2010006795A/en active IP Right Grant
- 2008-12-19 PL PL08865009T patent/PL2231590T3/en unknown
- 2008-12-19 UA UAA201009035A patent/UA104281C2/en unknown
- 2008-12-19 CN CN200880121840.6A patent/CN101903367B/en active Active
- 2008-12-19 UA UAA201009034A patent/UA106967C2/en unknown
- 2008-12-19 AU AU2008341670A patent/AU2008341670B2/en not_active Ceased
- 2008-12-19 MY MYPI2010002590A patent/MY148651A/en unknown
- 2008-12-19 JP JP2010538765A patent/JP5529038B2/en active Active
- 2008-12-19 CN CN2011100568656A patent/CN102174058A/en active Pending
- 2008-12-19 AU AU2008341671A patent/AU2008341671B2/en not_active Ceased
- 2008-12-19 CN CN201110073931.0A patent/CN102190643B/en active Active
- 2008-12-19 KR KR1020157016575A patent/KR101639772B1/en active IP Right Grant
- 2008-12-19 CA CA2715203A patent/CA2715203C/en active Active
- 2008-12-19 WO PCT/EP2008/068065 patent/WO2009080769A1/en active Application Filing
- 2008-12-19 DK DK08865009.8T patent/DK2231590T3/en active
- 2008-12-19 MY MYPI2014002392A patent/MY164533A/en unknown
- 2008-12-19 US US12/746,966 patent/US8710264B2/en active Active
- 2008-12-19 BR BRPI0821116A patent/BRPI0821116B8/en active IP Right Grant
- 2008-12-19 KR KR1020107015968A patent/KR101579553B1/en active IP Right Grant
- 2008-12-19 SI SI200830644T patent/SI2231590T1/en unknown
- 2008-12-19 ES ES08865009T patent/ES2384420T3/en active Active
- 2008-12-19 RU RU2010130180/04A patent/RU2493147C2/en active
- 2008-12-19 RS RS20120242A patent/RS52343B/en unknown
- 2008-12-19 CA CA2710087A patent/CA2710087C/en active Active
- 2008-12-19 EP EP13154647.5A patent/EP2597091B1/en active Active
- 2008-12-19 US US12/746,974 patent/US9187445B2/en active Active
- 2008-12-19 SI SI200831122T patent/SI2231633T1/en unknown
- 2008-12-19 UA UAA201406894A patent/UA119963C2/en unknown
- 2008-12-19 PL PL08864895T patent/PL2231633T3/en unknown
- 2008-12-19 AT AT08865009T patent/ATE549313T1/en active
- 2008-12-19 EP EP08864895.1A patent/EP2231633B1/en active Active
- 2008-12-19 NZ NZ586013A patent/NZ586013A/en unknown
- 2008-12-19 RS RS20140007A patent/RS53140B/en unknown
- 2008-12-19 CN CN2008801218410A patent/CN101903337B/en active Active
- 2008-12-19 JP JP2010538769A patent/JP5727228B2/en active Active
- 2008-12-19 PT PT88648951T patent/PT2231633E/en unknown
- 2008-12-19 ES ES13154647.5T patent/ES2578606T3/en active Active
- 2008-12-19 WO PCT/EP2008/068049 patent/WO2009080761A1/en active Application Filing
- 2008-12-19 EP EP08865009A patent/EP2231590B9/en active Active
- 2008-12-19 BR BRPI0821114A patent/BRPI0821114B8/en active IP Right Grant
- 2008-12-19 SG SG201102163-1A patent/SG170778A1/en unknown
- 2008-12-19 KR KR1020107015965A patent/KR101541436B1/en active IP Right Grant
- 2008-12-19 ES ES08864895.1T patent/ES2442140T3/en active Active
- 2008-12-19 NZ NZ586012A patent/NZ586012A/en unknown
- 2008-12-19 RU RU2010130253/04A patent/RU2489429C2/en active
- 2008-12-19 SG SG201102164-9A patent/SG170779A1/en unknown
- 2008-12-19 MY MYPI2010002591A patent/MY155342A/en unknown
-
2010
- 2010-06-04 ZA ZA2010/04017A patent/ZA201004017B/en unknown
- 2010-06-04 ZA ZA2010/04018A patent/ZA201004018B/en unknown
- 2010-06-15 IL IL206397A patent/IL206397A/en active IP Right Grant
- 2010-06-15 IL IL206396A patent/IL206396A/en active IP Right Grant
-
2011
- 2011-03-01 HK HK11102050.0A patent/HK1147990A1/en not_active IP Right Cessation
- 2011-03-01 HK HK13107821.5A patent/HK1180678A1/en not_active IP Right Cessation
- 2011-03-01 HK HK11102052.8A patent/HK1147998A1/en not_active IP Right Cessation
- 2011-08-31 ZA ZA2011/06371A patent/ZA201106371B/en unknown
-
2012
- 2012-06-01 HR HRP20120464AT patent/HRP20120464T1/en unknown
-
2013
- 2013-11-24 IL IL229594A patent/IL229594A/en active IP Right Grant
-
2014
- 2014-01-08 HR HRP20140015AT patent/HRP20140015T1/en unknown
- 2014-01-27 CY CY20141100069T patent/CY1117245T1/en unknown
- 2014-04-10 JP JP2014080887A patent/JP5860088B2/en active Active
-
2015
- 2015-08-12 US US14/824,690 patent/US9750759B2/en active Active
- 2015-08-12 US US14/824,699 patent/US9827257B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117894A1 (en) * | 2004-06-03 | 2005-12-15 | Kosan Biosciences Incorporated | Leptomycin compounds |
Non-Patent Citations (1)
Title |
---|
Total Synthesis of Hapalosin and Two Ring Expanded Analogs;Christoph Hermann et al.;《Tetrahedron》;20001231;第56卷(第43期);8461-8471 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102190643B (en) | Antitumoral compounds | |
CA2654334C (en) | Antitumoral dihydropyran-2-one compounds | |
AU2011203085A1 (en) | Antitumoral dihydropyran-2-one compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |